US Patent Applications in Excipients, Delivery and Release of
Pharmaceutical Compositions and Actives Published in 2009

Thank you for visiting FormulaScan . Please click on the Patent No to study the full patent document

US PATENT APPLICATIONS IN PHARMACEUTICAL EXCIPIENTS AND FORMULATION PUBLISHED IN 2009



Application No.: US20090004248A1  Published: 01/Jan/2009

Title: DUAL PORTION DOSAGE LOZENGE FORM

Applicant/Assignee:

Application No.: 12/143916   Filing Date: 23/Jun/2008

Abstract:The present invention relates to a dosage form including both a disintegrative tablet portion and a hard candy portion, wherein: (i) the disintegrative tablet portion comprises at least one pharmaceutically active agent, and (ii) the hard candy portion covers at least 20% of the surface of the disintegrative tablet portion, and wherein the disintegration time of the hard candy portion is at least ten times longer than the disintegration time of the disintegrative tablet portion.

Priority: US20070947004P Applic. Date: 2007-06-29

Inventor: BUNICK FRANK [US]; LUBER JOSEPH [US]; WIET STEPHAN G [US]; MCNALLY GERARD P [US]; WYNN DAVID [US]


Application No.: US20090004262A1  Published: 01/Jan/2009

Title: Nanoparticulate formulations and methods for the making and use therof

Applicant/Assignee: MARINUS PHARMACEUTICALS

Application No.: 11/998362   Filing Date: 28/Nov/2007

Abstract:The present invention is directed to size-stabilized drug nanoparticulate compositions and methods of preparation thereof.

Priority: US20060861616P Applic. Date: 2006-11-28

Inventor: SHAW KENNETH [US]; ZHANG MINGBAO [US]


Application No.: US20090004269A1  Published: 01/Jan/2009

Title: Pharmaceutical Composition Comprising a Proton Pump Inhibitor and a Protein Component

Applicant/Assignee: THE CURATORS OF THE UNIVERSITY OF MISSOURI

Application No.: 12/161247   Filing Date: 18/Jan/2007

Abstract:The present disclosure relates to, inter alia, pharmaceutical compositions comprising a H+K+-ATPase proton pump inhibitor and a protein component

to methods for manufacture of such compositions, and to use of such compositions in treating and preventing diseases and/or disorders.

Priority: US20060760256P Applic. Date: 2006-01-19; WO2007US60723 Applic. Date: 2007-01-18

Inventor: PHILLIPS JEFFREY O [US]


Application No.: US20090004281A1  Published: 01/Jan/2009

Title: MULTIPARTICULATE OSMOTIC DELIVERY SYSTEM

Applicant/Assignee: BIOVAIL LABORATORIES INTERNATIONAL S.R.L

Application No.: 11/768764   Filing Date: 26/Jun/2007

Abstract:The present invention relates to a multiparticulate osmotic delivery system. The system is a modified release composition suitable for oral administration. The composition includes a core that includes at least one drug in combination with at least one pharmaceutically acceptable excipient. The composition further includes an osmotic subcoat surrounding the core, and a modified release overcoat surrounding the osmotic subcoated core.

Priority:

Inventor: NGHIEM TIEN [IE]; JACKSON GRAHAM [IE]


Application No.: US20090010882A1  Published: 08/Jan/2009

Title: POLYMORPHS OF SODIUM 4-4[(4-CHLORO-2-HYDROXYBENZOYL) AMINO] BUTANOATE

Applicant/Assignee: EMISPHERE TECHNOLOGIES, INC

Application No.: 12/167126   Filing Date: 02/Jul/2008

Abstract:The present invention relates to amorphous and polymorphic forms of sodium 4-[(4-chloro-2-hydroxybenzoyl)amino]butanoate and their use for facilitating the delivery of active agents, such as insulin, to a target.

Priority: US2007-686341 Applic. Date: 2007-03-14; US2005-501205 Applic. Date: 2005-01-04; WO2003US00878 Applic. Date: 2003-01-09; US20020347610P Applic. Date: 2002-01-09

Inventor: BHANDARKAR SATEJ [US]; MAJURU SHINGAI [US]; LEUCHYK HALINA [US]


Application No.: US20090010949A1  Published: 08/Jan/2009

Title: POLYSIALIC ACID DERIVATIVES, METHODS OF PRODUCTION, AND USES IN ENHANCING CANCER ANTIGEN PRODUCTION AND TARGETING

Applicant/Assignee:

Application No.: 12/167909   Filing Date: 03/Jul/2008

Abstract:The present invention relates to compositions and methods of their production and use, including use in increasing de-N-acetyl sialic acid antigen of a mammalian cell and methods that exploit the increase in deNAc sialic acid antigen on such cells.

Priority: US20070958391P Applic. Date: 2007-07-03

Inventor: MOE GREGORY R [US]; HAGEN BRENT T [US]


Application No.: US20090010964A1  Published: 08/Jan/2009

Title: Lipid and Nitrous Oxide Combination as Adjuvant for the Enhancement of the Efficacy of Vaccines

Applicant/Assignee: NORTH-WEST UNIVERSITY

Application No.: 11/794503   Filing Date: 03/Aug/2006

Abstract:The invention provides for a method of enhancing immunological responses to an antigen in a vaccine formulation, and for a vaccine formulation that provides for an enhanced immunological response to an antigen. In the method and formulation the antigen is administered with an adjuvant which adjuvant comprises a solution of nitrous oxide gas in a pharmaceutically acceptable carrier solvent for the gas and which adjuvant includes at least one fatty acid or ester or other suitable derivative thereof selected from the group consisting of oleic acid, linoleic acid, alpha-linolenic acid, gamma-linolenic acid, arachidonic acid, eicosapentaenoic acid [C20: 5omega3], decosahexaenoic acid [C22: 6omega3], ricinoleic acid and derivatives thereof selected from the group consisting of the C1 to C6 alkyl esters thereof, the glycerol-polyethylene glycol esters thereof and the reaction product of hydrogenated natural oils composed largely of ricinoleic acid based oils, such as castor oil with ethylene oxide.

Priority: ZA20050000856 Applic. Date: 2005-01-28; WO2006IB50286 Applic. Date: 2006-01-26

Inventor: GROBLER ANNE [ZA]; KOTZE ABRAHAM FREDERIK [ZA]


Application No.: US20090010998A1  Published: 08/Jan/2009

Title: Drug-delivery patch comprising a dissolvable layer and uses thereof

Applicant/Assignee:

Application No.: 12/217393   Filing Date: 03/Jul/2008

Abstract:The present invention provides a drug-delivery patch having at least one dissolvable layer comprising an active material and an adhesive backing or cover. The present invention also provides a method of transdermally vaccinating an animal by ablating an area of the stratum corneum of the animal and applying the patch described herein to the area.

Priority: US20070947724P Applic. Date: 2007-07-03

Inventor: MARCHITTO KEVIN S [US]; FLOCK STEPHEN T [US]


Application No.: US20090011006A1  Published: 08/Jan/2009

Title: Once daily formulations of tetracyclines

Applicant/Assignee: SUPERNUS PHARMACEUTICALS, INC

Application No.: 12/155676   Filing Date: 06/Jun/2008

Abstract:Disclosed are once-daily formulations containing tetracyclines, especially doxycycline. Such formulations are useful, for instance, for the treatment of collagenase destructive enzyme-dependent diseases, such as periodontal disease and acne, and acute and chronic inflammatory disease states, such as rosacea and arthritis.

Priority: US2004-819620 Applic. Date: 2004-04-07; US20030460963P Applic. Date: 2003-04-07; US20040547964P Applic. Date: 2004-02-26

Inventor: CHANG RONG-KUN [US]; RAOUFINIA ARASH [US]; SHAH NIRAJ [US]


Application No.: US20090011007A1  Published: 08/Jan/2009

Title: Pharmaceutical Compositions Containing Mixtures of Polymers and Active Agents Poorly Soluble in Water

Applicant/Assignee: EVONIK ROEHM GMBH

Application No.: 12/159538   Filing Date: 17/Jan/2007

Abstract:The invention relates to a pharmaceutical composition comprising a mixture of at least one cationic, water-soluble (meth)acrylate copolymer, at least one water-insoluble polymer and at least one active ingredient having a solubility in demineralized water of 3.3 g/l or less, characterized in that the water-insoluble polymer and the active ingredient are present in a ratio of at most 3.5 to 1 parts by weight, and the pharmaceutical composition has the property of releasing the active ingredient present in a medium buffered to pH 1.2 in dissolved form in a concentration which, after 2 hours at pH 1.2, corresponds to at least sixteen times the solubility value of the active ingredient alone at pH 1.2.

Priority: DE200610005485 Applic. Date: 2006-02-03; WO2007EP50465 Applic. Date: 2007-01-17

Inventor: MEIER CHRISTIAN [DE]; NOLLENBERGER KATHRIN [DE]; GRYCZKE ANDREAS [DE]; PETEREIT HANS-ULRICH [DE]; DRESSMAN JENNIFER [DE]


Application No.: US20090011009A1  Published: 08/Jan/2009

Title: Microspheres comprising nanocapsules containing a lipophilic drug

Applicant/Assignee: YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREWUNIVERSITY OF JERUSALEM

Application No.: 12/219540   Filing Date: 23/Jul/2008

Abstract:The present invention provides microspheres comprising a plurality of nanocapsules accommodated in a gel forming polymer, the plurality of nanocapsules comprising an oil core carrying a non hydrophilic active agent and a shell of polymeric coating. The invention also provides a method for preparing the microspheres of the invention, pharmaceutical compositions comprising the same as well as methods of use of the microspheres, specifically, in therapeutic, cosmetic and diagnostic applications.

Priority: WO2007IL00084 Applic. Date: 2007-01-23; US20060760935P Applic. Date: 2006-01-23

Inventor: BENITA SHIMON [IL]; ROM ALONA [IL]; NASSER TAHER [IL]


Application No.: US20090011013A1  Published: 08/Jan/2009

Title: Tacrolimus Combination Products

Applicant/Assignee: LIFECYCLE PHARMA A/S

Application No.: 12/089082   Filing Date: 09/Oct/2006

Abstract:The present invention relates to a pharmaceutical composition comprising tacrolimus or an analogue thereof and a substance being a substrate for CYP3A4 and/or P-glycoprotein, oral solid dosage forms comprising the pharmaceutical composition such as tablets, methods for preparing the pharmaceutical composition and oral dosage forms and use of the pharmaceutical composition for preparing a medicament. The substance being a substrate for CYP3A4 and/or P-glycoprotein is preferably cyclosporine A. The invention further relates to treatment of a patient in need thereof by coadministration of the combination according to the invention. In a further aspect, the invention relates to the above combination further comprising a CYP3A4 inhibitor compound, preferably a compound naturally occurring in citrus juice, for example grapefruit juice, preferably a spiro ortho ester compound.

Priority: DK20050001411 Applic. Date: 2005-10-07; WO2006DK00569 Applic. Date: 2006-10-09

Inventor: RANKLOVE LISBET BONLOKKE [DK]; MIKKELSEN JAN MOLLER [DK]


Application No.: US20090011014A1  Published: 08/Jan/2009

Title: Tablet Formulation for Sustained Drug-Release

Applicant/Assignee: UNIVERSITE DE MONTREAL

Application No.: 11/793994   Filing Date: 20/Dec/2005

Abstract:Disclosed is a pharmaceutical sustained release tablet for oral administration of a drug which is made of a compressed blend of at least three dry powders including a powder of a drug, a powder of a sustained release matrix for the drug, and a powder of at least one electrolyte. The sustained release matrix consisting of an un-cross-linked high amylose starch wherein the high amylose is substituted by at least one organic substituent comprising at least one carboxyl group. This organic substituent is preferably a carboxyalkyl having 2 to 4 carbon atoms, its salt or mixture thereof. This tablet has the advantage of having an improved integrity.

Priority: CA20042491665 Applic. Date: 2004-12-24; WO2005CA01934 Applic. Date: 2005-12-20

Inventor: CARTILIER LOUIS [CA]; UNGUR MIHAELA [CA]; CHEBLI CHAFIC [CA]


Application No.: US20090011016A1  Published: 08/Jan/2009

Title: Crush-Resistant Oxycodone Tablets Intended For Preventing Accidental Misuse And Unlawful Diversion

Applicant/Assignee: ETHYPHARM SA

Application No.: 12/224385   Filing Date: 01/Mar/2007

Abstract:Water-insoluble matrix tablets based on oxycodone or one of its pharmaceutically acceptable salts and capable of prolonged release of oxycodone to the body, exhibiting a crush resistance of at least 4 MPa.

Priority: FR20060001842 Applic. Date: 2006-03-01; WO2007EP51969 Applic. Date: 2007-03-01

Inventor: CAILLY-DUFESTEL VINCENT [FR]; HERRY CATHERINE [FR]; BACON JOHNATAN [CA]; OURY PASCAL [FR]


Application No.: US20090011019A1  Published: 08/Jan/2009

Title: PHARMACEUTICAL COMPOSITIONS FOR GASTROINTESTINAL DRUG DELIVERY

Applicant/Assignee: LUPIN LTD

Application No.: 12/144894   Filing Date: 24/Jun/2008

Abstract:A novel pharmaceutical composition, which comprises a therapeutically effective amount of active principle(s) or a pharmaceutically acceptable salt or enantiomer or polymorph thereof, optionally one or more release controlling agent(s) and pharmaceutical acceptable excipient(s) thereof, wherein the composition is formulated to increase the residence time of the said pharmaceutical composition and/or active principle(s) in the gastrointestinal tract. A novel pharmaceutical composition comprising at least two entities wherein one entity is an immediate release/fast release and the other is controlled release. A pharmaceutical composition comprising at least two entities wherein one entity is an immediate release/fast release and the other is bioadhesive. A pharmaceutical composition comprising: at least two entities wherein one entity is controlled release and the other is bioadhesive All the three compositions are formulated to increase the residence time of active principle(s) in the gastrointestinal tract. A multilayered composition with active in a layer which provides immediate release or controlled release of active principles and layer providing increased residence time in the GI tract.

Priority: IN2007KO00969 Applic. Date: 2007-07-06

Inventor: JAHAGIRDAR HARSHAL ANIL [IN]; KULKARNI RAJESH [IN]; KULKARNI SHIRISHKUMAR [IN]


Application No.: US20090012146A1  Published: 08/Jan/2009

Title: SOLUBILITY-ENHANCED PHARMACEUTICAL COMPOSITIONS COMPRISING ZAFIRLUKAST

Applicant/Assignee:

Application No.: 12/166493   Filing Date: 02/Jul/2008

Abstract:Stable pharmaceutical compositions comprising zafirlukast and pharmaceutically acceptable salts, solvates, polymorphs, enantiomers or mixtures thereof, together with one or more pharmaceutically acceptable polymers, and processes for their preparation.

Priority: IN2007CH01412 Applic. Date: 2007-07-02; US20070968929P Applic. Date: 2007-08-30

Inventor: BUGGANA GIRIDHAR REDDY [IN]; BASETY SRIKANTH [IN]; GAWANDE RAHUL SUDHAKAR [IN]; KODIPYAKA RAVINDER [IN]; IRUKULLA SRINIVAS [IN]; BHUSHAN INDU [IN]; MOHAN MAILATUR SIVARAMAN [IN]; BEMBALOOR PRAVEEN KUMAR [IN]


Application No.: US20090012150A1  Published: 08/Jan/2009

Title: Stablized Pharmaceutical Composition Comprising an Amorphous Active Substance

Applicant/Assignee:

Application No.: 11/923059   Filing Date: 24/Oct/2007

Abstract:The invention relates to the pharmaceutical composition comprising the amorphous active substance which is atorvastatin calcium. The process of stabilization of the pharmaceutical composition comprising the pharmaceutical formulation with amorphous atorvastatin calcium, the process of stabilization of the pharmaceutical formulation comprising amorphous atorvastatin calcium and the process of stabilization of atorvastatin calcium in an amorphous form is described.

Priority: SI20020000244 Applic. Date: 2002-10-11; US2003-683683 Applic. Date: 2003-10-10

Inventor: GRAHEK ROK [SI]; BASTARDA ANDREJ [SI]; SALOBIR MATEJA [SI]


Application No.: US20090013998A1  Published: 15/Jan/2009

Title: INHALABLE TIOTROPIUM AND CONTAINER THEREFOR

Applicant/Assignee: BOEHRINGER INGELHEIM INTERNATIONAL GMBH

Application No.: 12/235803   Filing Date: 23/Sep/2008

Abstract:A medical product suitable for storing and delivering a pre-metered dose of tiotropium, devices containing the same, and methods of using the same.

Priority: SE20030003269 Applic. Date: 2003-12-03; SE20030003570 Applic. Date: 2003-12-22; US2004-834037 Applic. Date: 2004-04-29

Inventor: NILSSON THOMAS [SE]; MYRMAN MATTIAS [SE]; CALANDER SVEN [SE]; NIEMI ALF [SE]


Application No.: US20090017016A1  Published: 15/Jan/2009

Title: Treatment and prevention of hypersensitivity and/or anaphylaxis with anti-ige antibodies in patients receiving replacement therapy

Applicant/Assignee: TANOX INC

Application No.: 11/664777   Filing Date: 04/Oct/2005

Abstract:The present invention relates generally to a method of treatment and/or prevention of hypersensitivity including anaphylaxis in patients receiving replacement therapy molecules that elicit an IgE-mediated response by administering an anti-IgE antibody or a binding fragment thereof. Anti-IgE antibodies inhibit IgE-mediated allergic reactions in the mammals and can also lower the risk of an anaphylactic reaction to a replacement therapy molecule. The administration of anti-IgE antibodies over time also downregulates the high-affinity IgE receptor, further decreasing the risk of hypersensitivity and/or anaphylaxis. The anti-IgE antibody binds to circulating or serum IgE and/or membrane form IgE on B-cells, but not to IgE bound to mast cells or basophils, as this may cause crosslinking. This method also reduces the dose and/or frequency of administration of the replacement therapy molecule by reducing or eliminating neutralizing IgE antibodies specific for the replacement therapy molecule.

Priority: US20040616012P Applic. Date: 2004-10-05; WO2005US35770 Applic. Date: 2005-10-04

Inventor: FUNG SEK CHUNG [US]; LEWIS STANLEY T [US]


Application No.: US20090017085A1  Published: 15/Jan/2009

Title: Self-supporting films for pharmaceutical and food use

Applicant/Assignee:

Application No.: 10/577408   Filing Date: 27/Oct/2004

Abstract:Rapidly dissolving self-supporting films for food or pharmaceutical use comprising: a) a filmogenic substance consisting of a maltodextrin

b) a plasticiser

c) an active principle for food or pharmaceutical use, characterised in that said films are free of hydrocolloids.

Priority: IT2003MI02087 Applic. Date: 2003-10-27; WO2004EP52672 Applic. Date: 2004-10-27

Inventor: CILURZO FRANCESCO [IT]; MINGHETTI PAOLA [IT]; MONTANARI LUISA [IT]


Application No.: US20090017114A1  Published: 15/Jan/2009

Title: Tranexamic acid formulations with reduced adverse effects

Applicant/Assignee: XANODYNE PHARMACEUTICALS, INC

Application No.: 12/283694   Filing Date: 15/Sep/2008

Abstract:Tranexamic acid formulated in an oral dosage form with at least one agent that decreases tranexamic acid release in the stomach. Such formulations minimize nausea, vomiting, and other adverse gastric effects that may accompany tranexamic acid therapy, for example, to treat heavy menstrual bleeding. One embodiment is an extended release formulation with waxes, polymers, etc. that prevent a bolus release of tranexamic acid in the stomach. An alternative embodiment is a delayed release formulation with polymers that prevent release of tranexamic acid in the acid environment of the stomach and delay its release until the formulation reaches the less acid environment of the intestines. Such formulations enhance patient compliance with therapy because adverse effects of tranexamic acid therapy are reduced.

Priority: US2003-631371 Applic. Date: 2003-07-31

Inventor: HEASLEY RALPH A [US]; MOORE KEITH A [US]; GREIWE JEFFREY S [US]


Application No.: US20090018053A1  Published: 15/Jan/2009

Title: FORMULATIONS FOR AMYLIN AGONIST PEPTIDES

Applicant/Assignee: AMYLIN PHARMACEUTICALS, INC

Application No.: 11/962034   Filing Date: 20/Dec/2007

Abstract:The present invention is concerned with a pharmaceutical formulation comprising an amylin agonist and optionally a buffer, a tonicifier or stabilizer, and a preservative in a container, for example, a vial, prefilled cartridge, prefilled syringe or disposable pen. This formulation may be in liquid, gel, solid or powdered form for delivery, for example, via nasal, pulmonary, oral, sublingual, buccal, transdermal, or parenteral routes. Formulation with biocompatible polymers and release modifiers, such as sugars, can facilitate controlled release after injection, minimizing the number of administrations to a patient. These formulations maintain stability upon storage under refrigerated or room temperature conditions. Such formulations can be further combined with insulin for administration to a patient.

Priority: US2002-159779 Applic. Date: 2002-05-31; US1998-005262 Applic. Date: 1998-01-09

Inventor: L ITALIEN JAMES L [US]; STETSKO GREGG [US]


Application No.: US20090018175A1  Published: 15/Jan/2009

Title: Pharmaceutical excipient complex

Applicant/Assignee:

Application No.: 12/150152   Filing Date: 25/Apr/2008

Abstract:The present invention encompasses pharmaceutical excipient complexes comprising combining at least one carrier with an oily substance, and processes for preparing the same, stable pharmaceutical compositions comprising such complexes and active pharmaceutical ingredients and processes for preparing the same.

Priority: US20070926282P Applic. Date: 2007-04-25

Inventor: KANARI ITAMAR [IL]; FOX MICHAEL [IL]; LEIBOVICI MINUTZA [IL]


Application No.: US20090018205A1  Published: 15/Jan/2009

Title: METHODS FOR TREATMENT OF MIGRAINE AND SYMPTOMS THEREOF

Applicant/Assignee:

Application No.: 12/211619   Filing Date: 16/Sep/2008

Abstract:Compositions, methods and kits are provided for the treatment of migraines. The compositions, methods and kits include an effective dose of trimethobenzamide and an ethanolamine antihistamine that, when administered to an individual suffering from migraine headaches, will alleviate symptoms associated with the migraine headaches. Compositions, methods, and kits for the treatment of migraines include pharmaceutical compositions of trimethobenzamide and diphenhydramine.

Priority: US2004-871847 Applic. Date: 2004-06-17

Inventor: SALEHANI FOAD [US]


Application No.: US20090022657A1  Published: 22/Jan/2009

Title: Novel CXCL8 antagonists

Applicant/Assignee: APPLIED RESEARCH SYSTEMS ARS HOLDING N.V

Application No.: 10/573726   Filing Date: 22/Oct/2004

Abstract:Novel antagonists of the chemokine CXCL8 (also known as Interleukin-8) can be obtained by generating mutants having specific combinations of non-conservative substitutions of basic amino acids located in the C-terminal region. Compounds prepared in accordance with the present invention can be used to block CXCL8 activity in vivo, thereby providing therapeutic compositions for use in the treatment or prevention of CXCL8-related diseases.

Priority: EP20030103909 Applic. Date: 2003-10-22; WO2004EP52637 Applic. Date: 2004-10-22

Inventor: PROUDFOOT AMANDA [FR]; SHAW JEFFREY [CH]


Application No.: US20090022786A1  Published: 22/Jan/2009

Title: Oral pharmaceutical dosage form and manufacturing method thereof

Applicant/Assignee: YUNG SHIN PHARM. IND. CO., LTD

Application No.: 12/010829   Filing Date: 30/Jan/2008

Abstract:The present invention provides an coated oral pharmaceutical dosage form comprising a composition of a non-steroidal anti-inflammatory drug (NSAID) as multilayered spherical granule combined with a composition of prostaglandin, and a film coating. The present invention also provides a method for manufacturing the dosage form, which comprising the steps of preparing the compositions of NSAID and prostaglandin separately, combing the compositions to form a pharmaceutical dosage form, and coating the dosage form with a film coating.

Priority: US20070929878P Applic. Date: 2007-07-16

Inventor: LEE FANG-CHEN [TW]; CHEN BIN-KEN [TW]; KUO HAN-CHIANG [TW]; CHEN CHI-HUANG [TW]


Application No.: US20090022796A1  Published: 22/Jan/2009

Title: Novel Substituted Benzimidazole Dosage Forms and Method of Using Same

Applicant/Assignee: THE CURATORS OF THE UNIVERSITY OF MISSOURI

Application No.: 12/144473   Filing Date: 23/Jun/2008

Abstract:The present invention relates to pharmaceutical preparations comprising substituted benzimidazole proton pump inhibitors. There is provided a liquid or solid pharmaceutical composition consisting of a proton pump inhibitor, including preparations of s-omeprazole, and at least one buffering agent. Also provided is a pharmaceutical composition comprising a parietal cell activator, an anti-foaming agent, a flavoring agent and combinations thereof

a method for treating acid-related gastrointestinal disorders by administering a solid pharmaceutical composition

and a kit for the preparation of a liquid oral pharmaceutical composition. Dosage forms include: liquid, powder, tablet, capsule, effervescent powder, effervescent tablet, pellets, and granules

Priority: US2003-641732 Applic. Date: 2003-08-15; US2002-068437 Applic. Date: 2002-02-05; US2000-481207 Applic. Date: 2000-01-11; US1998-183422 Applic. Date: 1998-10-30; US1996-680376 Applic. Date: 1996-07-15; US19960009608P Applic. Date: 1996-01-04

Inventor: PHILLIPS JEFFREY O [US]


Application No.: US20090022798A1  Published: 22/Jan/2009

Title: FORMULATIONS OF NONOPIOID AND CONFINED OPIOID ANALGESICS

Applicant/Assignee: ABBOTT GMBH & CO. KG

Application No.: 11/780625   Filing Date: 20/Jul/2007

Abstract:The preferred exemplary embodiments in the present application provide formulations and methods for the delivery of drugs, particularly drugs of abuse, having an abuse-relevant drug substantially confined in the core and a non-abuse relevant drug in a non-core region. These formulations have reduced potential for abuse. In the formulation, preferably the abuse relevant drug is an opioid and the non-abuse relevant drug is acetaminophen or ibuprofen. More preferably, the opioid is hydrocodone, and the non-abuse relevant analgesic is acetaminophen. In certain preferred embodiments, the dosage forms are characterized by resistance to solvent extraction

tampering, crushing or grinding. Certain embodiments of the inventions provide dosage forms that provide an initial burst of release of drug followed by a prolonged period of controllable drug release.

Priority:

Inventor: ROSENBERG JOERG [DE]; WOEHRLE GERD H [DE]; KESSLER THOMAS Y [DE]; BREITENBACH JOERG [DE]; DURAK SALIH [DE]; RICHTER FRIEDRICH W [US]; LIU WEI [US]; DUTTA SANDEEP [US]


Application No.: US20090022806A1  Published: 22/Jan/2009

Title: Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists and formulations and uses thereof

Applicant/Assignee:

Application No.: 12/004979   Filing Date: 21/Dec/2007

Abstract:Disclosed are methods of treating subjects having conditions related to angiogenesis including administering an effective amount of a polymeric Nanoparticle form of thyroid hormone agonist, partial agonist or an antagonist thereof, to promote or inhibit angiogenesis in the subject. Compositions of the polymeric forms of thyroid hormone, or thyroid hormone analogs, are also disclosed.

Priority: US20060876770P Applic. Date: 2006-12-22; US20070922113P Applic. Date: 2007-04-05; US20070936223P Applic. Date: 2007-06-18; US20070959006P Applic. Date: 2007-07-09; US20070976016P Applic. Date: 2007-09-28; US20070994895P Applic. Date: 2007-09-21; US20070000262P Applic. Date: 2007-10-23; US20070003935P Applic. Date: 2007-11-20

Inventor: MOUSA SHAKER A [US]; DAVIS PAUL J [US]; HERCBERGS ALECK [US]


Application No.: US20090022809A1  Published: 22/Jan/2009

Title: STABLE TASTE MASKED FORMULATIONS OF CEPHALOSPORINS

Applicant/Assignee: LUPIN LTD

Application No.: 12/095767   Filing Date: 03/Oct/2008

Abstract:A stable taste masked, pharmaceutical composition comprising a plurality of coated, non-disintegrating discrete dosage units, said units comprising of a core comprising one or more cephalosporins such as cefuroxime axetil and cefpodoxime proxetil and one or more coating layers. Cefuroxime axetil is in alpha-crystalline and amorphous forms, where at least 30% of the Cefuroxime axetil is in the alpha-crystalline form, wherein the particle size distribution of the alpha-crystalline form being such that 100% of the particles have a particle size below 250mu. The ratio of the crystalline fraction to the amorphous fraction ranges from 0.3:0.7 to 0.99:0.01. The particle size of cefpodoxime proxetil is such that 90% of the particles are below 15mu. The process of preparation of coated, non-disintegrating pellets comprising the steps of reducing the particle size of the one or more cephalosporins, blending with the other excipients, wet granulation, extrusion, spheronization, drying and screening to obtain pellets, said pellets being further coated with one or more layers of film coating to achieve taste masking.

Priority: WO2005IN00394 Applic. Date: 2005-12-02

Inventor: KOLHE SACHIN PUNDLIK [IN]; KUNDU SUBRATA [IN]; WAGH SANJAY CHHAGAN [IN]; AVACHAT MAKARAND KRISHNAKUMAR [IN]; SEN HIMADRI [IN]


Application No.: US20090023696A1  Published: 22/Jan/2009

Title: USE OF C3-C10 17ALFA-ESTERS OF 9,11-DEHYDROCORTEXOLONE AS ANTI-GONADOTROPHIC AGENTS

Applicant/Assignee: COSMO BIO-TECHNOLOGIES SRL

Application No.: 12/066754   Filing Date: 08/Jun/2006

Abstract:The present invention relates to the use of C3-C10 17alpha-esters of 9,11-dehydrocortexolone as agents for inhibiting gonadotrophin secretion. The present invention therefore relates to the use of C3-C10 17 alpha-esters of 9,11-dehydrocortexolone for the preparation of a medicine for the treatment of disorders associated with the secretion of gonadotrophin and with the corresponding pharmaceutical compounds. The present invention relates specifically to the use of 9,11-dehydrocortexolone 17alpha-butyrate.

Priority: IT2005MI01695 Applic. Date: 2005-09-14; WO2006EP62995 Applic. Date: 2006-06-08

Inventor: MORO LUIGI [IT]; AJANI MAURO [IT]; CELASCO GIUSEPPE [IT]


Application No.: US20090023714A1  Published: 22/Jan/2009

Title: COMBINED PREPARATION OF A THIAZIDE DIURETIC AND A LOOP DIURETIC

Applicant/Assignee: HEXAL AG

Application No.: 12/065261   Filing Date: 29/Aug/2006

Abstract:The invention relates to pharmaceutical preparations which contain a combination of a thiazide diuretic and a low-dose loop diuretic and which are particularly useful for treating hypertension and heart failure. It is not only the overall natriuretic/diuretic effects which are increased due to said combination of thiazide diuretic and loop diuretic, but the undesired secondary effects regarding potassium and magnesium losses are significantly reduced as well. As a result, the desired hypocalciuric effect of the thiazide is maintained despite the presence of the loop diuretic.

Priority: DE200510040841 Applic. Date: 2005-08-29; WO2006EP08455 Applic. Date: 2006-08-29

Inventor: KNAUF HEINRICH [DE]; MUTSCHLER ERNST [DE]


Application No.: US20090023771A1  Published: 22/Jan/2009

Title: PHARMACEUTICAL COMPOSITION COMPRISING A PROTON PUMP INHIBITOR AND PROTEIN COMPONENT

Applicant/Assignee: THE CURATORS OF THE UNIVERSITY OF MISSOURI

Application No.: 12/175266   Filing Date: 17/Jul/2008

Abstract:The present disclosure relates to, inter alia, pharmaceutical compositions comprising a H+,K+-ATPase proton pump inhibitor and a protein component

to methods for manufacture of such compositions, and to use of such compositions in treating and preventing diseases and/or disorders.

Priority: US20070950549P Applic. Date: 2007-07-18

Inventor: PHILLIPS JEFFREY O [US]


Application No.: US20090023819A1  Published: 22/Jan/2009

Title: Use of an Artificial Sweetener to Enhance Absorption of Nicotine

Applicant/Assignee:

Application No.: 11/909150   Filing Date: 17/Mar/2006

Abstract:The present invention relates to increased absorption of nicotine over the prior art. In particular the absorption of nicotine is enhanced after administration of a composition containing nicotine and a sweetener such as an artificial sweetener like saccharin to the oral mucosa in the form of a spray.

Priority: DK20050000414 Applic. Date: 2005-03-22; WO2006EP02675 Applic. Date: 2006-03-17

Inventor: AXELSSON ANDERS [SE]


Application No.: US20090025719A1  Published: 29/Jan/2009

Title: Pre-metered dry powder inhaler for moisture-sensitive medicaments

Applicant/Assignee: BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG

Application No.: 11/448726   Filing Date: 08/Jun/2006

Abstract:The invention discloses a dry powder inhaler for use in a treatment of respiratory disorders.

Priority: SE20030003269 Applic. Date: 2003-12-03; SE20030003569 Applic. Date: 2003-12-22; US2004-933219 Applic. Date: 2004-09-03

Inventor: ZIERENBERG BERND [DE]; MEMMESHEIMER HOLGER [DE]; LUNKENHEIMER CHRISTINE [DE]; CALANDER SVEN [SE]; NIEMI ALF [SE]; NILSSON THOMAS [SE]; MYRMAN MATTIAS [SE]


Application No.: US20090028829A1  Published: 29/Jan/2009

Title: Fusion proteins for the treatment of CNS

Applicant/Assignee:

Application No.: 10/848564   Filing Date: 17/May/2004

Abstract:This disclosure relates to compositions capable of use in the treatment of spinal cord injuries and related disorders of the central nervous system (CNS), and in particular, compositions including proteoglycan degrading molecules and compositions capable of blocking and/or over coming the activity of neuronal growth inhibitory molecules, as well as fusion proteins which includes a proteoglycan degrading domain and a domain capable of blocking and or over coming the activity of neuronal growth inhibitory molecules.

Priority: US20030471239P Applic. Date: 2003-05-16; US20030471300P Applic. Date: 2003-05-16; US20030474372P Applic. Date: 2003-05-29; US20030471240P Applic. Date: 2003-05-16

Inventor: GRUSKIN ELLIOTT A [US]; CAGGIANO ANTHONY O [US]; ROY GARGI [US]; IACI JENNIFER [US]; ZIMBER MICHAEL P [US]


Application No.: US20090028891A1  Published: 29/Jan/2009

Title: Chlamydia Antigens and Uses Thereof

Applicant/Assignee: QUEENSLAND UNIVERSITY OF TECHNOLOGY UNIVERSITY OF NEWCASTLE

Application No.: 11/718743   Filing Date: 11/Nov/2005

Abstract:The invention provides protein and nucleic acid sequences of Chlamydia species which are particularly suitable for diagnosis, treatment and/or prevention of Chlamydia or Chlamydophila infection in mammals, particularly humans. The invention particularly provides a pharmaceutical composition and method for preventing or treating Chlamydia or Chlamydophila infection.

Priority: AU20040906459 Applic. Date: 2004-11-11; WO2005AU01724 Applic. Date: 2005-11-11

Inventor: TIMMS PETER [AU]; BEAGLEY KEN [AU]; HAFNER LOUISE [AU]


Application No.: US20090028935A1  Published: 29/Jan/2009

Title: CARVEDILOL FORMS, COMPOSITIONS, AND METHODS OF PREPARATION THEREOF

Applicant/Assignee:

Application No.: 12/183453   Filing Date: 31/Jul/2008

Abstract:Disclosed are amorphous carvedilol salt forms, controlled-release carvedilol compositions, and methods of preparing the forms and compositions.

Priority: US2007-949158 Applic. Date: 2007-12-03; US20060872097P Applic. Date: 2006-12-01

Inventor: ARNOLD KRISTIN [US]; ERKOBONI DAVID F [US]


Application No.: US20090028940A1  Published: 29/Jan/2009

Title: PHARMACEUTICAL COMPOSITIONS OF RIFAXIMIN

Applicant/Assignee: LUPIN LTD

Application No.: 12/144453   Filing Date: 23/Jun/2008

Abstract:A pharmaceutical composition comprising therapeutically effective amount of rifaximin or pharmaceutically acceptable salt or enantiomer or polymorph thereof, pharmaceutically acceptable excipient(s) and release controlling agent(s). Pharmaceutical composition of rifaximin comprising: at least two entities wherein one entity is an immediate release or fast release and the other is controlled release. The pharmaceutical composition in the form of multilayer tablet comprising, at least one layer comprising, therapeutically effective amount of rifaximin or pharmaceutically acceptable salt or enantiomer or polymorph thereof, pharmaceutically acceptable excipient(s)

said layer providing controlled release rifaximin

and at least one layer which provides increased residence time of the dosage form in the gastrointestinal tract. The pharmaceutical formulation comprising rifaximin having an in vitro dissolution profile, wherein about 70% of rifaximin is released in about 24 hours. The composition comprising therapeutically effective amount of rifaximin or pharmaceutically acceptable salt(s) or enantiomer(s) or polymorph(s) thereof, one or more release controlling agent(s) and pharmaceutically acceptable excipient(s) causing pathogenic eradication.

Priority: IN2007KO00968 Applic. Date: 2007-07-06

Inventor: JAHAGIRDAR HARSHAL ANIL [IN]; KULKARNI RAJESH [IN]; KULKARNI SHIRISHKUMAR [IN]


Application No.: US20090028943A1  Published: 29/Jan/2009

Title: PHARMACEUTICAL COMPOSITIONS

Applicant/Assignee:

Application No.: 12/094702   Filing Date: 21/Nov/2006

Abstract:Pharmaceutical compositions comprising AZD2171 or a pharmaceutically acceptable salt thereof, including pharmaceutical compositions comprising AZD2171 or a pharmaceutically acceptable salt and a plastic filler with a high surface area, excluding lactose.

Priority: GB20050023810 Applic. Date: 2005-11-23; WO2006GB04320 Applic. Date: 2006-11-21

Inventor: CAHILL JULIE KAY [GB]; CUMBERBATCH DAREN JAMES [GB]; HOLT DAVID JOHN [GB]; RICHER SEBASTIEN [GB]; SIMPSON DAVID BRADLEY BROOK [GB]; SWAIN ELIZABETH ANNE [GB]


Application No.: US20090028944A1  Published: 29/Jan/2009

Title: PHARMACEUTICAL COMPOSITIONS COMPRISING MESALAMINE

Applicant/Assignee:

Application No.: 12/173875   Filing Date: 16/Jul/2008

Abstract:Pharmaceutical compositions comprising mesalamine, wherein the compositions are free of a liphophilic matrix, and processes for preparing pharmaceutical compositions comprising mesalamine and being free of a liphophilic matrix.

Priority: US20070949903P Applic. Date: 2007-07-16

Inventor: SATHURAPPAN BALAJI [IN]; SANKARNARAYANAN ANAND [IN]; GORE SUBHASH PANDURANG [IN]; VISHWANATHAN NARAYANAN BADRI [IN]; BHUSHAN INDU [IN]; MOHAN MAILATUR SIVARAMAN [IN]


Application No.: US20090029901A1  Published: 29/Jan/2009

Title: Process for Crystallizing Lactose Particles for Use in Pharmaceutical Formulations

Applicant/Assignee:

Application No.: 11/815897   Filing Date: 19/Jan/2006

Abstract:A process for producing a plurality of lactose particles comprises subjecting a plurality of lactose particles, to conditions such that at least a portion of smaller lactose particles detach from the plurality of the lactose particles and disperse in the liquid medium

subjecting the liquid medium to conditions sufficient to cause crystallization to occur on the smaller lactose particle surfaces to form larger lactose particles

and subjecting the liquid medium to conditions such that at least a portion of the lactose particles smaller relative to the plurality of larger lactose particles are dissolved in the liquid medium, wherein crystallization occurs on the plurality of larger lactose particles.

Priority: US20050651754P Applic. Date: 2005-02-10; WO2006US02016 Applic. Date: 2006-01-19

Inventor: WOOD-KACZMAR MARIAN [GB]


Application No.: US20090029915A1  Published: 29/Jan/2009

Title: REGULATION OF MINERAL AND SKELETAL METABOLISM

Applicant/Assignee: ACOLOGIX, INC

Application No.: 11/926460   Filing Date: 29/Oct/2007

Abstract:A method is disclosed whereby levels of calcium, phosphate and parathyroid hormone are measured in a patient. The patient is treated with a formulation comprising a compound having phosphotonin activity and thereafter measurements are made again. Dosing of the formulation is adjusted based on measurements with measuring, administering and adjusting dosing continually repeated as needed.

Priority: US2006-466673 Applic. Date: 2006-08-23; US20050713154P Applic. Date: 2005-08-30; US20050717115P Applic. Date: 2005-09-13; US20060807797P Applic. Date: 2006-07-19

Inventor: HABERBERGER THOMAS [US]; ROSEN DAVID [US]; KUMAGAI YOSHINARI [US]


Application No.: US20090032427A1  Published: 05/Feb/2009

Title: Receptacles and Kits, Such as for Dry Powder Packaging

Applicant/Assignee: NEKTAR THERAPEUTICS

Application No.: 12/083079   Filing Date: 26/Sep/2006

Abstract:A receptacle (100) includes a holder (5) forming a cavity (25) that holds a pharmaceutical (110), a lid (15), and adhesive (17) that forms a bond (20) between the holder (5) and the lid (15). As an example, the bond (20) has a shape that includes a protrusion (30) that facilitates removal of the lid (15) from the holder (5). A kit (60) includes a plurality of containers containing powder including amphotericin B and pharmaceutically acceptable excipient. The kit (60) also includes an aerosolization apparatus (1100) and instructions. As an example, the pharmaceutical composition is made from panicles including amphotericin B having a mass median diameter less than about 3 mum, such as from about 1.1 mum to about 1.9 mum.

Priority: US20050722303P Applic. Date: 2005-09-29; WO2006US37422 Applic. Date: 2006-09-26

Inventor: CHEU SCOT [US]; CHAN LEO [US]


Application No.: US20090035229A1  Published: 05/Feb/2009

Title: PHARMACEUTICAL COMPOSITION FOR IMPROVING ORAL HYGIENE AND METHODS THEREOF

Applicant/Assignee:

Application No.: 11/833530   Filing Date: 03/Aug/2007

Abstract:An aqueous based pharmaceutical composition for use as a oral hygienic treatment is described. The composition contains a pharmaceutically effective amount of a tetracycline-based antibiotic

a water-soluble calcium salt that aids in solubilizing the tetracycline-based antibiotic

a thickener

a pH adjustment agent

an antifoaming agent

an excipient

a surfactant

a preservative

and a flavoring agent. A method of making the aqueous based pharmaceutical composition includes the steps of adjusting, defoaming, dispensing, dispersing, dissolving, flavoring, heating, minimizing, pouring, solubilizing, suspending, and sweetening. A method of using the aqueous based pharmaceutical composition is also disclosed which includes the steps of expectorating, gargling, obtaining, pouring, receiving, and swishing.

Priority:

Inventor: EIREW GARY H [US]


Application No.: US20090035257A1  Published: 05/Feb/2009

Title: Devices, compositions and methods for the protection and repair of cells and tissues

Applicant/Assignee: REPAIR TECHNOLOGIES, INC

Application No.: 11/990799   Filing Date: 25/Aug/2006

Abstract:The present invention relates to compositions that reduce the extent of cellular and tissue damage in response to injury or disease. Methods of using the compositions to repair reperfusion injury, and structural tissue damage due to trauma, disease or aging are provided. Also provided are methods of using the compositions to reduce damage to transplanted tissue and organs. The compositions may also be used in oncology applications.

Priority: US20050711885P Applic. Date: 2005-08-25; WO2006US33279 Applic. Date: 2006-08-25

Inventor: MOSELEY ANNEMARIE B [US]; SLAUTER RICHARD [US]; LUCERO-RAJARAM TAMARA [US]


Application No.: US20090035354A1  Published: 05/Feb/2009

Title: Device and Method for Treating the Anal Sphincter

Applicant/Assignee: MOR RESEARCH APPLICATIONS LTD

Application No.: 12/087246   Filing Date: 14/Dec/2006

Abstract:A rectally insertable device for localized drug delivery to the anal sphincter of a subject, a method of using the device and the use of the device is disclosed. The device comprises a shell for containing an active pharmaceutical ingredient, the shell being substantially impermeable to the active pharmaceutical ingredient wherein a lower portion of the shell is configured to release the active pharmaceutical ingredient from the shell and wherein when the device is inserted into the rectum of the subject, the lower portion of the shell is proximal to the anal sphincter, such that the active pharmaceutical ingredient is released proximal to the anal sphincter.

Priority: US20050754612P Applic. Date: 2005-12-30; WO2006IL01446 Applic. Date: 2006-12-14

Inventor: BARAK NIR [IL]


Application No.: US20090035356A1  Published: 05/Feb/2009

Title: MODIFIED BIODEGRADABLE POLYMERS, PREPARATION AND USE THEREOF FOR MAKING BIOMATERIALS AND DRESSINGS

Applicant/Assignee:

Application No.: 12/065932   Filing Date: 05/Sep/2006

Abstract:The invention concerns a method for preparing a modified biodegradable polymer in aqueous medium comprising at least two steps. The first step is a reaction between an amino acid, a peptide or a polypeptide and maleic anhydride to form a compound having an unsaturated vinyl-carboxylic acid function. In the second reaction step, the unsaturated diacid obtained in the first step is reacted with a biodegradable polymer having at least one primary amine function, such as a fibrous protein or a glycosaminoglycan. The preferred polymer used is collagen or chitosan. The invention also concerns the modified biodegradable polymer obtained by the method. The invention further concerns a biomaterial or a dressing containing the modified biodegradable polymer having biocompatible, cytocompatible, hemostatic, bactericidal and wound healing properties, and its medical, biomedical, pharmaceutical or cosmetic use.

Priority: CA20052518298 Applic. Date: 2005-09-06; WO2006CA01468 Applic. Date: 2006-09-05

Inventor: BUI-KHAC TRUNG [CA]; ONG NGOC LANG [CA]


Application No.: US20090035359A1  Published: 05/Feb/2009

Title: IMMUNOGENIC FRAGMENTS OF T-CELL RECEPTOR CONSTANT DOMAINS AND PEPTIDES DERIVED THEREFROM

Applicant/Assignee:

Application No.: 12/067652   Filing Date: 21/Sep/2006

Abstract:The present invention is directed to an isolated T-Cell Receptor constant domain and to peptides derived therefrom and recombinant constructs encoding same, effective in therapy of T cell mediated inflammatory disease, autoimmunity and graft rejection. Therapeutic and prophylactic vaccine compositions and methods utilizing these proteins and peptides, DNA vaccines encoding same and T cell vaccines thereof are further provided.

Priority: US20050719342P Applic. Date: 2005-09-22; WO2006IL01112 Applic. Date: 2006-09-21

Inventor: COHEN IRUN R [IL]; QUINTANA FRANCISCO J [AR]


Application No.: US20090035369A1  Published: 05/Feb/2009

Title: Composition and Methods for Treating and Preventing Age-Related Macular Degeneration

Applicant/Assignee:

Application No.: 12/224376   Filing Date: 25/Feb/2007

Abstract:The present invention relates to methods and compositions effective in preventing, attenuating, inhibiting the progression of, and treating eye diseases, e.g., age-related macular degeneration (AMD). The compositions comprise, as an active ingredient, an effective amount of 3,3'-diindolylmethane (DIM) and/or its precursor indole-3-carbinol (I3C). The compositions can further comprise additional agents such as carotenoids and other phytochemicals, which produce a synergistic effect in preventing, attenuating, inhibiting the progression of, and treating AMD and other eye diseases such as glaucoma, cataracts and diabetic retinopathy (DR). The compositions are particularly effective in treating and preventing wet AMD, and in preventing or inhibiting the progression of dry AMD (non-neovascular) to wet AMD (neovascular).

Priority: IL20060173971 Applic. Date: 2006-02-27; WO2007IL00247 Applic. Date: 2007-02-25

Inventor: SELA YORAM [IL]


Application No.: US20090035370A1  Published: 05/Feb/2009

Title: DOSAGE FORM AND METHOD OF USE

Applicant/Assignee: DRUGTECH CORPORATION

Application No.: 12/183989   Filing Date: 31/Jul/2008

Abstract:A method for treating a medical condition for which quetiapine is indicated in a subject comprises comprising orally administering to the subject quetiapine or a pharmaceutically acceptable salt thereof in a daily dosage amount effective to treat said condition

wherein the quetiapine or salt thereof is administered in one to a plurality of dosage forms collectively comprising (a) a major quetiapine component in immediate-release form in a sedative effective amount, administered not earlier than about 3 hours prior to the start of a sleep period

and (b) either (i) a minor quetiapine component in extended-release, delayed extended-release or delayed pulsed-release form, wherein time of administration and release properties of the minor component provide substantial onset of release of quetiapine therefrom not earlier than about 6 hours after the start of the sleep period, or (ii) a plurality of minor quetiapine components in immediate-release form, administered sequentially during a waking period following the sleep period but not earlier than about 6 hours after the start of the sleep period

said minor component or components collectively being administered in an anxiolytic effective amount insufficient to cause an unacceptable degree of sedation. A dosage form suitable for use in such a method is also provided.

Priority: US20070953641P Applic. Date: 2007-08-02

Inventor: BORTZ JONATHAN DAVID [US]; GRIMSHAW MICHAEL NORMAN [US]


Application No.: US20090035373A1  Published: 05/Feb/2009

Title: PHARMACEUTICAL COMPOSITION FOR CONTRACEPTION AND BLOOD PRESSURE REGULATION, KIT FOR CONTRACEPTION CONTAINING SAME AND METHOD OF PRODUCTION OF SAME

Applicant/Assignee:

Application No.: 12/135470   Filing Date: 09/Jun/2008

Abstract:The pharmaceutical composition for contraception and regulating blood pressure includes daily dosage units, which contain 2.0 mg of dienogest and 0.030 mg of ethinyl estradiol, 2.0 mg of dienogest and 0.020 mg of ethinyl estradiol, or 1.5 mg of dienogest and 0.015 mg of ethinyl estradiol, together with at least one excipient and/or carrier. Each daily dosage unit may be a coated tablet for oral administration consisting of a tablet core and a coating around the core. The coating contains all of the ethinyl estradiol and a part of the dienogest, which are released in a non-retarded fashion. The tablet core contains another part of the dienogest that is released in a retarded fashion. The risk of folate deficiency-induced congenital malformations in the event of pregnancy may be reduced by including (6S)-5-methyltetrahydrofolate in each daily dosage unit. A kit for a 28-day cycle is also disclosed.

Priority: US20070952940P Applic. Date: 2007-07-31

Inventor: MITTMANN KATRIN [DE]; ZIMMERMANN THOMAS [DE]


Application No.: US20090035374A1  Published: 05/Feb/2009

Title: METHOD OF MAKING A SINGLE-STAGE PHARMACEUTICAL PREPARATION FOR ORAL THERAPY TO REGULATE BLOOD PRESSURE AND KIT CONTAINING SAME

Applicant/Assignee:

Application No.: 12/182220   Filing Date: 30/Jul/2008

Abstract:The single-stage oral contraceptive preparation contains at least 21 daily dosage units, which each contain a contraceptive combination of 2.0 mg of dienogest (not an aidosterone antognist) and 0.030 mg of ethinyl estradiol, of 2.0 mg of dienogest and 0.020 mg of ethinyl estradiol, of 2.0 mg of dienogest and 0.015 mg of ethinyl estradiol, or of 1.5 mg of dienogest and 0.015 mg of ethinyl estradiol, together with one or more pharmaceutically acceptable excipients and/or carriers, and at the most 7 daily dosage units containing a placebo or no active ingredients. The contraceptive preparation also regulates the blood pressure, raising low blood pressure and lowering mildly elevated blood pressure, during its administration for contraception. It is especially suitable for long-duration use as a contraceptive preparation without risk of negatively influencing the blood pressure.

Priority: US2008-135470 Applic. Date: 2008-06-09; US20070952940P Applic. Date: 2007-07-31

Inventor: MITTMANN KATRIN [DE]; ZIMMERMANN THOMAS [DE]


Application No.: US20090035393A1  Published: 05/Feb/2009

Title: FAST ACTING INHIBITOR OF GASTRIC ACID SECRETION

Applicant/Assignee:

Application No.: 12/086379   Filing Date: 25/Jan/2007

Abstract:The present invention relates to the use of pharmaceutically acceptable zinc salts, preferably water soluble zinc salts alone or optionally, in combination with one or more of a protein pump inhibitor (PPI), H2 blocker, anti-H. pylori antibiotic/antimicrobial, cytoprotective agent or a combination agent as otherwise described herein for providing fast action with optional long duration effect in reducing gastric acid secretion, raising the pH of the stomach during resting phase as well as decreasing the duration of stomach acid release during a secretagogue phase and for treating conditions including gastroesophageal reflux disease (GERD), non-erosive reflux disease (NERD), Zollinger-Ellison syndrome (ZE disease), ulcer disease, and gastric cancer, as well as preventing or reducing the likelihood of ulcer disease. In addition, the present methods are useful for treating patients who are non-responsive to proton pump inhibitors (PPI) and as an alternative to traditional therapies or conditions which are caused by rapid and complete inhibition of secretagogue induced acid secretion.

Priority: US20060762595P Applic. Date: 2006-01-27; US20060764834P Applic. Date: 2006-02-03; US20060850891P Applic. Date: 2006-10-11; WO2007US01950 Applic. Date: 2007-01-25

Inventor: GEIBEL JOHN P [US]; KIRCHHOFF PHILIPP [DE]


Application No.: US20090038612A1  Published: 12/Feb/2009

Title: MEDICAL PRODUCT CONTAINING TIOTROPIUM

Applicant/Assignee: BOEHRINGER INGELHEIM INTERNATIONAL GMBH

Application No.: 12/255030   Filing Date: 21/Oct/2008

Abstract:The invention discloses a medical product that may be used in a treatment of respiratory disorders.

Priority: SE20030003571 Applic. Date: 2003-12-22; SE20030003269 Applic. Date: 2003-12-03; US2004-921192 Applic. Date: 2004-08-19

Inventor: NILSSON THOMAS [SE]; MYRMAN MATTIAS [SE]; CALANDER SVEN [SE]; NIEMI ALF [SE]


Application No.: US20090041679A1  Published: 12/Feb/2009

Title: HUMAN NEUTRALIZING MONOCLONAL ANTIBODIES TO H5N1 INFLUENZA A VIRUS

Applicant/Assignee:

Application No.: 12/140151   Filing Date: 16/Jun/2008

Abstract:A panel of IgG1 human monoclonal antibodies (HMAbs) identified by hemagglutination inhibition (HI) assay has been produced from peripheral B cells of an individual immunized with prototype H5N1 vaccine. Sequence analysis of antibody clones showed three clusters of different HMAbs as represented by HMAbs designated as BF1-1, BF1-19 and BF1-10. BF1-1 and BF1-10 have distinct CDR 1, 2 and 3 regions of both heavy and light chains. BF1-19 has the same heavy chain as BF1-1 but the light chain of BF1-10. Antibody binding affinity, KD, studies showed all three HMAbs ranging from at least about 10-8 to at least about 10-9. In vivo protection studies showed that these antibodies afforded significant protection against infection. These findings demonstrate that the antibodies of the invention are cross-neutralizing and therapeutic.

Priority: US20070944381P Applic. Date: 2007-06-15

Inventor: FOUNG STEVEN [US]; KECK ZHEN-YONG [US]; WEBBY RICHARD [US]


Application No.: US20090041682A1  Published: 12/Feb/2009

Title: MEDICAL PRODUCT

Applicant/Assignee: BOEHRINGER INGELHEIM INTERNATIONAL GMBH

Application No.: 12/255086   Filing Date: 21/Oct/2008

Abstract:The invention discloses a medical product for use in a treatment of respiratory disorders, and comprises a metered dose of a tiotropium dry powder formulation, directly loaded and sealed into a container made to act as a dry high barrier seal to prevent the capture and ingress of moisture into the tiotropium powder. The dose of tiotropium is further adapted for inhalation and the container is so tight that the efficacy of the dose when delivered is unaffected by moisture. In a further aspect of the invention a type of inhaler is illustrated, which may accept at least one sealed, moisture-tight container of a dose of tiotropium, to deliver the dose with a consistent fine particle dose, over the expected shelf life of the product.

Priority: SE20030003269 Applic. Date: 2003-12-03; US2003-728986 Applic. Date: 2003-12-08

Inventor: NILSSON THOMAS [SE]; MYRMAN MATTIAS [SE]; CALANDER SVEN [SE]; NIEMI ALF [SE]


Application No.: US20090041779A1  Published: 12/Feb/2009

Title: Aldosterone induced elastin production

Applicant/Assignee:

Application No.: 12/157141   Filing Date: 06/Jun/2008

Abstract:Compositions and methods for inducing the deposition of elastin in skin by administering compositions including a mineralocorticoid, such as, for example, aldosterone and, optionally, a secondary active agent for enhancing or modulating the effect of the mineralocorticoid are described herein.

Priority: US20070942305P Applic. Date: 2007-06-06

Inventor: MITTS THOMAS F [US]; HINEK ALEKSANDER [CA]


Application No.: US20090041829A1  Published: 12/Feb/2009

Title: PHARMACEUTICAL DOSAGE FORMS COMPRISING A LIPID PHASE

Applicant/Assignee: GALENICA TECHNOLOGY AB

Application No.: 11/912783   Filing Date: 27/Apr/2006

Abstract:A tablet for oral administration comprises a lipid phase, comprised to 80% by weight or more by a mixture of (a) triglyceride, (b) mono- or/and diglyceride, and (c) cell membrane lipid

(d) one or more pharmacologically active agents dissolved or dispersed in the lipid phase

(e) water and/or ethanol

and (f) an absorption controlling amount of particulate pharmaceutical excipient. Also disclosed are granules, a suppository for rectal administration, and a capsule filled with the granules. Methods for preparing the tablet, the suppository and the granules are also disclosed as well as uses of the granules and a method for coating them.

Priority: SE20050000966 Applic. Date: 2005-04-28; WO2006SE50102 Applic. Date: 2006-04-27

Inventor: HERSLOF BENGT [SE]; HANSSON HENRI [SE]; TINGVALL PER [SE]


Application No.: US20090041842A1  Published: 12/Feb/2009

Title: Partly Neutralised Anionic (Meth) Acrylate Copolymer

Applicant/Assignee: ROEHM GMBH

Application No.: 11/815632   Filing Date: 15/Dec/2005

Abstract:The invention relates to a partly neutralised anionic (meth)acrylate copolymer consisting of radically polymerised units containing 25-95% by weight (meth)acrylic acid C1 to C4 alkylesters and 5-75% by weight (meth)acrylate monomer with an anionic group, wherein 0.1 to 25% contained anionic groups are neutralised by a base. Said invention is characterised in that said base is embodied in the form of an cationic organic base whose molecular weight is greater than 150. A medical form containing said partly neutralised anionic (meth)acrylate copolymer and the use of said partly neutralised anionic (meth)acrylate copolymer for producing a medical form rapidly releasing an active substance having a determined pH value are also disclosed.

Priority: DE200510007059 Applic. Date: 2005-02-15; WO2005EP13513 Applic. Date: 2005-12-15

Inventor: LIZIO ROSARIO [DE]; PETEREIT HANS-ULRICH [DE]; ROTH ERNA [DE]; DAMM MICHAEL [DE]; ALEXOWSKY RUEDIGER [DE]


Application No.: US20090042774A1  Published: 12/Feb/2009

Title: Parathyroid hormone analogues and methods of use

Applicant/Assignee:

Application No.: 11/799816   Filing Date: 02/May/2007

Abstract:The present invention is directed to novel methods of treating a subject with a bone deficit disorder. The methods generally include administering to a subject in need thereof a pharmaceutically acceptable formulation comprising a parathyroid hormone (PTH) peptide analogue in a daily dose sufficient to result in an effective pharmacokinetic profile and maintained adenylate cyclase activity, while simultaneously reducing undesirable side effects.

Priority: US2007-650918 Applic. Date: 2007-01-05; US2006-517146 Applic. Date: 2006-09-06; US20070925639P Applic. Date: 2007-04-20; US20050714905P Applic. Date: 2005-09-06; US20060834980P Applic. Date: 2006-07-31; US20060837972P Applic. Date: 2006-08-15

Inventor: MORLEY PAUL [CA]; STOGNIEW MARTIN [US]; MACDONALD BRIAN [US]; MERUTKA GENE SCOTT [US]; PALEPU NAGESH [US]


Application No.: US20090042825A1  Published: 12/Feb/2009

Title: Composition, method of preparation & application of concentrated formulations of condensed nucleic acids with a cationic lipopolymer

Applicant/Assignee:

Application No.: 11/890805   Filing Date: 06/Aug/2007

Abstract:Compositions, methods, and applications that increase the efficiency of nucleic acid transfection are provided. In one aspect, a pharmaceutical composition may include at least about 0.5 mg/ml concentration of a nucleic acid condensed with a cationic lipopolymer suspended in an isotonic solution, where the cationic lipopolymer includes a cationic polymer backbone having cholesterol and polyethylene glycol covalently attached thereto, and wherein the molar ratio of cholesterol to cationic polymer backbone is within a range of from about 0.1 to about 10, and the molar ratio of polyethylene glycol to cationic polymer backbone is within a range of from about 0.1 to about 10. The composition further may include a filler excipient.

Priority:

Inventor: MATAR MAJED [US]; FEWELL JASON [US]; LEWIS DANNY H [US]; ANWER KHURSHEED [US]


Application No.: US20090042829A1  Published: 12/Feb/2009

Title: Nucleic Acid-Lipopolymer Compositions

Applicant/Assignee:

Application No.: 12/186945   Filing Date: 06/Aug/2008

Abstract:Compositions, methods, and applications that increase the efficiency of nucleic acid transfection are provided. In one aspect, a pharmaceutical composition may include at least about 0.5 mg/ml concentration of a nucleic acid condensed with a cationic lipopolymer suspended in an isotonic solution, where the cationic lipopolymer includes a cationic polymer backbone having cholesterol and polyethylene glycol covalently attached thereto, and wherein the molar ratio of cholesterol to cationic polymer backbone is within a range of from about 0.1 to about 10, and the molar ratio of polyethylene glycol to cationic polymer backbone is within a range of from about 0.1 to about 10. The composition further may include a filler excipient.

Priority: US2007-890805 Applic. Date: 2007-08-06

Inventor: MATAR MAJED [US]; FEWELL JASON [US]; LEWIS DANNY H [US]; ANWER KHURSHEED [US]


Application No.: US20090042843A1  Published: 12/Feb/2009

Title: Inhalation Device Containing Plural Doses of a Pharmaceutical Composition

Applicant/Assignee: BOEHRINGER INGELHEIM INTERNATIONAL GMBH

Application No.: 11/912089   Filing Date: 28/Apr/2006

Abstract:The invention relates to an inhalation device comprising plural of doses of a pharmaceutical composition in powder form, wherein the pharmaceutical composition comprises one or more, preferably one, anticholinergic, optionally in combination with a pharmaceutically acceptable excipient.

Priority: EP20050009773 Applic. Date: 2005-05-04; EP20050105426 Applic. Date: 2005-06-21; WO2006EP61947 Applic. Date: 2006-04-28

Inventor: KLAES HEINZ-GERD [DE]


Application No.: US20090047330A1  Published: 19/Feb/2009

Title: Oral fast dissolving films for erectile dysfunction bioactive agents

Applicant/Assignee:

Application No.: 12/228702   Filing Date: 09/Oct/2008

Abstract:A novel edible polymer based film dosage form manufactured using natural, synthetic, semisynthetic, pharmaceutically acceptable polymers addressing the issues of swallowing difficulties (Dysphagia and Dynaphagia), of tablet or capsule dosage forms and handling and storage difficulties associated with liquid dosage forms, that also includes materials such as emulsifying agents, suspending agents, buffering agents, effervescence agents, colorants, flavorants, sweeteners and specified amounts of bioactive agents, for erectile dysfunction. A flexible film dosage form containing sildenafil citrate, tadalafil or Vardenafil is presented. The film system is enabled to be used in various applications such as oral, mucosal and external environments.

Priority: US20070965047P Applic. Date: 2007-08-17; US20070964950P Applic. Date: 2007-08-17; US20070965022P Applic. Date: 2007-08-17

Inventor: BANGALORE RAMESH [US]


Application No.: US20090047346A1  Published: 19/Feb/2009

Title: Sustained release formulations of sotalol

Applicant/Assignee:

Application No.: 12/231896   Filing Date: 05/Sep/2008

Abstract:Sustained release compositions of sotalol, or a pharmaceutically acceptable salt thereof, are provided. In certain examples, sotalol, or a pharmaceutically acceptable salt thereof, may be administered in an effective amount to provide a therapeutic effect to a patient, such as, for example, a patient suffering from a cardiac disorder. In some examples, sotalol combined with a sustained release system may be administered to provide a sustained release of sotalol for a desired period, e.g., at least about 24 hours.

Priority: US2005-134089 Applic. Date: 2005-05-20; US20040573367P Applic. Date: 2004-05-20

Inventor: SINGH BRAMAH N [US]


Application No.: US20090047350A1  Published: 19/Feb/2009

Title: Perforated water soluble polymer based edible films

Applicant/Assignee:

Application No.: 12/228703   Filing Date: 14/Aug/2008

Abstract:A novel edible polymer based film dosage form manufactured using natural, synthetic, semisynthetic, pharmaceutically acceptable polymers addressing the issues of swallowing difficulties (Dysphagia and Dynaphagia), of tablet or capsule dosage forms and handling and storage difficulties associated with liquid dosage forms, that also includes materials such as emulsifying agents, suspending agents, buffering agents, effervescence agents, colorants, flavorants, sweetners and specified amounts of bioactive agents preferably having perforations in the body of the dosage form enabling it to disperse/dissolve rapidly upon application by the subject. A flexible film dosage form to accommodate higher drug loads without compromising the fast dispersing/dissolving characteristics is presented. The perforated film system is enabled to be used in various applications such as oral, mucosal and external environments. The perforated film dosage form therefore, additionally allows the usage of polymers that would otherwise have not been used due to insolubility or limited solubility in water.

Priority: US20070965043P Applic. Date: 2007-08-17; US20070965023P Applic. Date: 2007-08-17

Inventor: BANGALORE RAMESH [US]


Application No.: US20090047351A1  Published: 19/Feb/2009

Title:

Applicant/Assignee:

Application No.: 11/815890   Filing Date: 06/Feb/2006

Abstract:A process for forming lactose suitable for use in a pharmaceutical formulation comprises providing a plurality of lactose particles containing no more than 10% w/w of lactose particles having a volume average particle size of about 70 microns or less

milling the plurality of lactose particles to yield a plurality of milled lactose particles with an average particle size, (D50), ranging from about 50 microns to about 100 microns

and classifying the plurality of milled lactose particles into at least two fractions comprising a fine fraction and a coarse fraction wherein the fine fraction has an average particle size, (D50), ranging from about 3 microns to about 50 microns, and the coarse fraction has an average particle size, (D50), ranging from about 40 microns to about 250 microns.

Priority: US20050651755P Applic. Date: 2005-02-10; WO2006US04032 Applic. Date: 2006-02-06

Inventor: NEWMAN STEPHEN [GB]


Application No.: US20090048175A1  Published: 19/Feb/2009

Title: AGONISTS OF GUANYLATE CYCLASE USEFUL FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS, INFLAMMATION, CANCER AND OTHER DISORDERS

Applicant/Assignee: SYNERGY PHARMACEUTICALS, INC

Application No.: 12/133344   Filing Date: 04/Jun/2008

Abstract:The invention provides novel guanylate cyclase-C agonist peptides and their use in the treatment of human diseases including gastrointestinal disorders, inflammation or cancer (e.g., a gastrointestinal cancer). The peptides can be administered either alone or in combination with an inhibitor of cGMP-dependent phosphodiesterase. The gastrointestinal disorder may be classified as either irritable bowel syndrome, constipation, or excessive acidity etc. The gastrointestinal disease may be classified as either inflammatory bowel disease or other GI condition, including Crohn's disease and ulcerative colitis, and cancer.

Priority: US20070933194P Applic. Date: 2007-06-04

Inventor: SHAILUBHAI KUNWAR [US]; JACOB GARY S [US]


Application No.: US20090048204A1  Published: 19/Feb/2009

Title: NOVEL FORMS OF CDDO METHYL ESTER

Applicant/Assignee: REATA PHARMACEUTICALS, INC

Application No.: 12/191176   Filing Date: 13/Aug/2008

Abstract:A triterpenoid compound, methyl 2-cyano-3,12-dioxoleana-1,9(11)-dien-28-oate (CDDO methyl ester), has a non-crystalline, glassy solid form and a non-hydrous crystalline form that can prepared, for example, from a saturated methanol solution. The glassy form displays an enhanced bioavailability over the non-hydrous crystalline form. Each form of CDDO methyl ester is a superior candidate for use, typically in solid dosage form, for treating a variety of disease states, generally associated with inflammation.

Priority: US20070955939P Applic. Date: 2007-08-15

Inventor: WALLING JOHN [US]; PARENT STEPHAN D [US]; JONAITIS DAVID T [US]; KRAL JR ROBERT M [US]


Application No.: US20090048316A1  Published: 19/Feb/2009

Title: Pharmaceutical composition comprising candesartan cilexetil

Applicant/Assignee:

Application No.: 12/075414   Filing Date: 10/Mar/2008

Abstract:The present invention encompasses pharmaceutical compositions comprising candesartan cilexetil, an amino acid and a pharmaceutically acceptable excipient, and processes for preparing the same.

Priority: US20070906150P Applic. Date: 2007-03-08

Inventor: LEIBOVICI MINUTZA [IL]; KANARI ITAMAR [IL]; FOX MICHAEL [IL]


Application No.: US20090048317A1  Published: 19/Feb/2009

Title: Formulations of candesartan

Applicant/Assignee:

Application No.: 12/221365   Filing Date: 01/Aug/2008

Abstract:The present invention encompasses pharmaceutical compositions comprising candesartan and processes for preparing the same. In particular, a pharmaceutical composition comprising candesartan or a prodrug thereof or an analog thereof or a derivative thereof and at least one non-ionic surfactant, wherein the pharmaceutical composition has about 0.01% to about 10% of at least one non-ionic surfactant present in the total weight of the composition.

Priority: US20070963014P Applic. Date: 2007-08-01

Inventor: FOX MICHAEL [IL]; LEIBOVICI MINUTZA [IL]; KANARI ITAMAR [IL]


Application No.: US20090053147A1  Published: 26/Feb/2009

Title: Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules

Applicant/Assignee:

Application No.: 12/082389   Filing Date: 09/Apr/2008

Abstract:Compositions of modified cytokines and uses thereof generated using processes and systems for the high throughput directed evolution of peptides and proteins, particularly cytokines that act in complex biological settings, are provided. Also provided are modified cytokines formulated for oral delivery and uses thereof to treat diseases and conditions mediated by cytokines.

Priority: US2007-706088 Applic. Date: 2007-02-13; US2003-658834 Applic. Date: 2003-09-08; US20030457135P Applic. Date: 2003-03-21; US20020409898P Applic. Date: 2002-09-09

Inventor: GANTIER RENE [FR]; VEGA MANUEL [FR]; DRITTANTI LILA [FR]; GUYON THIERRY [FR]


Application No.: US20090053299A1  Published: 26/Feb/2009

Title: Methods for generating immune response using cationic-liposome-mediated nucleic acid delivery

Applicant/Assignee: GEORGETOWN UNIVERSITY

Application No.: 12/216715   Filing Date: 09/Jul/2008

Abstract:The present invention is in the fields of drug delivery, and specifically, cationic liposome-based vaccines. In embodiments, this invention provides methods of making ligand-targeted (e.g., antibody- or antibody fragment-targeted) liposomes useful for the delivery of molecules to induce immune responses against viral antigens or to treat or prevent viral diseases. The specificity of the delivery system is derived from the targeting ligands.

Priority: US20070929685P Applic. Date: 2007-07-09

Inventor: CHANG ESTHER H [US]; PIROLLO KATHLEEN F [US]


Application No.: US20090053304A1  Published: 26/Feb/2009

Title: Composition and method of producing a taste masking formulation of laxatives for bowel cleaning preparation prior to colonoscopy

Applicant/Assignee:

Application No.: 12/220296   Filing Date: 23/Jul/2008

Abstract:This invention relates to a solid taste masking formulation of laxatives which can be dispersed in water for oral use for bowel cleaning preparation prior to colonoscopy procedures. This invention also relates to the methods to produce the taste masking laxative formulations.

Priority: US20070957513P Applic. Date: 2007-08-23

Inventor: CHEN JINLING [US]; CHANG LAWRENCE THOMAS [US]


Application No.: US20090053306A1  Published: 26/Feb/2009

Title: Pharmaceutical Compositions of a 5-HT2A Serotonin Receptor Modulator Useful for the Treatment of Disorders Related Thereto

Applicant/Assignee:

Application No.: 11/992806   Filing Date: 28/Sep/2006

Abstract:The present invention relates to certain pharmaceutical compositions of a 5-HT2A serotonin receptor modulator and methods for preparing pharmaceutical composition related thereto. The pharmaceutical compositions are useful in the treatment of platelet aggregation, coronary artery disease, myocardial infarction, transient ischemic attack, angina, stroke, atrial fibrillation, reducing the risk of blood clot formation, asthma or symptoms thereof, agitation or a symptom, behavioral disorders, drug induced psychosis, excitative psychosis, Gilles de la Tourette's syndrome, manic disorder, organic or NOS psychosis, psychotic disorder, psychosis, acute schizophrenia, chronic schizophrenia, NOS schizophrenia and related disorders, sleep disorders, diabetic-related disorders, progressive multifocal leukoencephalopathy and the like.

Priority: US20050721783P Applic. Date: 2005-09-29; WO2006US38267 Applic. Date: 2006-09-28

Inventor: AGARWAL RAJESH K [US]; GULLAPALLI RAMPURNA PRASAD [US]; MARTIN MICHAEL [US]; MORGAN MICHAEL [US]; CHAPMAN DENNIS [US]; SPEER JOSEPH BELIER [US]; SHAN YUN [US]


Application No.: US20090053315A1  Published: 26/Feb/2009

Title: Thermo-Kinetic Mixing for Pharmaceutical Applications

Applicant/Assignee: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM

Application No.: 12/196154   Filing Date: 21/Aug/2008

Abstract:Compositions and methods for making a pharmaceutical dosage form include making a pharmaceutical composition that includes one or more active pharmaceutical ingredients (API) with one or more pharmaceutically acceptable excipients by thermokinetic compounding into a composite. Compositions and methods of preprocessing a composite comprising one or more APIs with one or more excipients include thermokinetic compounding, comprising thermokinetic processing the APIs with the excipients into a composite, wherein the composite can be further processed by conventional methods known in the art, such as hot melt extrusion, melt granulation, compression molding, tablet compression, capsule filling, film-coating, or injection molding.

Priority: US20070957044P Applic. Date: 2007-08-21; US20080050922P Applic. Date: 2008-05-06

Inventor: BROUGH CHRIS [US]; MCGINITY JAMES W [US]; MILLER DAVE A [US]; DINUNZIO JAMES C [US]; WILLIAMS ROBERT O [US]


Application No.: US20090053317A1  Published: 26/Feb/2009

Title: MICROPARTICULATE SYSTEMS FOR THE ORAL ADMINISTRATION OF BIOLOGICALLY ACTIVE SUBSTANCES

Applicant/Assignee:

Application No.: 12/158044   Filing Date: 22/Dec/2006

Abstract:The present invention relates to gastroresistant and enterosoluble microparticulate systems for the encapsulation of biologically active substances selected from: flavonoids, vitamins, antioxidants, immunostimulants, starchy and non-starchy polysaccharides, probiotics, prebiotics, intestinal trophism regulators, oligoelements, enzymes and bioactive peptides. Such microparticulate systems allow the administration of the aforementioned nutraceutic substances to animals such as porcines, bovines, caprines, ovines, equids, canids, felines, camelids, lagomorphs, rodents, fowl, and other mammals, including humans, fish and crustaceans, increasing the bioavailability.

Priority: IT2005MI02461 Applic. Date: 2005-12-22; WO2006IT00874 Applic. Date: 2006-12-22

Inventor: VIGO DANIELE [IT]; FAUSTINI MASSIMO [IT]; SCOCCA SARAH [IT]; MUNARI ELEONORA [IT]; TORRE MARIA LUISA [IT]; CONTE UBALDO [IT]; DE SIMONE FRANCESCO [IT]; AQUINO RITA PATRIZIA [IT]; LAURO MARIA ROSARIA [IT]


Application No.: US20090054383A1  Published: 26/Feb/2009

Title: Pharmaceutical compositions

Applicant/Assignee: ENDORECHERCHE, INC

Application No.: 12/221847   Filing Date: 07/Aug/2008

Abstract:Novel methods for treating or reducing the likelihood of acquiring symptoms or diseases due to the menopause, in postmenopausal women, particularly osteoporosis, vaginal atrophy and dryness, hypogonadism, diminished libido, skin atrophy, connective tissue disease, urinary incontinence, breast, endometrial, ovarian and uterine cancers, hot flashes, loss of muscle mass, insulin resistance, fatigue, loss of energy, aging, physical symptoms of menopause, in susceptible warm-blooded animals including humans involving administration of a sex steroid precursor are disclosed. Said method comprising novel ways of administering and dosing dehydroepiandrosterone (DHEA) in order to take advantage of positive androgenic effects in the vaginal layers lamina propia and/or the layer muscularis, without undesirably causing systemic estrogenic effects in order to avoid the risk of breast and uterine cancer. Pharmaceutical compositions for delivery of active ingredient(s) useful to the invention are also disclosed.

Priority: US20070964270P Applic. Date: 2007-08-10; US20070964673P Applic. Date: 2007-08-13

Inventor: LABRIE FERNAND [CA]


Application No.: US20090054503A1  Published: 26/Feb/2009

Title: COMPOSITION

Applicant/Assignee: SLOTERVAART PARTICIPATIES BV VERENIGING HET NEDERLANDS KANKER INSTITUUT

Application No.: 12/197432   Filing Date: 25/Aug/2008

Abstract:Pharmaceutical compositions and methods for the treatment of neoplastic disease and comprising the combination of a taxane, such as docetaxel, with a CYP3A4 inhibitor, such as ritonavir. Methods of treatment of neoplastic disease incorporating the administration of a taxane and the administration of a CYP3A4 inhibitor, either simultaneously or separately, are also included. Further, kits for carrying out the methods are included. Solid pharmaceutical taxane compositions for oral administration comprising a substantially amorphous taxane, a carrier and a surfactant are also included.

Priority: US20070957764P Applic. Date: 2007-08-24

Inventor: BEIJNEN JACOB HENDRIK [NL]; SCHELLENS JOHANNES HENRICUS MATTHIAS [NL]; MOES JOHANNES [NL]; NUIJEN BASTIAAN [NL]


Application No.: US20090054623A1  Published: 26/Feb/2009

Title: Lipo-Conjugation of Peptides

Applicant/Assignee: NEOSE TECHNOLOGIES, INC

Application No.: 11/792610   Filing Date: 19/Dec/2005

Abstract:The present invention provides peptide conjugates that are formed between a modified lipid and a glycosyl residue and/or an amino acid residue on a peptide. The modified lipid includes a modifying group and a lipid linking group. Exemplary lipid linking groups include myristoyl, palmitoyl, and isoprenyl moieties.

Priority: US20040637179P Applic. Date: 2004-12-17; WO2005US46198 Applic. Date: 2005-12-19

Inventor: DEFREES SHAWN [US]


Application No.: US20090060956A1  Published: 05/Mar/2009

Title: AGENT FOR REDUCING THE USEABLE CALORIE CONTENT OF FOOD AND FOR THERAPEUTIC REDUCTION OF WEIGHT, IN PARTICULAR FOR USE IN THE CASE OF ADIPOSITY (OBESITY)

Applicant/Assignee:

Application No.: 12/094648   Filing Date: 23/Nov/2006

Abstract:An agent for reducing the useable calorie content of food is described which contains a compound effecting the dehydrogenation of fructose to 5-keto-D-fructose. In addition, a combination agent is described which also contains a compound that converts glucose to fructose. These agents can be used in particular in the therapy of adiposity (obesity).

Priority: DE200510056170 Applic. Date: 2005-11-23; DE200510060767 Applic. Date: 2005-12-16; DE200510061330 Applic. Date: 2005-12-20; DE200510063194 Applic. Date: 2005-12-30; DE200610001016 Applic. Date: 2006-01-05; DE200610013623 Applic. Date: 2006-03-22; DE200610014420 Applic. Date: 2006-03-27; US20060757413P Applic. Date: 2006-01-10; US20060831173P Applic. Date: 2006-07-17; WO2006EP11231 Applic. Date: 2006-11-23

Inventor: WYROBNIK DANIEL HENRY [DE]; WYROBNIK ISAAC HARRY [DE]; SILCOFF ELLIAD RONEN [IL]


Application No.: US20090060970A1  Published: 05/Mar/2009

Title: Compositions and methods of administering paclitaxel with other drugs using medical devices

Applicant/Assignee:

Application No.: 11/548974   Filing Date: 12/Oct/2006

Abstract:Systems and compositions comprising paclitaxel and a second drug, such as rapamycin, analogs, derivatives, salts and esters thereof are disclosed, as well as methods of delivery wherein the drugs have effects that complement each other. Medical devices comprising supporting structures capable of including or supporting a pharmaceutically acceptable carrier or excipient, which carrier or excipient can contain one or more therapeutic agents or substances, with the carrier preferably including a coating on the surface thereof, and the coating including the therapeutic substances, such as, for example, drugs. Supporting structures for the medical devices that are suitable for use in this invention include coronary stents, peripheral stents, catheters, arterio-venous grafts, by-pass grafts, and drug delivery balloons used in the vasculature. These compositions and systems can be used in combination with other drugs, including anti-proliferative agents, anti-platelet agents, anti-inflammatory agents, anti-thrombotic agents, cytotoxic drugs, agents that inhibit cytokine or chemokine binding, cell de-differentiation inhibitors, anti-lipaedemic agents, matrix metalloproteinase inhibitors, cytostatic drugs, or combinations of these and other drugs.

Priority: US2002-235572 Applic. Date: 2002-09-06; US2001-950307 Applic. Date: 2001-09-10; US1999-433001 Applic. Date: 1999-11-02; US1998-159945 Applic. Date: 1998-09-24; US19970060105P Applic. Date: 1997-09-26; US20050727080P Applic. Date: 2005-10-14; US20050726878P Applic. Date: 2005-10-14; US20050732577P Applic. Date: 2005-10-17; US20050727196P Applic. Date: 2005-10-14

Inventor: TONER JOHN L [US]; BURKE SANDRA E [US]; CROMACK KEITH R [US]; MACK MATTHEW [US]


Application No.: US20090060988A1  Published: 05/Mar/2009

Title: Nell-1 enhanced bone mineralization

Applicant/Assignee:

Application No.: 11/977031   Filing Date: 22/Oct/2007

Abstract:The present invention provides Nell-1 genes and gene products and pharmaceutical compositions comprising the same that promote bone mineralization and osteoblast differentiation. The Nell-1 genes and gene products also represent targets for screening for modulators of bone mineralization and osteoblast differentiation. In addition, Nell-1-associated compounds and compositions can be used to increase bone density and facilitate repair of bone fractures.

Priority: US2006-392294 Applic. Date: 2006-03-28; US1999-412297 Applic. Date: 1999-10-05; US2005-527786 Applic. Date: 2005-09-28; WO2003US29281 Applic. Date: 2003-09-15; US20020410846P Applic. Date: 2002-09-13

Inventor: TING KANG [US]


Application No.: US20090060993A1  Published: 05/Mar/2009

Title: SOLID PHARMACEUTICAL COMPOSITION FOR ENHANCED DELIVERY OF COENZYME Q-10 AND UBIQUINONES

Applicant/Assignee:

Application No.: 11/849764   Filing Date: 04/Sep/2007

Abstract:The present invention describes a solid oral dosage form of ubiquinones (e.g., ubidecarenone, coenzyme Q-10, idebenone or mixture thereof), providing on contact with water or body fluids the regulated release of an "in situ" formed oil-in-water emulsion with ubiquinone incorporated in the oil phase. Described formulation demonstrates improved bioavailability.

Priority:

Inventor: SCHWARZ JOSEPH [US]; WEISSPAPIR MICHAEL [US]


Application No.: US20090062343A1  Published: 05/Mar/2009

Title: Polymorphic forms of 3-(4-amino-1-oxo-1, 3 dihydro-isoindol-2-yl)-piperidine-2,6-dione

Applicant/Assignee: CELGENE CORPORATION

Application No.: 12/220336   Filing Date: 23/Jul/2008

Abstract:Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione are disclosed. Compositions comprising the polymorphic forms, methods of making the polymorphic forms and methods of their use are also disclosed.

Priority: US2004-934863 Applic. Date: 2004-09-03; US20030499723P Applic. Date: 2003-09-04

Inventor: JAWORSKY MARKIAN S [US]; CHEN ROGER SHEN-CHU [US]; MULLER GEORGE W [US]


Application No.: US20090068125A1  Published: 12/Mar/2009

Title: TREATMENT FOR MUCOSITIS

Applicant/Assignee: HEPTAGEN LTD

Application No.: 11/814796   Filing Date: 25/Jan/2006

Abstract:This invention relates to a medicament for protecting human mucosal cells from chemotherapy or radiotherapy induced cell death using formulations comprising adenosine or adenosine analogues as a reversible inhibitor of epithelial cell proliferation. The invention also relates to formulations containing adenosine for the prevention of or reduction in mucositis symptoms.

Priority: GB20050001476 Applic. Date: 2005-01-25; WO2006GB00241 Applic. Date: 2006-01-25

Inventor: EDWARDS RICHARD MARK [GB]; CLEMENTS JOHN MARTIN [GB]


Application No.: US20090068165A1  Published: 12/Mar/2009

Title: Uniformly Conjugated Serine Hydrolases

Applicant/Assignee:

Application No.: 11/916483   Filing Date: 08/Jun/2006

Abstract:An organophosphate scavenger is provided, with extended residence time in the mammalian circulation, which can be used in preventive and therapeutic treatment of organophosphate poisoning. The scavenger is a uniformly pegylated serine hydrolase, in which a part of lysine residues were replaced with other residues by site-directed mutagenesis. One part of lysine residues in the hydrolase amino acid sequence is selected for the PEG-coupling, and the other part for the replacement, wherein the selection should ensure that the hydrolase surface shows at least one free amino acid for PEG coupling for all possible views obtained by rotating a 3-D model generated for the hydrolase.

Priority: IL20050169377 Applic. Date: 2005-06-23; WO2006IL00669 Applic. Date: 2006-06-08

Inventor: COHEN OFER [IL]; KRONMAN CHANOCH [IL]; VELAN BARUCH [IL]; SHAFFERMAN AVIGDOR [IL]


Application No.: US20090068174A1  Published: 12/Mar/2009

Title: THERAPEUTIC ALKALINE PROTEASE COMPOSITIONS AND USE IN FACILITATING THE TRANSPORT OF AGENTS ACROSS THE GASTROINTESTINAL MUCOSAL LINING

Applicant/Assignee: KANSAS UNIVERSITY MEDICAL CENTER RESEARCH INSTITUTE, INC

Application No.: 11/853880   Filing Date: 12/Sep/2007

Abstract:A method of treating an inflammatory condition involving TNF-alpha in a mammal by administering to a patient a composition with an effective amount of an isolated alkaline protease in an amount effective to inactive TNF-alpha. The invention also involves compositions, including pharmaceutical compositions containing an isolated alkaline protease in an amount effective to inactive TNF-alpha especially those from Aspergillus oryzae and/or serve as a transepithial carrier.

Priority:

Inventor: PARMELY MICHAEL J [US]; MEDHEKAR ROHIT [US]; COLLIER ANTHONY [US]


Application No.: US20090068190A1  Published: 12/Mar/2009

Title: ANTI-PROLIFERATIVE COMBINATIONS

Applicant/Assignee: DRUGTECH CORPORATION

Application No.: 12/199503   Filing Date: 27/Aug/2008

Abstract:Combinations of a polyunsaturated fatty acid and diindolylmethane and pharmaceutical composition containing such combinations. Further provided are combinations including a polyunsaturated fatty acid, diindolylmethane, and folic acid. Also provided are combinations including diindolylmethane and folic acid. Also provided is a method for increasing the number of normal cells and decreasing the number of aberrant cells in a subject having the steps of administering to the subject a combination comprising a polyunsaturated fatty acid and diindolylmethane.

Priority: US20070968695P Applic. Date: 2007-08-29

Inventor: BORTZ JONATHAN DAVID [US]


Application No.: US20090068255A1  Published: 12/Mar/2009

Title: USE OF MATRIX METALLOPROTEINASE INHIBITORS IN SKIN CARE

Applicant/Assignee:

Application No.: 12/112374   Filing Date: 30/Apr/2008

Abstract:The application of matrix metalloproteinase (MMP) inhibitors to the skin inhibits the degradation of proteins found in the skin including collagen, elastin, and other basement membrane and extracellular matrix protein. MMP inhibitors may be used in both cosmetic compositions and pharmaceutical compositions for application to skin. MMP inhibitors are formulated with a cosmetically suitable vehicle or pharmaceutically acceptable excipient for application to the skin as creams, lotions, ointments, solutions, face masks, etc. As cosmetics, the inventive MMP inhibitor compositions are applied to the skin to prevent or reduce the appearance of wrinkles, pigmentation changes, loss of elasticity, or other effects associated with aging or sun damage. As pharmaceuticals, the inventive MMP inhibitor compositions may also be applied to the skin to treat or prevent a skin disease (e.g., proliferative disease, inflammatory disease).

Priority: US20070914873P Applic. Date: 2007-04-30

Inventor: YU BETTY [US]; NASHAT AMIR [US]; ANDERSON DANIEL GRIFFITH [US]; PUERTA DAVID THOMAS [US]; ADAMS BENJAMIN [US]; CLARK SCOTT [US]; KIM YUSHAN [US]; SPENGLER ERIC GEORGE [US]; MCLAUGHLIN RONALD P [US]; BEDFORD SUSAN EILIDH [US]; LI ZHI [US]


Application No.: US20090068260A1  Published: 12/Mar/2009

Title: BETA-1-SELECTIVE ADRENOCEPTOR BLOCKING AGENT COMPOSITIONS AND METHODS FOR THEIR PREPARATION

Applicant/Assignee:

Application No.: 12/129535   Filing Date: 29/May/2008

Abstract:The present invention provides extended release pharmaceutical compositions of a beta blocker such as, but not limited to, metoprolol succinate as the active ingredient, optionally also comprising a diuretic such as but not limited to hydrochlorothiazide, and methods of preparing such extended release pharmaceutical compositions.

Priority: US2006-437192 Applic. Date: 2006-05-18; US20060776706P Applic. Date: 2006-02-24; US20070932207P Applic. Date: 2007-05-29

Inventor: GOLD TOMER [IL]; MOSHE BENNY [IL]; REINBERG RONNY [IL]


Application No.: US20090068261A1  Published: 12/Mar/2009

Title: ORAL RAPID RELEASE PHARMACEUTICAL FORMULATION FOR PYRIDYLMETHYLSULFINYL-BENZIMIDAZOLES

Applicant/Assignee:

Application No.: 12/298083   Filing Date: 23/Apr/2007

Abstract:The invention relates to solid oral pharmaceutical compositions in the form of pellets, mini-tablets, tablets, or capsules, comprising an optionally substituted 2-(pyridylmethylsulfinyl)-1H-benzimidazole, for example esomeprazole, and carrageenan, and optionally one or more excipients. Surprisingly, it has been found that these compositions are stable and rapidly release the active ingredient. The pellets or mini-tablets may be coated as such, or filled in capsules or pressed into tablets, with a polymer, which dissolves only at a pH value of 5 or higher, optionally over a stabilizing intermediate layer.

Priority: CH20060000673 Applic. Date: 2006-04-24; WO2007EP53942 Applic. Date: 2007-04-23

Inventor: REHER MARKUS [CH]; LUTOLF WALTER [CH]; SPITZ MARCO [DE]


Application No.: US20090068266A1  Published: 12/Mar/2009

Title: SIROLIMUS HAVING SPECIFIC PARTICLE SIZE AND PHARMACEUTICAL COMPOSITIONS THEREOF

Applicant/Assignee:

Application No.: 12/125225   Filing Date: 22/May/2008

Abstract:Sirolimus particles having d90 value of from about 2mu to about 10mu have been developed. Further, pharmaceutical composition comprising sirolimus particles having d90 value of from about 2mu to about 10mu have also been developed.

Priority: IN2007DE01922 Applic. Date: 2007-09-11

Inventor: RAHEJA PRAVEEN [IN]; KAUSHIK ATUL [IN]; GANDHI RAJESH [IN]; SINGH ROMI BARAT [IN]; MATHUR RAJEEV SHANKER [IN]


Application No.: US20090068267A1  Published: 12/Mar/2009

Title: Novel Pharmaceutical Compositions

Applicant/Assignee: COMBINO PHARM, S.L

Application No.: 12/205008   Filing Date: 05/Sep/2008

Abstract:The present invention relates to novel lamivudine/cyclodextrin complexes and processes for preparing said complexes. The present invention also relates to novel solid pharmaceutical compositions comprising lamivudine, wherein lamivudine is present in the form of said lamivudine/cyclodextrin complexes. The present invention further relates to processes for preparing said compositions.

Priority: US20070967612P Applic. Date: 2007-09-06

Inventor: LLORET PEREZ SERGIO [ES]; PUIGVERT COLOMER MARINA [ES]


Application No.: US20090074857A1  Published: 19/Mar/2009

Title: Glycerophospholipids for the improvement of cognitive functions

Applicant/Assignee: ENZYMOTEC LTD

Application No.: 12/215080   Filing Date: 24/Jun/2008

Abstract:Disclosed herein are alternative, enhanced, and cheaper methods of improving cognitive functions in a subject using a lipid composition conjugated with omega-3 and omega-6 fatty acids, with specific amounts and specific conjugation patterns of LA, linolenic acid (alpha-linolenic acid, gamma-linolenic acid) DHA and eicosapentaenoyl (EPA), e.g. utilizing different sources of lipids. Disclosed herein is a lipid preparation, said preparation comprising a phosphatidylserine moiety, and poly-unsaturated fatty acid (PUFA) acyl groups, particularly long-chain poly-unsaturated fatty acid (LC-PUFA) acyl groups such as omega-3 and/or omega-6 acyl groups, wherein said PUFA is covalently bound to said glycerophospholipid. Said lipid preparations are particularly useful in the treatment of mental and cognitive disorders, e.g. ADHD (attention deficit hyperactivity disorder) and Alzheimer's disease. The disclosed preparations present improved bioactivity, and are useful in the treatment of various cognitive and mental conditions and disorders, as well as for maintenance of normal functions of brain-related systems and processes.

Priority: IL20030158552 Applic. Date: 2003-10-22; US2006-414150 Applic. Date: 2006-04-28; US2004-994175 Applic. Date: 2004-11-19; WO2004IL00957 Applic. Date: 2004-10-21

Inventor: DROR GAI BEN [IL]; PLATT DORIT [IL]; FARKASH ORLY [IL]; ZUABI RASSAN [IL]; BAR-ON ZOHAR [IL]; SHULMAN AVIDOR [IL]; PELLED DORI [IL]; RICHTER YAEL [IL]


Application No.: US20090074862A1  Published: 19/Mar/2009

Title: LOW-DOSE DOXEPIN FORMULATIONS AND METHODS OF MAKING AND USING THE SAME

Applicant/Assignee:

Application No.: 12/101917   Filing Date: 11/Apr/2008

Abstract:The invention disclosed herein generally relates to low-dose oral doxepin pharmaceutical formulations and the use of these formulations to promote sleep.

Priority: US20070911806P Applic. Date: 2007-04-13

Inventor: SCHIOPPI LUIGI [US]; DORSEY BRIAN TALMADGE [US]; SKINNER MICHAEL [US]; CARTER JOHN [CA]; MANSBACH ROBERT [US]; JOCHELSON PHILIP [US]; ROGOWSKI ROBERTA L [US]; CASSEDAY CARA [US]; PERRY MEREDITH [US]; KNOX BRYAN [US]


Application No.: US20090074864A1  Published: 19/Mar/2009

Title: NOVEL ANTIMICROBIAL PEPTIDES WITH HEPARIN BINDING ACTIVITY

Applicant/Assignee: DERMAGEN AB

Application No.: 11/877394   Filing Date: 23/Oct/2007

Abstract:The invention relates to an antimicrobial peptide with heparin binding activity, being derived from endogenous mammalian proteins being substantially free from antimicrobial activity selected from the group consisting of laminin isoforms, complement factor C3, histidin rich glycoprotein and kininogen and having from 10 to 36 amino acid residues, wherein the antimicrobial peptide consists of at least four amino acid residues selected from the group consisting of K, R and H. The invention also relates to pharmaceutical compositions comprising said antimicrobial peptide and use of the antimicrobial peptide and/or antimicrobial/pharmaceutical composition.

Priority: SE20030001431 Applic. Date: 2003-05-19; US2004-557455 Applic. Date: 2004-05-19; WO2004SE00797 Applic. Date: 2004-05-19

Inventor: SCHMIDTCHEN ARTUR [SE]; MALMSTEN MARTIN [SE]


Application No.: US20090074865A1  Published: 19/Mar/2009

Title: Oral formulations of glycyl-2-methylprolyl-glutamate

Applicant/Assignee:

Application No.: 12/283684   Filing Date: 15/Sep/2008

Abstract:Oral formulations of G-2MePE including microemulsions, coarse emulsions, liquid crystals, tablets and encapsulated forms of G-2MePE have improved bioavailability than conventional aqueous formulations. In particular, microparticles, nanoparticles and microemulsions can exhibit great neuroprotective effects after oral administration. In a microemulsion formulation, G-2MePE can nearly completely inhibit cerebral infarction in an animal model of stroke even after the stroke had been initiated. Thus, improved oral formulations can be desirably used to treat a variety of neurodegenerative conditions with improved convenience and improved efficacy.

Priority: WO2007US06528 Applic. Date: 2007-03-14; US20060782148P Applic. Date: 2006-03-14

Inventor: WEN JINGYUAN [NZ]; THOMAS GREGORY BRIAN [AU]; BICKERDIKE MIKE JOHN [NZ]


Application No.: US20090081133A1  Published: 26/Mar/2009

Title: Mucoadhesive xyloglucan-containing formulations useful in medical devices and in pharmaceutical fromulations

Applicant/Assignee:

Application No.: 11/921286   Filing Date: 01/Jun/2006

Abstract:Mucoadhesive and controlled release formulations consisting of aqueous solutions containing 0.05% to 5% by weight of a natural purified polymer having xyloglucan structure and 10% to 70% by weight of glycerol. These formulations are suitable for the application on human mucous membranes, such as nasal, oral and vaginal mucous membranes, as moisturizing and softening agents or as pharmaceutical release system. Further objects of the invention are pharmaceutical formulations and medical devices suitable for the application to human mucous membranes, containing the mucoadhesive and controlled release formulations together with active ingredients and excipients.

Priority: IT2005BO00388 Applic. Date: 2005-06-06; WO2006EP05240 Applic. Date: 2006-06-01

Inventor: BOTTONI GIUSEPPE [IT]; MAFFEI PAOLA [IT]; SFORZINI ANNALISA [IT]; FEDERICI MASCIA [IT]; CARAMELLA CARLA [IT]; ROSSI SILVIA [IT]; CLAUDIO VISCOMI GIUSEPPE [IT]


Application No.: US20090081167A1  Published: 26/Mar/2009

Title: FOLIC ACID PRODUCING BIFIDOBATERIUM BACTERIAL STRAINS, FORMULATIONS AND USE THEREOF

Applicant/Assignee: ANDIRAL S.R.L

Application No.: 11/659058   Filing Date: 05/Aug/2004

Abstract:The present invention relates to folic acid-producing bacterial strains belonging to the genus Bifidobacterium, pharmaceutical, veterinary or food formulations containing them and the use thereof. In particular, the invention relates to new bacterial strains of human origin belonging to the genus Bifidobacterium, adolescentis species (2), the genus Bifidobacterium, breve species (1) and the genus Bifidobacterium, pseudocatenulatum species (2) deposited in the DSMZ collection center (Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH

Braunsweig, Germany), in accordance with the Treaty of Budapest, on 21 Jul. 2004.

Priority: WO2004IT00444 Applic. Date: 2004-08-05

Inventor: MOGNA GIOVANNI [IT]; STROZZI GIAN PAOLO [IT]


Application No.: US20090081204A1  Published: 26/Mar/2009

Title: SYNTHETIC IMMUNOGENIC BUT NON-AMYLOIDOGENIC PEPTIDES HOMOLOGOUS TO AMYLOID BETA FOR INDUCTION OF AN IMMUNE RESPONSE TO AMYLOID BETA AND AMYLOID DEPOSITS

Applicant/Assignee: NEW YORK UNIVERSITY

Application No.: 12/234456   Filing Date: 19/Sep/2008

Abstract:The present invention relates to synthetic immunogenic but non-amyloidogenic peptides homologous to amyloid beta which can be used alone or conjugated to an immunostimulatory molecule in an immunizing composition for inducing an immune response to amyloid beta peptides and amyloid deposits.

Priority: US2003-666423 Applic. Date: 2003-09-19; US2001-861847 Applic. Date: 2001-05-22; US20000205578P Applic. Date: 2000-05-22

Inventor: FRANGIONE BLAS [US]; WISNIEWSKI THOMAS [US]; SIGURDSSON EINAR M [US]


Application No.: US20090081289A1  Published: 26/Mar/2009

Title: PLANT AND A PROCESS FOR PRODUCTION OF TABLETS

Applicant/Assignee: NIRO A/S

Application No.: 12/158530   Filing Date: 17/Oct/2008

Abstract:The invention relates to a plant for production of tablets, a process for production of tablets and tablets as such. The plant comprises a mixing device producing a mixed liquid feed of active pharmaceutical ingredient and excipients. A spray dryer atomizes the mixed liquid feed and dried particles with a high flowability are produced. The dried particles are subsequently compressed to tablets in a tablet press. The invention possesses several advantages, including the possibility of using an auto mated rotary tablet press directly, thereby reducing the number of unit operations in the tablet production.

Priority: WO2005DK00829 Applic. Date: 2005-12-23

Inventor: MADSEN MICHELLE MILLING [DK]; SCHWARTZBACH HENRIK [DK]


Application No.: US20090081300A1  Published: 26/Mar/2009

Title: AGENT FOR USE IN THE CASE OF FRUCTOSE INTOLERANCE

Applicant/Assignee: PRO NATURA GESELLSCHAFT FUER GESUNDE ERNAEHRUNG MB

Application No.: 12/093822   Filing Date: 15/Nov/2006

Abstract:The present invention refers to an agent for use in the case of fructose intolerance and any form of impairment and affliction of health and well being which is caused by the administration of fructose or fructose containing foodstuffs or by the release of fructose in the digestive tract of humans or animals from other substances, such as e.g. sucrose. The agent according to the invention comprises 5-D-fructose dehydrogenase, optionally in combination with invertase and/or maltase and/or glucose isomerase, which enzyme or combination of enzymes is/are used in the medical field for the first time. Preferably the agent is in the form of a pharmaceutical composition which is useful for treatment of fructose intolerance.

Priority: DE200510055081 Applic. Date: 2005-11-16; DE200510056169 Applic. Date: 2005-11-23; DE200510060768 Applic. Date: 2005-12-16; DE200510060769 Applic. Date: 2005-12-16; DE200610000873 Applic. Date: 2006-01-04; DE200610000881 Applic. Date: 2006-01-04; DE200610001015 Applic. Date: 2006-01-05; DE200610012244 Applic. Date: 2006-03-15; DE200610013624 Applic. Date: 2006-03-22; DE200610014423 Applic. Date: 2006-03-27; US20060757414P Applic. Date: 2006-01-10; US20060757424P Applic. Date: 2006-01-10; US20060831050P Applic. Date: 2006-07-17; US20060831174P Applic. Date: 2006-07-17; WO2006IB03223 Applic. Date: 2006-11-15

Inventor: WYROBNIK DANIEL HENRY [DE]; WYROBNIK ISAAC HARRY [DE]; SILCOFF ELLIAD RONEN [IL]


Application No.: US20090082290A1  Published: 26/Mar/2009

Title: Intra-vascular kidney gene therapy with plasmid encoding BMP-7

Applicant/Assignee:

Application No.: 11/801798   Filing Date: 11/May/2007

Abstract:The present invention relates to recombinant vectors expressing the BMP-7 polypeptide in host cells and to pharmaceutical compositions comprising such recombinant vectors. The invention also encompasses methods for prevention and/or treatment of both acute and chronic renal failure in mammals, advantageously in humans, dogs and cats, by intra-vascular kidney administration of the recombinant vectors and pharmaceutical compositions of the invention.

Priority: US2006-599026 Applic. Date: 2006-11-14; US20050736452P Applic. Date: 2005-11-14

Inventor: FISHER LAURENT BERNARD [FR]


Application No.: US20090082316A1  Published: 26/Mar/2009

Title: Composition and Method Of Stabilized Sensitive Ingredient

Applicant/Assignee: THE PROCTER & GAMBLE COMPANY

Application No.: 12/235711   Filing Date: 23/Sep/2008

Abstract:The present invention comprises a method of achieving ingredient stabilization in a composition comprising the steps of: combining a pregelatinized starch with at least one sensitive ingredient

adsorbing said sensitive ingredient onto the pregelatinized starch

and wherein said sensitive ingredient is evenly distributed throughout said pregelatinized starch.

Priority: US20080042350P Applic. Date: 2008-04-04; US20070995019P Applic. Date: 2007-09-24

Inventor: CIMILUCA PAUL ALFRED [US]; ARNAL SONSOLES [VE]; ZAMBRANO JORGE [VE]


Application No.: US20090087478A1  Published: 02/Apr/2009

Title: Orally Deliverable and Anti-Toxin Antibodies and Methods for Making and Using Them

Applicant/Assignee: PROGENICS PHARMACEUTICALS (NEVADA), INC

Application No.: 11/794491   Filing Date: 22/Dec/2005

Abstract:The invention provides antibodies with superior therapeutic efficacy and related methods of engineering such antibodies to increase their stability and resistance to proteases, e.g., in the digestive tract. Protease cleavage motifs are identified and subsequently modified to reduce or eliminate cleavage at that site. Methods of employing these orally deliverable antibodies as therapeutic compositions, particularly against gastrointestinal pathogens are also provided herein. In one aspect, the invention provides combinations of monoclonal antibodies, e.g., "synthetic polyclonals," that work synergistically to neutralize bacterial toxins, particularly enteric bacterial toxins such as Clostridium difficile toxin A.

Priority: US20040639827P Applic. Date: 2004-12-27; WO2005US47100 Applic. Date: 2005-12-22

Inventor: HANSEN GENEVIEVE [US]; DEMAREST STEPHEN J [US]


Application No.: US20090087487A1  Published: 02/Apr/2009

Title: Paliperidone sustained release formulation

Applicant/Assignee:

Application No.: 12/229344   Filing Date: 21/Aug/2008

Abstract:The present invention provides sustained release dosage forms comprising Paliperidone and processes for preparing the same.

Priority: US20070935597P Applic. Date: 2007-08-21

Inventor: FOX MICHAEL [IL]; DI CAPUA SIMONA [IL]; REINBERG RONNY [IL]


Application No.: US20090087489A1  Published: 02/Apr/2009

Title: IMATINIB COMPOSITIONS

Applicant/Assignee:

Application No.: 12/238314   Filing Date: 25/Sep/2008

Abstract:The invention relates to a pharmaceutical composition, preferably a tablet, containing about 23-29% w/w imatinib and processes for its preparation.

Priority: US20070995321P Applic. Date: 2007-09-25; US20070995651P Applic. Date: 2007-09-26

Inventor: GERBER BELLA [IL]; DOANI ZVIKA [IL]


Application No.: US20090088370A1  Published: 02/Apr/2009

Title: Method for Improved Isolation of Recombinantly Produced Proteins

Applicant/Assignee: OCTAPHARMA AG

Application No.: 11/887677   Filing Date: 29/Mar/2006

Abstract:The present invention provides a method for increasing the yield of a protein produced by cultivating eukaryotic cells and adding an ionic substance to the culture medium prior to harvest of the protein. Suitable ionic substances are the salts of the Hofmeister series, amino acids and peptone.

Priority: EP20050102475 Applic. Date: 2005-03-29; WO2006EP61148 Applic. Date: 2006-03-29

Inventor: WINGE STEFAN [SE]


Application No.: US20090088408A1  Published: 02/Apr/2009

Title: PHARMACEUTICAL COMPOSITIONS ON ANTICHOLINERGICS, CORTICOSTEROIDS AND BETAMIMETICS

Applicant/Assignee:

Application No.: 12/201149   Filing Date: 29/Aug/2008

Abstract:The present invention relates to novel pharmaceutical compositions based on anticholinergics, corticosteroids and betamimetics, processes for preparing them and their use in the treatment of respiratory diseases.

Priority: DE20011030371 Applic. Date: 2001-06-23; US2005-267354 Applic. Date: 2005-11-04; US2002-173194 Applic. Date: 2002-06-17

Inventor: MEADE CHRISTOPHER J M [DE]; PAIRET MICHEL [DE]; PIEPER MICHAEL P [DE]


Application No.: US20090088415A1  Published: 02/Apr/2009

Title: Controlled release pharmaceutical compositions

Applicant/Assignee: PANACEA BIOTEC LTD

Application No.: 11/482185   Filing Date: 06/Jul/2006

Abstract:A non-disintegrating, non-eroding, non-bioadhesive and non-swelling oral controlled release pharmaceutical composition and process for preparation of such compositions is provided which comprises at least one high dose water soluble active ingredient, at least one diluent, at least one binder, and a polymer system comprising of at least one release controlling polymer wherein the composition formulated into a suitable dosage form maintains its geometric shape even after the drug has diffused from the dosage form and provides the concentrations of active ingredient above effective levels for extended periods of time, optionally with other pharmaceutically acceptable excipients. The compositions preferably comprise antibiotic(s) as active ingredient, more preferably Amoxicillin or its pharmaceutically acceptable salts, hydrates, polymorphs, esters, and derivatives thereof, most preferably amoxicillin sodium, either alone or in combination with other antibiotic(s). Also described are controlled release compositions which provide an initial burst release of approximately 20%-40% of the active ingredient within one hour for achieving blood levels equivalent to minimum inhibitory concentration, while maintaining these levels for an extended period of time.

Priority: IN2004DE00023 Applic. Date: 2004-01-06; IN2004DE00028 Applic. Date: 2004-01-06; WO2005IN00004 Applic. Date: 2005-01-05

Inventor: JAIN RAJESH [IN]; JINDAL KOUR CHAND [IN]; SINGH SUKHJEET [IN]


Application No.: US20090088465A1  Published: 02/Apr/2009

Title: Pharmaceutical Compositions of Amorphous Atorvastatin and Process for Preparing Same

Applicant/Assignee:

Application No.: 11/795438   Filing Date: 23/Nov/2005

Abstract:Solid pharmaceutical compositions containing atorvastatin are disclosed. The compositions include a solid dispersion of amorphous atorvastatin and one or more optional pharmaceutically acceptable excipients. The solid dispersion is prepared by mixing crystalline atorvastatin with a melt-processable polymer and an optional stabilizer at a temperature sufficiently high to soften or melt the polymer and to melt or dissolve the crystalline atorvastatin in the polymer, thereby forming a dispersion of amorphous atorvastatin.

Priority: US20040632559P Applic. Date: 2004-12-02; WO2005IB03661 Applic. Date: 2005-11-23

Inventor: DYAR STEPHEN CRAIG [US]; LODAYA MAYUR P [US]; MOLLAN JR MATTHEW J [US]; SHAH UMANG [US]; SUN HEI JEN [US]; TEWELDEMEDHIN ZERI [US]


Application No.: US20090092665A1  Published: 09/Apr/2009

Title: OPHTHALMIC COMPOSITIONS COMPRISING CALCINEURIN INHIBITORS OR mTOR INHIBITORS

Applicant/Assignee: LUX BIOSCIENCES, INC

Application No.: 12/247701   Filing Date: 08/Oct/2008

Abstract:The embodiments disclosed herein relate to ophthalmic compositions comprising calcineurin inhibitors or mTOR inhibitors, and more particularly to methods for treating an ocular disease and/or condition using the disclosed compositions. According to aspects illustrated herein, there is provided a pharmaceutical composition that includes a calcineurin inhibitor or an mTOR inhibitor

a first surfactant with an HLB index greater than about 10

and a second surfactant with an HLB index of greater than about 13, wherein an absolute difference between the HLB index of the first surfactant and the HLB index of the second surfactant is greater than about 3, and wherein the composition forms mixed micelles.

Priority: US20070997796P Applic. Date: 2007-10-08; US20070992205P Applic. Date: 2007-12-04; US20080038223P Applic. Date: 2008-03-20; US20080099420P Applic. Date: 2008-09-23

Inventor: MITRA ASHIM K [US]; VELAGALETI POONAM R [US]; NATESAN SUBRAMANIAN [IN]


Application No.: US20090092672A1  Published: 09/Apr/2009

Title: ORALLY DISINTEGRATING TABLET COMPOSITIONS OF LAMOTRIGINE

Applicant/Assignee:

Application No.: 12/166757   Filing Date: 02/Jul/2008

Abstract:The compositions of the present invention composition comprise a therapeutically effective amount of particles comprising lamotrigine, in combination with granules comprising a disintegrant, and a sugar alcohol and/or a saccharide. These compositions are useful in treating epilepsy and bipolar disorder, particularly for patients with dysphagia, and to improve compliance with bipolar patients.

Priority: US20070929536P Applic. Date: 2007-07-02

Inventor: VENKATESH GOPI M [US]; VYAS NEHAL H [US]; GOSSELIN MICHAEL [US]; LAI JIN-WANG [US]


Application No.: US20090093499A1  Published: 09/Apr/2009

Title: Pharmaceutical composition

Applicant/Assignee: LEK PHARMACEUTICALS D.D

Application No.: 12/158413   Filing Date: 18/Dec/2006

Abstract:A chemically stable formulation of (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl]-(3R, 5S)-3,5-dihydroxyhept-6-enoic acid or a pharmaceutically-acceptable salt thereof for oral use, such as tablets, capsules, powders, granules has been developed using the substances which stabilize against formation of degradation products: lactone and oxidation product.

Priority: SI20050000344 Applic. Date: 2005-12-20; WO2006EP12180 Applic. Date: 2006-12-18

Inventor: JAKLIC MIHA TOMAZ [SI]; NAVERSNIK KLEMEN [SI]


Application No.: US20090098167A1  Published: 16/Apr/2009

Title: PHL P 1 Allergen Derivative

Applicant/Assignee: BIOMAY AG ALLERGOPHARMA JOACHIM GANZER KG

Application No.: 12/299292   Filing Date: 03/May/2007

Abstract:Method for producing derivatives of wild-type protein allergen Phl p 1 with reduced allergenic activity compared to the wild-type allergen, comprising the following steps: providing wild-type protein allergen Phl p 1, fragmenting said wild-type protein allergen into at least three fragments, wherein at least one fragment of said at least three fragments comprises at least one T-cell epitope and said at least three fragments have a reduced allergenic activity or lack allergenic activity and rejoining said at least three fragments in an order differing from the order of the fragments in the wild-type allergen.

Priority: AT20060000755 Applic. Date: 2006-05-03; WO2007AT00208 Applic. Date: 2007-05-03

Inventor: BALL TANJA [AT]; LINHART BIRGIT [AT]; VALENT PETER [AT]; STOCKLINGER ANGELIKA [AT]; LUPINEK CHRISTIAN [AT]; THALHAMER JOSEF [AT]; VALENTA RUDOLF [AT]


Application No.: US20090099085A1  Published: 16/Apr/2009

Title: Amylin Derivatives

Applicant/Assignee: NOVO NORDISK A/S

Application No.: 12/282042   Filing Date: 15/Mar/2007

Abstract:The present invention relates to novel amylin derivatives having a protracted action profile, to pharmaceutical compositions comprising these derivatives and to the use of the derivatives for the treatment of diseases related to obesity, diabetes and other metabolic disorders.

Priority: EP20060111172 Applic. Date: 2006-03-15; WO2007EP52456 Applic. Date: 2007-03-15

Inventor: HANSEN THOMAS KRUSE [DK]; SCHAFFER LAUGE [DK]; LAU JESPER [DK]


Application No.: US20090099109A1  Published: 16/Apr/2009

Title: INTERFERING RNAS AGAINST THE PROMOTER REGION OF P53

Applicant/Assignee:

Application No.: 12/035982   Filing Date: 22/Feb/2008

Abstract:The present invention relates to the inhibition of p53 transcription by interfering with the activity of a p53 promoter using inhibitory double-stranded RNAs. Use of these inhibitory RNAs in the treatment of cancers also is disclosed.

Priority: US20070891615P Applic. Date: 2007-02-26

Inventor: SHAMES DAVID S [US]; COREY DAVID R [US]; GREER RACHEL S [US]; MINNA JOHN D [US]


Application No.: US20090099148A1  Published: 16/Apr/2009

Title: COMBINATIONS COMPRISING ANTIMUSCARINIC AGENTS AND PDE4 INHIBITORS

Applicant/Assignee:

Application No.: 12/335849   Filing Date: 16/Dec/2008

Abstract:Combinations comprising (a) a PDE4 inhibitor and (b) an antagonist of M3 muscarinic receptors which is 3(R)-(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octane, in the form of a salt having an anion X, which is a pharmaceutically acceptable anion of a mono or polyvalent acid are useful, e.g., for the treatment of respiratory disease, e.g., asthma or chronic obstructive pulmonary diseases.

Priority: ES20040001312 Applic. Date: 2004-05-31; US2007-726982 Applic. Date: 2007-03-23; US2006-375308 Applic. Date: 2006-03-14; US2005-141169 Applic. Date: 2005-05-31

Inventor: GRAS ESCARDO JORDI [ES]; LLENAS CALVO JESUS [ES]; RYDER HAMISH [ES]; ORVIZ DIAZ PIO [ES]


Application No.: US20090099151A1  Published: 16/Apr/2009

Title: Modified Release Pharmaceutical Compositions and Processes Thereof

Applicant/Assignee: PANACEA BIOTEC LTD

Application No.: 11/922961   Filing Date: 29/Jun/2006

Abstract:Novel modified release pharmaceutical composition comprising at least one active agent(s)

a polymer system in an amount less than about 80% w/w of the composition comprising at least two swellable pH independent polymers wherein at least one is hydrophilic

optionally other pharmaceutically acceptable excipients is provided. Process for preparation of such compositions and methods of using them is also provided. The compositions are formulated into suitable dosage forms that provide therapeutic concentrations of active agent for extended periods of time.

Priority: IN2005DE01681 Applic. Date: 2005-06-29; WO2006IN00224 Applic. Date: 2006-06-29

Inventor: JAIN RAJESH [IN]; JINDAL KOUR CHAND [IN]; SINGH SUKHJEET [IN]; BOLDHANE SANJAY [IN]


Application No.: US20090099154A1  Published: 16/Apr/2009

Title: Pharmaceutical Sustained Release Compositions and Processes Thereof

Applicant/Assignee: PANACEA BIOTEC LTD

Application No.: 11/922960   Filing Date: 29/Jun/2006

Abstract:Pharmaceutical sustained release composition comprising at least one active agent(s), or its tautomeric forms, analogues, isomers, polymorphs, solvates, or salts thereof

preferably an antiviral active agent is provided. Also provided is a process of preparation of such composition and method of using them. The sustained release compositions of the present invention are able to deliver the active agent in a desired manner for an extended period of time.

Priority: IN2005DE01680 Applic. Date: 2005-06-29; WO2006IN00225 Applic. Date: 2006-06-29

Inventor: JAIN RAJESH [IN]; JINDAL KOUR CHAND [IN]; SINGH SUKHJEET [IN]; BOLDHANE SANJAY [IN]


Application No.: US20090104249A1  Published: 23/Apr/2009

Title: Exotoxin Inhibitory Factor

Applicant/Assignee: REGENTS OF THE UNIVERSITY OF MINNESOTA

Application No.: 11/995411   Filing Date: 23/Dec/2005

Abstract:The invention provides an exotoxin inhibitory factor, compositions containing the factor, methods of using the compositions.

Priority: US20040638958P Applic. Date: 2004-12-23; WO2005US46948 Applic. Date: 2005-12-23

Inventor: SCHLIEVERT PATRICK M [US]; PETERSON MARNIE L [US]


Application No.: US20090104251A1  Published: 23/Apr/2009

Title: HEAT STABLE MICROCAPSULES AND METHODS FOR MAKING AND USING THE SAME

Applicant/Assignee: SENSIENT FLAVORS INC

Application No.: 11/876247   Filing Date: 22/Oct/2007

Abstract:A method of manufacturing a microcapsule that may include complex coacervating a protein and a polyanionic polymer to form a coacervate, the coacervate being at least a portion of the microcapsule, and wherein a cross-linking reagent is not used during the coacervation.

Priority:

Inventor: LEE PHILLIP K [US]


Application No.: US20090104262A1  Published: 12/Jul/2007

Title: Chlorthalidone combinations

Applicant/Assignee:

Application No.: 11/329538   Filing Date: 11/Jan/2006

Abstract:The invention relates to favourable combinations of the thiazide diuretic chlorthalidone with Angiotensin II Receptor Blockers (ARBs) for the treatment of hypertension.

Priority: WO2004EP07634 Applic. Date: 2004-07-10; US20030487835P Applic. Date: 2003-07-16

Inventor: BRAND GERRIT [CA]; BAKRIS GEORGE L [US]; DAVIDAI GIORA [US]


Application No.: US20090104277A1  Published: 23/Apr/2009

Title: Preparation of Molecular Imprinted Polymers

Applicant/Assignee: MIPSALUS APS

Application No.: 12/279238   Filing Date: 21/Feb/2007

Abstract:One aspect is a method for improved preparation of molecular imprinted polymer (MIP) particles, where initial compositions comprising insoluble MIP particles are enriched for those MIP particles that bind a particular target molecule, thus excluding non-binding and weakly binding particles from the final composition. Enrichment is typically accomplished via use of chromatographic methods capable of separating particulate material or by means of agglutination. Another aspect is preparation of improved insoluble MIPs by use of extended micronization of raw MIP particles with a view to expose a large number of binding sites per mass unit of MIP particles. In preferred embodiments the two aspects are combined. The resulting improved MIPs may be used for diagnostic, analytical and therapeutic purposes, notably as orally administered drugs which can bind substances such as cholesterol and bile acids and bile acid salts in the gastrointestinal tract.

Priority: DK20060000248 Applic. Date: 2006-02-21; US20060743330P Applic. Date: 2006-02-21; WO2007DK00083 Applic. Date: 2007-02-21

Inventor: KRISTENSEN JESPER SVENNING [DK]; NIELSEN KLAUS GREGORIUS [DK]; KROGH NICOLAS OTTO [DK]


Application No.: US20090105265A1  Published: 23/Apr/2009

Title: Pharmaceutical Compositions of Combinations of Dipeptidyl Peptidase-4 Inhibitors With Metformin

Applicant/Assignee: MERCK & CO., INC

Application No.: 12/085722   Filing Date: 12/Dec/2006

Abstract:Disclosed are pharmaceutical compositions comprising fixed-dose combinations of a dipeptidyl peptidase-4 inhibitor and metformin, methods of preparing such pharmaceutical compositions, and methods of treating Type 2 diabetes with such pharmaceutical compositions.

Priority: US20050750954P Applic. Date: 2005-12-16; WO2006US47380 Applic. Date: 2006-12-12

Inventor: KAMALI ASHKAN [US]; ALANI LAMAN [US]; FLISZAR KYLE A [US]; GHOSH SOUMOJEET [US]; TIJERINA MONICA [US]


Application No.: US20090110722A1  Published: 30/Apr/2009

Title: Composition

Applicant/Assignee: BIAL- PORTELA & CA, S.A

Application No.: 12/257240   Filing Date: 23/Oct/2008

Abstract:A pharmaceutical composition comprising licarbazepine acetate, especially eslicarbazepine acetate, in combination with suitable excipients, in particular a binder, and a disintegrant. Also disclosed is a granulation process, especially a wet granulation process, for making the pharmaceutical composition.

Priority: US20070982790P Applic. Date: 2007-10-26

Inventor: CARDOSO DE VASCONCELOS TEOFILO [PT]; DOS SANTOS LIMA RICARDO JORGE [PT]; CERDEIRA DE CAMPOS COSTA RUI [PT]


Application No.: US20090110725A1  Published: 30/Apr/2009

Title: SOLID, ORODISPERSIBLE AND/OR DISPERSIBLE COMPOSITION, WITHOUT AN EXCIPIENT OF KNOWN EFFECT AND ITS PROCESS OF PREPARATION

Applicant/Assignee: GALENIX INNOVATIONS

Application No.: 12/201078   Filing Date: 29/Aug/2008

Abstract:The present invention relates to a solid, orodispersible and/or dispersible composition comprising (a) from 0.1 to 59% by weight of at least one active substance with particle size not exceeding 50 mum

(b) from 40 to 99% by weight of at least one diluent without known effect, non water-soluble

(c) from 0.1 to 15% by weight of at least one disintegrating agent

and (d) from 0.05 to 10% by weight at least of one sweetening agent with particle size not exceeding 50 mum, percentages by weight being expressed compared to the total weight of the aforementioned composition. The present invention also relates to the use of said composition as a drug, a food supplement or in cosmetics and a method of preparation of an orodispersible and/or dispersible compound implementing said composition.

Priority: FR20070057295 Applic. Date: 2007-08-31; US20070973216P Applic. Date: 2007-09-18

Inventor: BESSE JEROME [FR]; BESSE LAURENCE [FR]; POURNIN JULIEN [FR]


Application No.: US20090111749A1  Published: 30/Apr/2009

Title: Delivery of Active Agents

Applicant/Assignee:

Application No.: 12/258341   Filing Date: 24/Oct/2008

Abstract:A method of introducing a physiologically-active agent into the circulatory system of a mammal is disclosed herein. The method utilizes a rapid drug delivery system which prevents deactivation or degradation of the active agent being administered to a patient in need of treatment. In particular, the drug delivery system is designed for pulmonary drug delivery such as by inhalation, for delivery of the active agents such as proteins and peptides to the pulmonary circulation in a therapeutically effective manner avoiding degradation of the active agents in peripheral and vascular tissue before reaching the target site.

Priority: US20070982368P Applic. Date: 2007-10-24; US20070985620P Applic. Date: 2007-11-05; US20080022274P Applic. Date: 2008-01-18; US20080033740P Applic. Date: 2008-03-04; US20080052127P Applic. Date: 2008-05-09; US20080094823P Applic. Date: 2008-09-05

Inventor: RICHARDSON PETER [US]; BAUGHMAN ROBERT A [US]; LEONE-BAY ANDREA [US]; COSTELLO DONALD [US]


Application No.: US20090111770A1  Published: 30/Apr/2009

Title: Pharmaceutical Composition Free From Dexpanthenol, Calcium Ions, and Phosphate and Use of Calcium Chelating Agent and Ophthalmologically Compatible Viscosity Regulator

Applicant/Assignee:

Application No.: 12/084803   Filing Date: 17/Nov/2006

Abstract:The invention relates to a pharmaceutical composition free from dexpanthenol, calcium ions and phosphate, comprising at least one calcium chelating agent and at least one opthalmologically compatible viscosity regulator and optionally one or more pharmaceutical excipients. The invention further relates to the use of a calcium chelating agent and an opthalmologically compatible viscosity regulator for the production of a phosphate-free pharmaceutical composition for the treatment and/or prevention of epithelial defects.

Priority: DE200510055275 Applic. Date: 2005-11-17; WO2006EP11053 Applic. Date: 2006-11-17

Inventor: HOLZER FRANK [DE]; GROSS DOROTHEA [DE]


Application No.: US20090111788A1  Published: 30/Apr/2009

Title: ANTIBIOTIC COMPOSITIONS OF MODIFIED RELEASE AND PROCESS OF PRODUCTION THEREOF

Applicant/Assignee:

Application No.: 12/294353   Filing Date: 07/Mar/2007

Abstract:Novel modified release pharmaceutical compositions wherein the composition comprises at least one antibiotic(s) preferably amoxicillin or its pharmaceutically acceptable salts, esters, polymorphs, isomers, prodrugs, solvates, hydrates, or derivatives thereof either alone or in combination with other antibiotic(s) as active ingredient, with at least one release modifying agent(s) for controlling the release of the beta lactam antibiotic optionally with one or more other pharmaceutically acceptable excipient(s) is provided, wherein the dosage form provides a release of not more than about 60% of the antibiotic in about 30 minutes and not less than about 70% of the antibiotic after 8 hours when subjected to in vitro dissolution study or when tested in vivo. Further, the compositions of the present invention which when tested in a group of healthy humans provide a mean peak plasma concentration (Cmax) after at least about 0.5 hour of administration of the dosage form. The present invention also provides process of preparing such dosage form and methods of using such dosage form.

Priority: IN2006DE00824 Applic. Date: 2006-03-24; WO2007IN00086 Applic. Date: 2007-03-07

Inventor: JAIN RAJESH [IN]; JINDAL KOUR CHAND [IN]; TALWAR MUNISH [IN]


Application No.: US20090117180A1  Published: 07/May/2009

Title: STABLE DIGESTIVE ENZYME COMPOSITIONS

Applicant/Assignee:

Application No.: 12/163530   Filing Date: 27/Jun/2008

Abstract:Compositions of the present invention, comprising at least one digestive enzyme (e.g., pancrelipase) are useful for treating or preventing disorders associated with digestive enzyme deficiencies. The compositions of the present invention can comprise a plurality of coated particles, each of which is comprised of a core coated with an enteric coating comprising at least one enteric polymer and 4-10% of at least one alkalinizing agent, or have moisture contents of about 9% or less or 3% or less, water activities of about 0.6 or less, or exhibit a loss of activity of no more than about 25%, about 20%, about 15% or about 10% after six months of accelerated stability testing and the titer level of a viral contaminant present in the pancreatin is at least about 1000 times less than the titer level of the viral contaminant present in a preparation from which the pancreatin is obtained.

Priority: US2008-034480 Applic. Date: 2008-02-20; US2008-034488 Applic. Date: 2008-02-20; US2008-034491 Applic. Date: 2008-02-20; WO2008IB00770 Applic. Date: 2008-02-20; US20070902091P Applic. Date: 2007-02-20; US20070902093P Applic. Date: 2007-02-20; US20070902092P Applic. Date: 2007-02-20

Inventor: ORTENZI GIOVANNI [IT]; MARCONI MARCO [IT]; MAPELLI LUIGI [IT]


Application No.: US20090117183A1  Published: 07/May/2009

Title: ORAL CONTRACEPTIVE CONTAINING A GESTAGEN AND AN ESTROGEN COMBINED WITH PHARMACEUTICALLY ACCEPTABLE AUXILIARY AGENTS AND/OR EXCIPIENTS, BUT NOT CONTAINING LACTOSE, AND METHOD OF MAKING SAME

Applicant/Assignee:

Application No.: 12/258737   Filing Date: 27/Oct/2008

Abstract:The method produces a lactose-free oral contraceptive composition containing a combination of a gestagen and an estrogen together with one or more pharmaceutically acceptable auxiliary agents and/or excipients. The contraceptive composition is a tablet, powder, or capsule that contains the gestagen and estrogen, filler material such as microcrystalline cellulose and a binder such as hydroxypropylcellulose, but no lactose. Preferably the gestagen is dienogest, chlormadinone acetate, or levonorgestrel and the estrogen is ethinylestradiol, 17beta-estradiol, or estradiol valerate. A method is provided for improving the prophylaxis of lactose intolerance in women taking oral contraceptives. The oral contraceptive preparations for a standard 28-day cycle or for long-term use contain at least 21 daily dose units of the gestagen and the estrogen in a low-dosage but without lactose and at most 7 daily dose units containing no active ingredient or a placebo.

Priority: US20070985443P Applic. Date: 2007-11-05

Inventor: FRICKE SABINE [DE]; PFEIFER MANUELA [DE]; CLAUSSEN CLAUS [DE]; LADWIG RALF [DE]; BUERGLEN BEATE [DE]


Application No.: US20090117184A1  Published: 07/May/2009

Title: Use of a gestagen in combination with an estrogen and one or more pharmaceutically acceptable auxiliary agents/excipients for lactose-free oral contraception

Applicant/Assignee:

Application No.: 12/258817   Filing Date: 27/Oct/2008

Abstract:Gestagens, preferably dienogest, chlormadinone acetate or levonorgestrel, in combination with estrogens, for example ethinylestradiol, 17beta-estradiol or estradiol valerate, and one or more pharmaceutically acceptable auxiliary agents/excipients provide lactose-free oral contraception. The possibility is provided of improving the prophylaxis for lactose intolerance concerning a possibly contributing factor and also in regard to the costly examinations for lactose intolerance. The invention is also suitable for long-term use.

Priority: US20070985443P Applic. Date: 2007-11-05

Inventor: FRICKE SABINE [DE]; PFEIFER MANUELA [DE]; CLAUSSEN CLAUS [DE]; LADWIG RALF [DE]; BUERGLEN BEATE [DE]


Application No.: US20090117197A1  Published: 07/May/2009

Title: COMPOSITIONS AND METHODS FOR AMELIORATING CACHEXIA

Applicant/Assignee: VICUS THERAPEUTICS LLC

Application No.: 12/257282   Filing Date: 23/Oct/2008

Abstract:The invention provides preparations, formulations, kits and other products of manufacture (e.g., blister packs) comprising combinations of beneficial ingredients that are serviceable as therapies for improving states and disease symptoms such as involving inflammation, excessive sympathoneural drive, cachexia, anorexia, and anorexia-cachexia, as well as stress or anxiety related thereto, and methods of making and using them. The invention provides compositions and therapies comprising use of a beta adrenergic antagonist (also called "beta blockers", e.g., propranolol) in combination with an anti-inflammatory agent, e.g., a nonsteroidal anti-inflammatory drug (NSAID), an angiotensin-converting enzyme (ACE) inhibitor, an angiotensin receptor blocker (ARB), an anabolic steroid, a natural oil or fatty acid or any combination thereof.

Priority: WO2006US10510 Applic. Date: 2006-03-21; US20050664225P Applic. Date: 2005-03-21

Inventor: BASCOMB NEWELL [US]; MAKI JOHN [US]; YOUNG FREDRIC [US]


Application No.: US20090117232A1  Published: 07/May/2009

Title: LIPOIC ACID PELLETS

Applicant/Assignee: EURAND PHARMACEUTICALS LIMITED LABORATORIO CHIMICO INTERNAZIONALE S.P.A

Application No.: 12/302260   Filing Date: 25/May/2007

Abstract:Lipoic acid pellets are described, obtained from inert cores externally coated with lipoic acid. The so obtained active cores are coated with a first layer of insulating polymeric material and then with a polymeric coat that is insoluble at the gastric pH. Pellet are then formulated pharmaceutically, for instance in jelly capsules or controlled release capsules or as oral suspensions, dispersible powders, sachets, etc.

Priority: IT2006MI01024 Applic. Date: 2006-05-25; WO2007EP55124 Applic. Date: 2007-05-25

Inventor: BOLTRI LUIGI [IT]; FABIANI FLAVIO [IT]; MAPELLI LUIGI [IT]; SALVI ANNIBALE [IT]; MAGRI PAOLO [CH]; NARDI ANTONIO [IT]; VILLANI FLAVIO [IT]


Application No.: US20090117658A1  Published: 07/May/2009

Title: Macrophage transfection method

Applicant/Assignee: GREENVILLE HOSPITAL SYSTEM

Application No.: 12/149097   Filing Date: 25/Apr/2008

Abstract:Described are a method and a composition for transfecting monocytes, as well as use of the same for therapeutic purposes. The composition is composed of a nucleic acid component, a lysosome evading component and a digestible particle that can be phagocytized. Preferably, the monocyte is a macrophage and the digestible particle is from a natural source, such as from a microbial source. More preferably, the digestible particle is a yeast cell wall particle such as zymosan. The composition itself, or cells pretreated with the composition, are useful in all gene medicine applications, such as gene therapy, gene vaccination, cancer treatment as well as immunomodulation and tissue repair.

Priority: US20070907977P Applic. Date: 2007-04-25; US20070924868P Applic. Date: 2007-06-04

Inventor: WAGNER THOMAS E [US]; SCHWAMBERGER GUNTER [AT]; YU XIANZHONG [US]


Application No.: US20090118174A1  Published: 07/May/2009

Title: Novel peptides and methods for the treatment of inflammatory disorders

Applicant/Assignee: AUCKLAND UNISERVICES LIMITED

Application No.: 11/911980   Filing Date: 19/Apr/2006

Abstract:Novel peptides, nucleic acids encoding them, and derivatives of the peptides are described. The peptides and nucleic acids are of use in modulating beta2 integrin function and in treating beta2 integrin-mediated inflammatory disorders.

Priority: AU20050901975 Applic. Date: 2005-04-19; WO2006NZ00080 Applic. Date: 2006-04-19

Inventor: KRISSANSEN GEOFFREY WAYNE [NZ]; KANWAR RUPINDER KAUR [NZ]


Application No.: US20090118202A1  Published: 07/May/2009

Title: COMPOSITIONS AND METHODS OF TREATING HYPERTENSION WITH TANNIN COMPLEXES

Applicant/Assignee: TEXAS TECH UNIVERSITY

Application No.: 12/263197   Filing Date: 31/Oct/2008

Abstract:The present invention includes methods and compositions to ameliorate one or more symptom of hypertension through the inhibitor of an AT1 receptor by transcriptional down regulation of an angiotensin II type 1 receptor. The composition includes an effective amount of one or more tannic acids disposed in a pharmaceutically acceptable carrier.

Priority: US20070984265P Applic. Date: 2007-10-31

Inventor: THEKKUMKARA THOMAS J [US]


Application No.: US20090118215A1  Published: 07/May/2009

Title: Bioresorbable Controlled-Release Composition

Applicant/Assignee: LIDDS AB

Application No.: 12/224942   Filing Date: 14/Mar/2007

Abstract:A novel method for the preparation of a highly densified and at least partly, preferably fully or almost fully hydrated ceramic for use in the preparation of a pharmaceutical composition notably for controlled-release of one or more therapeutically, prophylactically and/or diagnostically active substance. The method involves a concomitant step of hydrating and densifying a bioresorbable and hydratable ceramic such as calcium sulphate. The invention also relates to compositions comprising such a highly densified ceramic. The pharmaceutical composition is useful for targeted and controlled local prolonged release of active substances, e.g. anti-cancer agents, whereby the spectrum and severity of side effects are minimized due to an optimized local concentration-time profile.

Priority: DK20060000361 Applic. Date: 2006-03-14; WO2007EP02250 Applic. Date: 2007-03-14

Inventor: LENNERNAS HANS [SE]; AXEN NIKLAS [SE]


Application No.: US20090118331A1  Published: 07/May/2009

Title: Use of Lobeline Epimers in the Treatment of Central Nervous System Diseases, Pathologies, and Drug Abuse

Applicant/Assignee:

Application No.: 12/263458   Filing Date: 01/Nov/2008

Abstract:Methods of delivering or administering stabilized formulations or compositions having predetermined ratios, or range of ratios, of constituent epimers to an individual or a mammal for treatment of central nervous system diseases, pathologies, and drug abuse and compositions for stabilizing the compositions. In one embodiment, the predetermined ratios of constituent epimers, or range of ratios, are predetermined ratios of 2-[6S-(2S-hydroxy-2-phenyl-ethyl)-1-methyl-piperidin-2R-yl]-1-phenyl-ethanone (2R-lobeline) and its epimer, 2-[6S-(2S-hydroxy-2-phenyl-ethyl)-1-methyl-piperidin-2S-yl]-1-phenyl-ethanone (2S-lobeline). In embodiments, the stabilized formulations or compositions of 2R- and 2S-lobeline are provided in the ranges between 1 part 2R-lobeline to 10000 parts 2S-lobeline to 10000 parts 2R-lobeline to 1 part 2S-lobeline, or in the range of a 1 to 1 mixture of 2R- and 2S-lobeline, so that the predetermined epimeric ratio of 2R- and 2S-lobeline is delivered or administered to the blood, plasma or tissues of a patient so treated.

Priority: US20070985189P Applic. Date: 2007-11-02

Inventor: CROOKS PETER A [US]; DWOSKIN LINDA P [US]


Application No.: US20090123390A1  Published: 14/May/2009

Title: COMPOSITIONS FOR THE TREATMENT OF GASTROINTESTINAL INFLAMMATION

Applicant/Assignee: MERITAGE PHARMA, INC

Application No.: 12/269832   Filing Date: 12/Nov/2008

Abstract:Provided herein are methods for preventing or alleviating the symptoms of and inflammation associated with inflammatory diseases and conditions of the gastrointestinal tract, for example, those involving the esophagus. Also provided herein are pharmaceutical compositions useful for the methods of the present invention.

Priority: US20080035348P Applic. Date: 2008-03-10; US20080054103P Applic. Date: 2008-05-16; US20080054105P Applic. Date: 2008-05-16; US20070012012P Applic. Date: 2007-12-06; US20080054107P Applic. Date: 2008-05-16; US20070015998P Applic. Date: 2007-12-21; US20080019818P Applic. Date: 2008-01-08; US20080034941P Applic. Date: 2008-03-07; US20080054106P Applic. Date: 2008-05-16; US20080090658P Applic. Date: 2008-08-21; US20070987720P Applic. Date: 2007-11-13; US20080054104P Applic. Date: 2008-05-16

Inventor: HILL MALCOLM [US]


Application No.: US20090123541A1  Published: 14/May/2009

Title: Pharmaceutical Composition

Applicant/Assignee: SUN PHARMACEUTICAL INDUSTRIES LIMITED

Application No.: 11/884770   Filing Date: 22/Feb/2006

Abstract:The present invention relates to an oral controlled release pharmaceutical composition in the form of a unit dosage form comprising: (a) a highly soluble high dose active ingredient consisting essentially of therapeutically effective amount of levetiracetam or a pharmaceutically acceptable derivative thereof, and (b) a rate controlling means comprising a rate-controlling agent and/or a coating selected from (i) a active ingredient permeable coating surrounding the unit dosage form, and (ii) an active ingredient impermeable coating covering one or more surfaces but not all the surfaces of the unit dosage form, wherein the composition is in the form of a compact tablet and the levetiracetam or a pharmaceutically acceptable derivative thereof is present in an amount ranging from about 55% to about 90% by weight of the tablet.

Priority: IN2005MU00196 Applic. Date: 2005-02-22; WO2006IN00059 Applic. Date: 2006-02-22

Inventor: ZALA YASHORAJ RUPSINH [IN]; DHARMADHIKARI NITIN BHALACHANDRA [IN]


Application No.: US20090123545A1  Published: 14/May/2009

Title: Rapid Onset and Short Term Modafinil Compositions and Methods of Use Thereof

Applicant/Assignee:

Application No.: 11/988695   Filing Date: 21/Jul/2006

Abstract:Compositions are described that comprise a modafÊnil component that is a combination of the d- and l-enantiomers of modafinil and wherein the modafÊnil component is greater than 50% by weight d-modafÊnil for use in promoting or enhancing the state of wakefulness, alertness, and/or central nervous system stimulation in an individual.

Priority: US20050701281P Applic. Date: 2005-07-21; WO2006US28150 Applic. Date: 2006-07-21

Inventor: RON EYAL S [US]; FARBER NEAL M [US]; KATZMAN DANIEL E [US]; GAMZU ELKAN R [US]


Application No.: US20090123550A1  Published: 14/May/2009

Title: CORTICOSTEROID COMPOSITIONS

Applicant/Assignee: MERITAGE PHARMA, INC

Application No.: 12/269816   Filing Date: 12/Nov/2008

Abstract:Provided herein are methods for treating, preventing or alleviating the symptoms of and inflammation associated with inflammatory diseases and conditions of the gastrointestinal tract, for example, those involving the esophagus. Also provided herein are pharmaceutical compositions useful for the methods of the present invention.

Priority: US20080035348P Applic. Date: 2008-03-10; US20080054103P Applic. Date: 2008-05-16; US20080054105P Applic. Date: 2008-05-16; US20070012012P Applic. Date: 2007-12-06; US20080054107P Applic. Date: 2008-05-16; US20070015998P Applic. Date: 2007-12-21; US20080019818P Applic. Date: 2008-01-08; US20080034941P Applic. Date: 2008-03-07; US20080054106P Applic. Date: 2008-05-16; US20080090658P Applic. Date: 2008-08-21; US20070987720P Applic. Date: 2007-11-13; US20080054104P Applic. Date: 2008-05-16

Inventor: PHILLIPS ELAINE [US]; HILL MALCOLM [US]; LICALSI CYNTHIA [US]; DESHMUKH HEMANT [US]; JOHNSON KEITH [US]


Application No.: US20090123551A1  Published: 14/May/2009

Title: GASTROINTESTINAL DELIVERY SYSTEMS

Applicant/Assignee: MERITAGE PHARMA, INC

Application No.: 12/269821   Filing Date: 12/Nov/2008

Abstract:Provided herein are compositions suitable for the delivery of therapeutic agents to the gastrointestinal tract. Also provided herein are methods for treating, preventing or alleviating disorders of the gastrointestinal tract, for example, those involving the esophagus, by orally administering compositions described herein.

Priority: US20080054105P Applic. Date: 2008-05-16; US20070012012P Applic. Date: 2007-12-06; US20080054107P Applic. Date: 2008-05-16; US20070015998P Applic. Date: 2007-12-21; US20080019818P Applic. Date: 2008-01-08; US20080034941P Applic. Date: 2008-03-07; US20080054106P Applic. Date: 2008-05-16; US20080090658P Applic. Date: 2008-08-21; US20070987720P Applic. Date: 2007-11-13; US20080054104P Applic. Date: 2008-05-16

Inventor: PHILLIPS ELAINE [US]; HILL MALCOLM [US]


Application No.: US20090123562A1  Published: 14/May/2009

Title: Pharmaceutical Formulations of Gallium Salts

Applicant/Assignee: EMISPHERE TECHNOLOGIES, INC

Application No.: 11/722618   Filing Date: 29/Dec/2005

Abstract:The present invention relates to pharmaceutical formulations containing a pharmaceutically acceptable gallium salt (such as gallium nitrate), a delivery agent, and optionally, one or more chemotherapeutic agents and/or adjunctive chemotherapeutic agents.

Priority: US20040640739P Applic. Date: 2004-12-29; US20050677533P Applic. Date: 2005-05-03; WO2005US47603 Applic. Date: 2005-12-29

Inventor: BENDER LEWIS [US]; SHANKAR BAVANI [US]; O'SHAUGHNESSY CATHERINA [IE]


Application No.: US20090123974A1  Published: 14/May/2009

Title: Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules

Applicant/Assignee:

Application No.: 12/082365   Filing Date: 09/Apr/2008

Abstract:Compositions of modified cytokines and uses thereof generated using processes and systems for the high throughput directed evolution of peptides and proteins, particularly cytokines that act in complex biological settings, are provided. Also provided are modified cytokines formulated for oral delivery and uses thereof to treat diseases and conditions mediated by cytokines.

Priority: US2007-706088 Applic. Date: 2007-02-13; US2003-658834 Applic. Date: 2003-09-08; US20030457135P Applic. Date: 2003-03-21; US20020409898P Applic. Date: 2002-09-09

Inventor: GANTIER RENE [FR]; VEGA MANUEL [FR]; DRITTANTI LILA [FR]; GUYON THIERRY [FR]


Application No.: US20090124565A1  Published: 14/May/2009

Title: COMPOSITION COMPRISING AT LEAST ONE NUCLEOSIDIC MOIETY AS A THERAPEUTIC AGENT, AND CKC

Applicant/Assignee: NOVAGALI PHARMA SA

Application No.: 11/939840   Filing Date: 14/Nov/2007

Abstract:Composition comprising at least one nucleosidic moiety and cetalkonium chloride and pharmaceutical use thereof for prevention, treatment or relief of eye, lung, and/or respiratory tract conditions.

Priority:

Inventor: LAMBERT GREGORY [FR]; LALLEMAND FREDERIC [FR]


Application No.: US20090130192A1  Published: 21/May/2009

Title: CLASS III SLRP AGONISTS FOR THE REDUCTION OF BLOOD VESSEL FORMATION

Applicant/Assignee: THE UNIVERSITY OF MANCHESTER

Application No.: 12/101717   Filing Date: 11/Apr/2008

Abstract:The invention relates to the use of an agent that promotes class III SLRP activity in the manufacture of a medicament for the inhibition of blood vessel formation. In addition the invention relates to the use of an agent that promotes class III SLRP activity in the manufacture of a medicament for the prevention and/or treatment of conditions characterised by excessive activity and/or migration of monocytes and/or macrophages. Suitable agents may include class III SLRPs such as opticin. Methods of treatment using agents able to promote class III SLRP activity are also provided.

Priority: GB20030012292 Applic. Date: 2003-05-29; GB20040000547 Applic. Date: 2004-01-12; US2005-558606 Applic. Date: 2005-11-29; WO2004GB02269 Applic. Date: 2004-05-28

Inventor: BISHOP PAUL N [GB]


Application No.: US20090130205A1  Published: 13/Mar/2008

Title: Solid Pharmaceutical Composition Comprising Donepezil Hydrochloride

Applicant/Assignee: KRKA, TOVARNA ZDRAVIL D.D., NOVO MESTO

Application No.: 11/577414   Filing Date: 19/Oct/2005

Abstract:The invention relates to a solid pharmaceutical composition comprising donepezil hydrochloride hydrate and a process for its preparation. In particular it relates to a composition and a process wherein the donepezil hydrochloride retains its polymorphic form and is therefore highly stable against conversion into other polymorphic forms.

Priority: DE200410051055 Applic. Date: 2004-10-19; WO2005EP11249 Applic. Date: 2005-10-19

Inventor: VRBINC MIHA [SI]; KOTAR-JORDAN BERTA [SI]; ZUPET ROK [SI]; SMRKOLJ MATEJ J [SI]


Application No.: US20090130208A1  Published: 21/May/2009

Title: Modified release niacin formulations

Applicant/Assignee: CAPRICORN PHARMA INC

Application No.: 12/275634   Filing Date: 21/Nov/2008

Abstract:Modified release niacin formulations, methods for making the formulations, and methods of using the formulations.

Priority: US20070003997P Applic. Date: 2007-11-21

Inventor: CHERUKURI SUBRAMAN RAO [US]; MUTYALA REVANTH BABU [US]; RAVELLA VENKAT [IN]


Application No.: US20090130210A1  Published: 21/May/2009

Title: PHARMACEUTICAL COMPOSITIONS OF SIROLIMUS

Applicant/Assignee:

Application No.: 12/127130   Filing Date: 27/May/2008

Abstract:A pharmaceutical composition of sirolimus comprising an inert core and a sugar overcoat, wherein said sugar overcoat comprises sirolimus, a poloxamer other than poloxamer 188, microcrystalline cellulose and binder has been developed.

Priority: IN2007DE01920 Applic. Date: 2007-09-11; IN2008DE01147 Applic. Date: 2008-05-08

Inventor: RAHEJA PRAVEEN [IN]; KAUSHIK ATUL [IN]; GANDHI RAJESH [IN]; SINGH ROMI BARAT [IN]; MATHUR RAJEEV SHANKER [IN]


Application No.: US20090131318A1  Published: 21/May/2009

Title: Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules

Applicant/Assignee:

Application No.: 12/157150   Filing Date: 06/Jun/2008

Abstract:Compositions of modified cytokines and uses thereof generated using processes and systems for the high throughput directed evolution of peptides and proteins, particularly cytokines that act in complex biological settings, are provided. Also provided are modified cytokines formulated for oral delivery and uses thereof to treat diseases and conditions mediated by cytokines.

Priority: US2007-656921 Applic. Date: 2007-01-22; US2003-658834 Applic. Date: 2003-09-08; US20030457135P Applic. Date: 2003-03-21; US20020409898P Applic. Date: 2002-09-09

Inventor: GANTIER RENE [FR]; VEGA MANUEL [FR]; DRITTANTI LILA [FR]; GUYON THIERRY [FR]


Application No.: US20090131360A1  Published: 21/May/2009

Title: Tripartite RNAi constructs

Applicant/Assignee: RXI PHARMACEUTICALS, CORP

Application No.: 12/286896   Filing Date: 02/Oct/2008

Abstract:The present invention provides compositions and methods for inhibiting expression of a target gene in a cell. The process comprises introduction of double-stranded tripartite RNAi constructs into the cells and reducing the expression of the corresponding messenger RNA in the cells. The constructs, which may be packaged in or delivered as sequestered RNAi constructs, differ from the canonical siRNA in that they comprise a tripartite structure which follows the general formula of having (1) an RNAi core (either native or abbreviated), (2) one or more terminal moieties attached to the RNAi core and optionally (3) a linker between the RNAi core and the terminal moiety. Once packaged into sequestration vehicles, the constructs are activated for gene regulation by the application of certain forms of energy

Priority: US20070976855P Applic. Date: 2007-10-02; US20070976858P Applic. Date: 2007-10-02

Inventor: WOOLF TOD M [US]; PAVCO PAMELA A [US]; SALOMON WILLIAM [US]; SAMARSKY DMITRY [US]; USMAN NASSIM [US]; WAGNER RICK [US]


Application No.: US20090131383A1  Published: 21/May/2009

Title: Pharmaceutical compositions of a neuroactive steriod and methods of use thereof

Applicant/Assignee:

Application No.: 11/921889   Filing Date: 09/Jun/2006

Abstract:The present invention relates to pharmaceutical compositions of the neuroactive steroid 3alpha-hydroxy-3beta-methoxymethyl-21-(1'-imidazolyl)-5alpha-pregnan-20-one or a pharmaceutically-acceptable salt or solvate thereof, with properties desirable for use in treating mood disorders and the like. The pharmaceutical compositions provide sustained therapeutic plasma levels of 3alpha-hydroxy-3beta-methoxymethyl-21-(1'-imidazolyl)-5alpha-pregnan-20-one. The present invention also relates to methods of treating these disorders by administering the pharmaceutical compositions.

Priority: US20050688905P Applic. Date: 2005-06-09; WO2006EP05574 Applic. Date: 2006-06-09

Inventor: WOODWARD RICHARD M [US]


Application No.: US20090136445A1  Published: 28/May/2009

Title: SUSTAINED RELEASE EYE DROP FORMULATIONS

Applicant/Assignee:

Application No.: 12/236877   Filing Date: 24/Sep/2008

Abstract:This invention provides for biocompatible, biodegradable eye drop pharmaceutical formulations useful for the treatment of ocular indications. In particular, tocopherols and their esters of low water solubility, notably alpha-tocopheryl acetate, are exceptional vehicles for biocompatible, nonirritating topical eye drop formulations that provide sustained release of active agents.

Priority: US2007-826833 Applic. Date: 2007-07-18; US2005-236426 Applic. Date: 2005-09-27; US20050709665P Applic. Date: 2005-08-19; US20040614484P Applic. Date: 2004-10-01; US20060831991P Applic. Date: 2006-07-19

Inventor: WONG VERNON G [US]; WOOD LOUIS L [US]


Application No.: US20090137522A1  Published: 28/May/2009

Title: Pharmaceutical Composition on Basis of Reverse Transcriptase Inhibitor and Meldonium

Applicant/Assignee: LATVIAN INSTITUTE OF ORGANIC SYNTHESIS

Application No.: 11/990285   Filing Date: 08/Aug/2006

Abstract:Novel pharmaceutical compositions which contain one of the reverse transcriptase inhibitors, viz., Zidovudine, Lamivudine or Stavudine in clinically efficacious amount and Meldonium as well as pharmaceutically applicable excipients. It has been proved that inclusion of Meldonium in these pharmaceutical compositions essentially diminishes the cardio- and neuro-toxicity of the reverse transcriptase inhibitor.

Priority: LV20050000095 Applic. Date: 2005-08-15; WO2006LV00005 Applic. Date: 2006-08-08

Inventor: KLUSHA VIJA [LV]; ISAJEVS SERGEJS [LV]; PUPURE JOLANTA [LV]; RUMAKS JURIS [LV]; GORDJUSHINA VALENTINA [LV]; TAIVANS IMMANUELS [LV]; KALVINSH IVARS [LV]


Application No.: US20090137606A1  Published: 28/May/2009

Title: Chewable formulations

Applicant/Assignee:

Application No.: 12/291265   Filing Date: 06/Nov/2008

Abstract:The invention encompasses a solid dose pharmaceutical composition comprising a disagreeable-tasting drug and processes for preparation of the pharmaceutical composition. The pharmaceutical composition is designed not to be swallowed immediately.

Priority: US20070985836P Applic. Date: 2007-11-06

Inventor: COHEN RAKEFET [IL]


Application No.: US20090142303A1  Published: 04/Jun/2009

Title: METHODS AND COMPOSITIONS FOR DRIED CELLULAR FORMS

Applicant/Assignee:

Application No.: 12/063485   Filing Date: 11/Aug/2006

Abstract:Methods and compositions of spray drying cellular material are provided that allow preservation of the cellular material. In one aspect, the cellular material is spray dried with a quantity of excipient. In another aspect, the cellular material is spray dried using a cryoprotectant.

Priority: US20050707425P Applic. Date: 2005-08-11; US20060788133P Applic. Date: 2006-03-31; WO2006US31580 Applic. Date: 2006-08-11

Inventor: EDWARDS DAVID [US]; WONG YUN-LING [US]; PULLIAM BRIAN [US]; PARKER KEVIN KIT [US]; SHEEHY SEAN [US]


Application No.: US20090142392A1  Published: 04/Jun/2009

Title: Composition Comprising a NSAID and Paracetamol

Applicant/Assignee: RECKITT BENCKISER HEALTHCARE (UK) LIMITED

Application No.: 12/067507   Filing Date: 07/Sep/2006

Abstract:A process for producing a granular composition comprising a plurality of solidified melt granules including a non-steroidal anti-inflammatory drug (NSAID) and paracetamol (acetaminophen), the process comprising the steps of: (a) forming a melt mixture by mixing a molten NSAID free acid and paracetamol, optionally with one or more excipients

and (b) forming the melt mixture into solidified melt granules. The granules are useable in compositions for treating pain and/or inflammation and/or fever.

Priority: GB20050019350 Applic. Date: 2005-09-22; WO2006GB03297 Applic. Date: 2006-09-07

Inventor: SHERRY ROBERT [GB]


Application No.: US20090142395A1  Published: 04/Jun/2009

Title: DEFERASIROX PHARMACEUTICAL COMPOSITIONS

Applicant/Assignee:

Application No.: 12/274281   Filing Date: 19/Nov/2008

Abstract:The present invention provides a process of preparing a high-load formulation of deferasirox with a sufficiently high dissolution rate and good bioavailability, which reduces the effect of the active material's physical characteristics on the chemical and physical properties of the final product.

Priority: US20070003798P Applic. Date: 2007-11-19; US20080011949P Applic. Date: 2008-01-22

Inventor: ZADOK URI [IL]; GAL YARON [IL]; ZALIT ILAN [IL]


Application No.: US20090142398A1  Published: 04/Jun/2009

Title: NOVEL PHARMACEUTICAL COMPOSITIONS COMPRISING A DISINTEGRATION MATRIX

Applicant/Assignee: PHARMASCIENCE INC

Application No.: 12/273937   Filing Date: 19/Nov/2008

Abstract:The present invention relates to a stable pharmaceutical composition comprising a pharmaceutically active substance having poor water solubility dispersed in a pharmaceutically acceptable disintegration matrix, said disintegration matrix comprising at least one pharmaceutically acceptable disintegrant, a pharmaceutically acceptable basic agent provided in a molar ratio of basic agent to active substance of 1:1 to 10:1, a water-insoluble pharmaceutically acceptable diluent, optionally, if desired or necessary at least one pharmaceutically acceptable excipients and/or pharmaceutically acceptable adjuvants, and optionally a pharmaceutically acceptable surfactant or emulsifier. The present invention also provides a process to make such.

Priority: US20070003977P Applic. Date: 2007-11-21

Inventor: PHILIP MATHEW [CA]; TALWAR NARESH [CA]; PATEL RASIK [CA]; PATHAK VINAYAK [CA]


Application No.: US20090142443A1  Published: 04/Jun/2009

Title: MULTI-REGION CHEWING GUM WITH ACTIVES

Applicant/Assignee: CADBURY ADAMS USA LLC

Application No.: 12/277685   Filing Date: 25/Nov/2008

Abstract:Some embodiments of the present invention include multi-region chewing gum compositions containing at least one active in a solid candy composition and an elastomer region, specifically where the active is caffeine. Methods of masking off-tastes of active ingredients are provided. Further, methods of manufacturing a caffeinated solid candy center fill gum composition are provided. Methods of delivering a dosage of caffeine to a user of the gum composition are additionally provided.

Priority: US20070991015P Applic. Date: 2007-11-29

Inventor: ROBINSON MARY K [US]; SCHMITZ KRISTEN [US]


Application No.: US20090143283A1  Published: 04/Jun/2009

Title: Pituitary Adenylate Cyclase Activating Peptide (PACAP) Receptor (VPAC2) Agonists and Their Pharmacological Methods of Use

Applicant/Assignee: BAYER PHARMACEUTICALS CORPORATION

Application No.: 10/586124   Filing Date: 27/Jan/2005

Abstract:This invention provides novel peptides that function in vivo as agonists of the VPAC2 receptor. These insulin secretagogue polypeptides are shown to lower blood glucose in vivo more than controls upon glucose challenge. The polypeptides of this invention are also stable in formulation and have long half-lives. The peptides of the present invention provide a new therapy for patients with decreased endogenous insulin secretion, in particular type 2 diabetics. In particular, the invention is a polypeptide selected from a specific group of VPAC2-related polypeptides, or functional equivalents thereof. The invention is also directed to a method of treating a metabolic disease in a mammal comprising administering a therapeutically effective amount of the insulin secretagogue peptides to said mammal. Also disclosed are methods of making the peptides, both recombinant and synthetic.

Priority: US20040539550P Applic. Date: 2004-01-27; US20040566499P Applic. Date: 2004-04-29; WO2005US02609 Applic. Date: 2005-01-27

Inventor: CLAIRMONT KEVIN [US]; LUMB KEVIN J [US]; BUCKHOLZ THOMAS [US]; SALHANICK ARTHUR I [US]


Application No.: US20090143292A1  Published: 04/Jun/2009

Title: Liquid Formulation of G-CSF Conjugate

Applicant/Assignee: NEOSE TECHNOLOGIES, INC BIOGENERIX AG

Application No.: 12/201705   Filing Date: 29/Aug/2008

Abstract:The present invention relates to a liquid pharmaceutical composition comprising a granulocyte colony stimulating factor polypeptide conjugated with a polymer. In various embodiments, the composition has a pH value in the range of 4.5 to 5.5. Exemplary compositions further comprise a surfactant and optionally one or more other pharmaceutically acceptable excipients. The invention provides, inter alia, formulations free from tartaric acid or salts thereof and/or from succinic acid and salts thereof as buffering agents. Exemplary formulations are essentially devoid of not amino acids as stabilizers. The composition has good storage stability and is especially useful for the prophylaxis and treatment of disorders and medical indications where granulocyte colony stimulating factor preparations are considered as useful remedies.

Priority: US20070968735P Applic. Date: 2007-08-29

Inventor: HINDERER WALTER [DE]; SCHECKERMANN CHRISTIAN [DE]


Application No.: US20090143343A1  Published: 04/Jun/2009

Title: COMPOSITIONS FOR THE TREATMENT OF INFLAMMATION OF THE GASTROINTESTINAL TRACT

Applicant/Assignee: MERITAGE PHARMA, INC

Application No.: 12/269740   Filing Date: 12/Nov/2008

Abstract:Provided herein are methods for treating the symptoms of and inflammation associated with gastroesophageal reflux disease (GERD) and other conditions. Also provided herein are pharmaceutical compositions useful for the methods of the present invention.

Priority: US20080035348P Applic. Date: 2008-03-10; US20080054103P Applic. Date: 2008-05-16; US20080054105P Applic. Date: 2008-05-16; US20070012012P Applic. Date: 2007-12-06; US20080054107P Applic. Date: 2008-05-16; US20070015998P Applic. Date: 2007-12-21; US20080019818P Applic. Date: 2008-01-08; US20080034941P Applic. Date: 2008-03-07; US20080054106P Applic. Date: 2008-05-16; US20080090658P Applic. Date: 2008-08-21; US20070987720P Applic. Date: 2007-11-13; US20080054104P Applic. Date: 2008-05-16

Inventor: HILL MALCOLM [US]


Application No.: US20090143360A1  Published: 04/Jun/2009

Title: Oxcarbazepine Formulation

Applicant/Assignee:

Application No.: 11/988433   Filing Date: 07/Jul/2006

Abstract:The present invention relates to novel uncoated, color-stable tablet formulations comprising oxcarbazepine, a disintegrant and iron oxide pigments. The oxcarbazepine of the present invention has a particle size of about 14 to about 30 microns with a maximum residue on a 40 micron sieve from about 10% to about 35%. The present invention further provides for a process of preparing the tablet formulations, and a method of treating mammals in need of oxcarbazepine with the novel formulation.

Priority: US20050697840P Applic. Date: 2005-07-08; WO2006US26311 Applic. Date: 2006-07-07

Inventor: SAFADI MUHAMMED [IL]; KATZIR ELLA [IL]; DINISMAN-ZAVULUNOV ELEONORA [IL]; ZISSMAN NATALY [IL]; BLUMBERG TAMAR [IL]


Application No.: US20090143362A1  Published: 04/Jun/2009

Title: CARBAMAZEPINE FORMULATIONS

Applicant/Assignee:

Application No.: 12/328027   Filing Date: 04/Dec/2008

Abstract:The present invention relates to a process for preparing a pharmaceutical composition comprising carbamazepine that has a constant release profile.

Priority: IN2007DE02543 Applic. Date: 2007-12-04

Inventor: BARABDE UMESH VINAYAKRAO [IN]; VERMA RAJAN KUMAR [IN]; RAGHUVANSHI RAJEEV SINGH [IN]


Application No.: US20090148437A1  Published: 11/Jun/2009

Title: POLYPEPTIDES, ANTIBODY VARIABLE DOMAINS & ANTAGONISTS

Applicant/Assignee:

Application No.: 12/323632   Filing Date: 26/Nov/2008

Abstract:The present invention relates to polypeptides e.g. protease resistant polypeptides, immunoglobulin (antibody) single variable domains e.g. which are protease resistant and also to vascular endothelial growth factor (VEGF) antagonists comprising these. The invention further relates to uses, formulations, and compositions comprising such polypeptides e.g. for delivery to the eye.

Priority: GB20070024331 Applic. Date: 2007-12-13; WO2008GB50399 Applic. Date: 2008-06-03; WO2008GB50400 Applic. Date: 2008-06-03; WO2008GB50403 Applic. Date: 2008-06-03; WO2008GB50404 Applic. Date: 2008-06-03; WO2008GB50405 Applic. Date: 2008-06-04; WO2008GB50406 Applic. Date: 2008-06-04; WO2008GB50407 Applic. Date: 2008-06-04; US20070933632P Applic. Date: 2007-06-06

Inventor: COOK FIONA [GB]; GOUGH GERALD [GB]; STEWARD MICHAEL [GB]; JESPERS LAURENT [GB]


Application No.: US20090148513A1  Published: 11/Jun/2009

Title: Compositions and methods for crystallizing antibodies

Applicant/Assignee:

Application No.: 12/228038   Filing Date: 08/Aug/2008

Abstract:The present invention relates to a batch crystallization method for crystallizing anti-human TNFalpha (hTNFalpha) antibody and antibody fragments which allows the production of said antibody on an industrial scale

a method of controlling the size of antibody crystals, for example, crystals of anti-hTNFalpha antibody fragments, compositions containing said crystals as well as methods of use of said crystals and compositions.

Priority: US20070963964P Applic. Date: 2007-08-08

Inventor: FRAUNHOFER WOLFGANG [US]; BORHANI DAVID W [US]; WINTER GERHARD [DE]; GOTTSCHALK STEFAN [DE]


Application No.: US20090148518A1  Published: 11/Jun/2009

Title: Pharmaceutical Formulations

Applicant/Assignee:

Application No.: 12/266896   Filing Date: 07/Nov/2008

Abstract:The present invention is directed to novel pharmaceutically acceptable polymeric compositions suitable for melt extrusion and injection moulding of single or multi-component pharmaceutical dosage forms comprising a plurality of drug substance containing sub-units, being capsule compartments and/or solid sub-units comprising a solid matrix of a polymer which contains a drug substance, the sub-units being connected together in the assembled dosage form.

Priority: US20070986383P Applic. Date: 2007-11-08

Inventor: BROWN ADRIAN [GB]; GORRINGE LEE J [GB]; MCALLISTER STEPHEN MARK [GB]; MATTHEWS WAYNE M [GB]; RUSSELL DANIELLE G R [GB]


Application No.: US20090149390A1  Published: 11/Jun/2009

Title: OXIDANT RESISTANT APOLIPOPROTEIN A-1 AND MIMETIC PEPTIDES

Applicant/Assignee: THE CLEVELAND CLINIC FOUNDATION

Application No.: 12/256822   Filing Date: 23/Oct/2008

Abstract:A purified polypeptide includes an ApoA1 mimetic or fragment thereof that are resistant to oxidation.

Priority: US20070981887P Applic. Date: 2007-10-23

Inventor: SMITH JONATHAN D [US]; HAZEN STANLEY L [US]


Application No.: US20090149497A1  Published: 11/Jun/2009

Title: POLYMORPHS OF FEXOFENADINE HYDROCHLORIDE

Applicant/Assignee: TEVA PHARMACEUTICALS USA, INC

Application No.: 12/207372   Filing Date: 09/Sep/2008

Abstract:The present invention provides novel crystal forms of fexofenadine hydrochloride Forms V, VI and VIII through XV and processes for their preparation and preparation of amorphous form and other crystalline forms of fexofenadine hydrochloride. Forms XIV and XV are solvates of ethyl acetate, while Form IX is anhydrous, but can be crystallized as a solvate of MTBE or cyclohexane. The forms are useful for administration to humans and animals to alleviate symptoms caused by histamine. The present invention further provides pharmaceutical compositions of the new crystalline forms.

Priority: US2002-118807 Applic. Date: 2002-04-08; US20010282521P Applic. Date: 2001-04-09; US20010307752P Applic. Date: 2001-07-25; US20010314396P Applic. Date: 2001-08-23; US20010336930P Applic. Date: 2001-11-08; US20010339041P Applic. Date: 2001-12-07; US20010344114P Applic. Date: 2001-12-28; US20020361780P Applic. Date: 2002-03-04; US20020363482P Applic. Date: 2002-03-11

Inventor: DOLITZKY BEN-ZION [IL]; WIZEL SHLOMIT [IL]; KROCHMAL BARNABA [IL]; DILLER DOV [IL]; GROSS IRWIN [IL]


Application No.: US20090149499A1  Published: 11/Jun/2009

Title: POLYMORPHIC FORMS OF 3-(4-AMINO-1-OXO-1,3 DIHYDRO-ISOINDOL-2-YL)-PIPERIDINE-2,6-DIONE)

Applicant/Assignee: CELGENE CORPORATION

Application No.: 12/335350   Filing Date: 15/Dec/2008

Abstract:Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione are disclosed. Compositions comprising the polymorphic forms, methods of making the polymorphic forms and methods of their use are also disclosed.

Priority: US2004-934863 Applic. Date: 2004-09-03; US20030499723P Applic. Date: 2003-09-04

Inventor: JAWORSKY MARKIAN S [US]; CHEN ROGER SHEN-CHU [US]; MULLER GEORGE W [US]; SAINDANE MANOHAR T [US]; CAMERON LOUISE M [US]


Application No.: US20090149500A1  Published: 11/Jun/2009

Title: POLYMORPHIC FORMS OF 3-(4-AMINO-1-OXO-1,3 DIHYDRO-ISOINDOL-2-YL)-PIPERIDINE-2,6-DIONE

Applicant/Assignee:

Application No.: 12/335395   Filing Date: 15/Dec/2008

Abstract:Polymorphic forms of 3-(amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione are disclosed. Compositions comprising the polymorphic forms, methods of making the polymorphic forms and methods of their use are also disclosed.

Priority: US2004-934863 Applic. Date: 2004-09-03; US20030499723P Applic. Date: 2003-09-04

Inventor: JAWORSKI MARKIAN S [US]; CHEN ROGER SHEN-CHU [US]; MULLER GEORGE W [US]; SAINDANE MANOHAR T [US]; CAMERON LOUISE M [US]


Application No.: US20090155358A1  Published: 18/Jun/2009

Title: PHARMACEUTICAL COMPOSITIONS OF SHORT-ACTING HYPNOTIC AGENTS IN MODIFIED-RELEASE FORMS AND THE PROCEDURES TO PREPARE THE MENTIONED FORMULATION

Applicant/Assignee: GADOR S.A

Application No.: 12/096700   Filing Date: 05/Dec/2006

Abstract:This application refers to a modified-release pharmaceutical composition containing, as the active agent, a short-acting hypnotic agent or a pharmaceutically acceptable salt thereof, comprising two sustained-release pharmaceutical entities, differentiated from each other by a different release rate of the active agent wherein the release of the active agent from one of the entities starts before the release of the active agent from the second entity.

Priority: AR2005P105132 Applic. Date: 2005-12-07; WO2006EP11636 Applic. Date: 2006-12-05

Inventor: DIAZ LILIANA ELISABETH [AR]; ANDRADE GUSTAVO ALEJANDRO [AR]


Application No.: US20090155360A1  Published: 18/Jun/2009

Title: ORALLY DISINTEGRATING TABLETS COMPRISING DIPHENHYDRAMINE

Applicant/Assignee:

Application No.: 12/331963   Filing Date: 10/Dec/2008

Abstract:The compositions of the present invention comprise a therapeutically effective amount of particles consisting of diphenhydramine or pharmaceutically acceptable salts thereof, optionally in combination with another drug such as pseudoephedrine, or phenylephrine and hydrocodone, in combination with rapidly-dispersing microgranules comprising a disintegrant and a sugar alcohol and/or a saccharide. These compositions are useful in treating the symptoms of one or more diseases or conditions in which diphenhydramine (alone or in combination with one or two other drugs) is a therapeutically effective, e.g. allergic rhinitis, sinusitis, upper respiratory tract infections, motion sickness, Parkinson's disease, insomnia, the common cold, and nighttime pain management, particularly for subjects or patients with dysphagia, and people 'on the move'.

Priority: US20070012531P Applic. Date: 2007-12-10

Inventor: VENKATESH GOPI M [US]; LAI JIN-WANG [US]; PERCEL PHILLIP [US]; KRAMER CRAIG [US]


Application No.: US20090155368A1  Published: 18/Jun/2009

Title: Pharmaceutical compositions

Applicant/Assignee: GENZYME CORPORATION

Application No.: 12/314554   Filing Date: 12/Dec/2008

Abstract:The present invention relates to crosslinked polyamine particles and/or pharmaceutical compositions comprising, at least in part, crosslinked polyamine particles and aggregates of such particles (including cured aggregates of crosslinked polyamine particles). The compositions may be in the form of tablets comprising, for example, particles larger than 500 mum, and used for treating patients, for example, patients with hyperphosphatemia.

Priority: US20070006019P Applic. Date: 2007-12-14

Inventor: HOLMES-FARLEY STEPHEN RANDALL [US]; HARRIS DAVID J [US]; POLOMOSCANIK STEVEN C [US]; SALAMEH ADNAN [US]; SHUTTS BRUCE [US]; SILVA RICHARD [US]; DHAL PRADEEP K [US]; SOLE LYNNE [US]


Application No.: US20090155369A1  Published: 18/Jun/2009

Title: PHARMACEUTICAL COMPOSITION CONTAINING LEVODOPA, ENTACAPONE AND CARBIDOPA

Applicant/Assignee: LABORATORIOS LESVI, S.L

Application No.: 12/112761   Filing Date: 30/Apr/2008

Abstract:The present invention refers to a solid pharmaceutical composition of entacapone, levodopa and carbidopa or pharmaceutically acceptable salts thereof characterized in that entacapone is in the form of granules and it is added separately to levodopa and carbidopa. In addition, this invention provides the process for its preparation.

Priority: EP20070380354 Applic. Date: 2007-12-13

Inventor: HUGUET RIBA MARTA [ES]; DIEZ MARTIN IGNACIO [ES]


Application No.: US20090155370A1  Published: 18/Jun/2009

Title: METHODS AND COMPOSITIONS FOR SELECTIVELY REMOVING POTASSIUM ION FROM THE GASTROINTESTINAL TRACT OF A MAMMAL

Applicant/Assignee: RELYPSA, INC

Application No.: 12/088625   Filing Date: 02/Oct/2006

Abstract:The present invention provides methods and compositions for the treatment of ion imbalances using core-shell composites and compositions comprising such core-shell composites. In particular, the invention provides core-shell particles and compositions comprising potassium binding polymers, and core-shell particles and compositions comprising sodium binding polymers, and in each case, pharmaceutical compositions thereof. Methods of use of the polymeric and pharmaceutical compositions for therapeutic and/or prophylactic benefits are also disclosed. The compositions and methods of the invention offer improved approaches for treatment of hyperkalemia and other indications related to potassium ion homeostasis, and for treatment of hypertension and other indicates related to sodium ion homeostasis.

Priority: US20050723073P Applic. Date: 2005-09-30; WO2006US38602 Applic. Date: 2006-10-02

Inventor: COPE MICHAEL J [US]; MANSKY PAUL [US]; LIU FUTIAN [US]; CHANG HAN-TING [US]; CHARMOT DOMINIQUE [US]; CONNOR ERIC [US]; BIYANI KALPESH [US]; LIU MINGJUN [US]; MONG TONY KWOK-KONG [CN]; CHEN YAN [US]


Application No.: US20090155375A1  Published: 18/Jun/2009

Title: Compositions comprising a lipid and copolymer of styrene and maleic acid

Applicant/Assignee:

Application No.: 11/921262   Filing Date: 31/May/2006

Abstract:A composition comprising a lipid and copolymer of styrene and maleic acid, wherein the copolymer of styrene and maleic acid is non-alternating, and wherein the polymer and lipid are in the form of macromolecular assemblies.

Priority: GB20050010968 Applic. Date: 2005-05-31; WO2006GB50134 Applic. Date: 2006-05-31

Inventor: TONGE STEPHEN [GB]


Application No.: US20090156549A1  Published: 18/Jun/2009

Title: MUCOSAL TREATMENT

Applicant/Assignee: NTNU TECHNOLOGY TRANSFER AS

Application No.: 12/089530   Filing Date: 06/Oct/2006

Abstract:The invention provides a method of treatment of a female human or non-human subject to enhance cervical mucus penetrability by spermatozoa, which method comprises vaginally applying to said subject an effective amount of a spermicide-free, physiologically tolerable oligouronate.

Priority: GB20050020375 Applic. Date: 2005-10-06; WO2006GB03732 Applic. Date: 2006-10-06

Inventor: TAYLOR CATHERINE [NO]; DRAGET KURT INGAR [NO]; SMIDSROD OLAV ASMUND [NO]


Application No.: US20090156631A1  Published: 18/Jun/2009

Title: Controlled Release Compositions Containing Zolpidem

Applicant/Assignee: WOCKHARDT LTD

Application No.: 11/991361   Filing Date: 15/Dec/2006

Abstract:The present invention relates to controlled release compositions of Zolpidem or pharmaceutically acceptable salts thereof adapted to release Zolpidem over a predetermined time period, according to a monophasic and/or a biphasic profile of dissolution. The present invention also relates to monolithic matrix based formulations of Zolpidem or pharmaceutically acceptable salts thereof.

Priority: IN2005MU01586 Applic. Date: 2005-12-16; IN2005MU01588 Applic. Date: 2005-12-16; IN2006MU00047 Applic. Date: 2006-01-12; WO2006IB03624 Applic. Date: 2006-12-15

Inventor: MANDAOGADE PRASHANT MANOHAR [IN]; JOSHI VENKATESH MADHAVACHARYA [IN]; JAIN GIRISH KUMAR [IN]


Application No.: US20090162366A1  Published: 25/Jun/2009

Title: HUMAN MONOCLONAL ANTIBODIES TO INFLUENZA M2 PROTEIN AND METHODS OF MAKING AND USING SAME

Applicant/Assignee: KIRIN PHARMA KABUSHIKI KAISHA

Application No.: 12/039632   Filing Date: 28/Feb/2008

Abstract:Human, humanized and chimeric monoclonal antibodies that bind to influenza M2 protein. The antibodies are useful for, among other things, treatment, diagnostics, purifying and isolating M2 or influenza virus, and identifying the presence of M2 or influenza virus in a sample or a subject.

Priority: WO2003US08147 Applic. Date: 2003-03-13; US2004-909851 Applic. Date: 2004-08-02; US2003-389221 Applic. Date: 2003-03-13; US20020364997P Applic. Date: 2002-03-13

Inventor: MIKAYAMA TOSHIFUMI [JP]; WANG RONGFANG [CN]; KATO SHINICHIRO [JP]


Application No.: US20090162413A1  Published: 25/Jun/2009

Title: COMPOSITIONS AND METHODS OF ADMINISTERING RAPAMYCIN ANALOGS WITH PACLITAXEL USING MEDICAL DEVICES

Applicant/Assignee: ABBOTT LABORATORIES

Application No.: 12/090253   Filing Date: 12/Oct/2006

Abstract:Systems and compositions comprising paclitaxel and a second drug, such as rapamycin, analogs, derivatives, salts and esters thereof are disclosed, as well as methods of delivery wherein the drugs have effects that complement each other. Medical devices comprising supporting structures capable of including or supporting a pharmaceutically acceptable carrier or excipient, which carrier or excipient can contain one or more therapeutic agents or substances, with the carrier preferably including a coating on the surface thereof, and the coating including the therapeutic substances, such as, for example, drugs. Supporting structures for the medical devices that are suitable for use in this invention include coronary stents, peripheral stents, catheters, arterio-venous grafts, by-pass grafts, and drug delivery balloons used in the vasculature. These compositions and systems can be used in combination with other drugs, including anti-proliferative agents, anti-platelet agents, anti-inflammatory agents, anti-thrombotic agents, cytotoxic drugs, agents that inhibit cytokine or chemokine binding, cell de-differentiation inhibitors, anti-lipaedemic agents, matrix metalloproteinase inhibitors, cytostatic drugs, or combinations of these and other drugs.

Priority: US2002-235572 Applic. Date: 2002-09-06; US2001-950307 Applic. Date: 2001-09-10; US1999-433001 Applic. Date: 1999-11-02; US1998-159945 Applic. Date: 1998-09-24; US2005-084172 Applic. Date: 2005-03-18; US20050726878P Applic. Date: 2005-10-14; US20050727196P Applic. Date: 2005-10-14; US20050727080P Applic. Date: 2005-10-14; US20050732577P Applic. Date: 2005-10-17; US20040554730P Applic. Date: 2004-03-19; WO2006US40027 Applic. Date: 2006-10-12

Inventor: BURKE SANDRA E [US]; CROMACK KEITH R [US]; MACK MATTHEW [US]; TONER JOHN L [US]


Application No.: US20090162428A1  Published: 25/Jun/2009

Title: Immediate disintegration polyvalent polymeric matrix for modified release solid oral preparations and method of preparation thereof

Applicant/Assignee: I.P.S. INTERNATIONAL PRODUCTS & SERVICES S.R.L

Application No.: 12/317427   Filing Date: 23/Dec/2008

Abstract:An immediate disintegrating polymeric matrix for oral administration with modified release is disclosed, obtained without using inert supports such as sugar spheres, comprising particles of active substance directly covered with a release regulating membrane. Use of such a matrix to prepare various administration forms for oral use as well as the method of its preparation are also disclosed.

Priority: IT2007MI02427 Applic. Date: 2007-12-24

Inventor: PASOTTI GINO [IT]; SPALLA ANDREA [IT]; DE ZANET EZIO [IT]


Application No.: US20090162429A1  Published: 25/Jun/2009

Title: Slow-Release Composition, Method for the Preparation Thereof, and Use Thereof

Applicant/Assignee:

Application No.: 12/085501   Filing Date: 23/Nov/2006

Abstract:The pharmaceutical or nutraceutical composition with sustained release of an active ingredient according to the present invention comprises at least one coated granule

the coated granule being composed of a particle that comprises said active ingredient and is coated with at least two coatings that comprise a combination of excipients. The present invention relates also to a process for the preparation of the composition.

Priority: FR20050012189 Applic. Date: 2005-12-01; WO2006FR02577 Applic. Date: 2006-11-23

Inventor: BERTHOUMIEU DIDIER [FR]; DUPINAY PIERRE [FR]; TRANNOY PHILIPPE [FR]


Application No.: US20090162444A1  Published: 25/Jun/2009

Title: RALOXIFENE COMPOSITION

Applicant/Assignee:

Application No.: 12/339975   Filing Date: 19/Dec/2008

Abstract:A pharmaceutical composition comprising raloxifene or a pharmaceutically acceptable salt thereof, a mixed cellulose excipient, and a disintegrant can be conveniently made.

Priority: US20070009027P Applic. Date: 2007-12-21

Inventor: JANSEN KORINDE ANNEMARIE [NL]


Application No.: US20090162483A1  Published: 25/Jun/2009

Title: SPORTS BEVERAGE AND METHOD OF MAKING

Applicant/Assignee:

Application No.: 12/337787   Filing Date: 18/Dec/2008

Abstract:Disclosed herein are sports beverage compositions in liquid drink form for optimizing muscle performance during exercise. The composition is formulated to contain an acid component and a flavor package that minimize off flavors and dry mouthfeel imparted by elevated levels of protein used in the beverage.

Priority: US20070015439P Applic. Date: 2007-12-20

Inventor: CONSTANTINE WENDY LYNN [US]; DIXON ALTALEE STACEY ANN [US]; KRAMER STEVEN [US]; VARHOL MARGARET WATKINS [US]


Application No.: US20090163521A1  Published: 25/Jun/2009

Title: Novel Pyrazolopyrimidinone Derivatives

Applicant/Assignee: ORCHID RESEARCH LABORATORIES LIMITED

Application No.: 11/921926   Filing Date: 28/Jun/2006

Abstract:The present invention relates to novel pyrazolopyrimidinones of the general formula (I), their derivatives, their analogs, their pharmaceutically acceptable salts and pharmaceutically acceptable compositions containing them. The present invention more particularly provides novel pyrazolopyrimidinones derivatives of the general formula (I).

Priority: IN2005CH00813 Applic. Date: 2005-06-28; WO2006IB01791 Applic. Date: 2006-06-28

Inventor: TADIPARTHI RAVIKUMAR [IN]; PUSHPAN SIMI [IN]; RAJAGOPAL SRIRAM [IN]; BARIK RAJIB [IN]


Application No.: US20090163528A1  Published: 25/Jun/2009

Title: Pharmaceutical composition having analgesic effects

Applicant/Assignee:

Application No.: 11/574413   Filing Date: 01/Sep/2005

Abstract:The pharmaceutical compositions having analgesic effect referred to in this invention are composed of the aconitine ingredients as the active medical ingredients and other acceptable auxiliary ingredients. The active medical ingredients shall at least include the fuziline compound of Formula (I). The drugs exert desirable analgesic effect with low toxicity. They can be made into commonly used oral preparations, injectable preparations and/or external preparations, including ointments, suppositories lotions, medicinal dressings, etc.

Priority: CN20041040598 Applic. Date: 2004-09-03; WO2005CN01384 Applic. Date: 2005-09-01

Inventor: WANG JIANSHENG [CN]


Application No.: US20090169617A1  Published: 02/Jul/2009

Title: Controlled Release Formulations Comprising Uncoated Discrete Unit(s) and an Extended Release Matrix

Applicant/Assignee:

Application No.: 12/296456   Filing Date: 26/Apr/2007

Abstract:A controlled-release formulation comprising one or more distinct and discrete units located in physical juxtaposition to enable administration to a patient in need of treatment in a single dose, characterised in that the or each unit comprise(s): (i) a unit dose of an active pharmaceutical ingredient or pharmaceutically acceptable salt thereof

(ii) one or more extended-release agent(s)

and, optionally, (iii) one or more pharmaceutically acceptable excipients, wherein the sum of the unit dose(s) constitutes a pharmaceutically effective amount of the active pharmaceutical ingredient.

Priority: AU20060902139 Applic. Date: 2006-04-26; AU20070901159 Applic. Date: 2007-03-07; WO2007AU00544 Applic. Date: 2007-04-26

Inventor: KERAMIDAS PANAGIOTIS [AU]; MOONEY BRETT ANTONY [AU]; FERGUSON PHILLIP JOHN [AU]


Application No.: US20090169618A1  Published: 02/Jul/2009

Title: Zolpidem pharmaceutical compositions

Applicant/Assignee:

Application No.: 12/317834   Filing Date: 29/Dec/2008

Abstract:The present invention provides extended release pharmaceutical compositions comprising zolpidem or a salt thereof.

Priority: US20070009280P Applic. Date: 2007-12-26

Inventor: ARI-PARDO LIMOR [IL]; ANTLER SIVAN [IL]


Application No.: US20090169619A1  Published: 02/Jul/2009

Title: CARBAMAZEPINE EXTENDED RELEASE DOSAGE FORM

Applicant/Assignee: COREPHARMA LLC

Application No.: 12/400513   Filing Date: 09/Mar/2009

Abstract:Extended release pharmaceutical dosage forms of carbamazepine for oral administration to maintain a patient's blood concentration for at least a 12 hour period, methods of administering dosage forms and processes for the preparation of such dosage form.

Priority: US2006-359813 Applic. Date: 2006-02-22; US20050656294P Applic. Date: 2005-02-25

Inventor: GANDE MUKTEESHWAR [US]; GONDALIA RASIK [US]; KOTHAPALLI MADHUSUDANARAO [US]; VELISHALA NAGA MAHENDAR [US]; KOPPURI VAMSI [US]


Application No.: US20090169620A1  Published: 02/Jul/2009

Title: ORALLY DISINTEGRATING TABLET COMPOSITIONS OF TEMAZEPAM

Applicant/Assignee:

Application No.: 12/339908   Filing Date: 19/Dec/2008

Abstract:The compositions of the present invention are orally disintegrating tablet compositions comprising a therapeutically effective amount of at least one drug such as temazepam, 0.5-3% of an ODT binder polymer, a sugar alcohol and/or saccharide, and a disintegrant.

Priority: US20070015931P Applic. Date: 2007-12-21

Inventor: VENKATESH GOPI M [US]; CLEVENGER JAMES M [US]; LAI JIN-WANG [US]; PUROHIT VIVEK [US]


Application No.: US20090169631A1  Published: 02/Jul/2009

Title: MICRONIZED OPIOID COMPOSITIONS, FORMULATIONS AND DOSAGE FORMS AND METHODS OF MAKING SAME

Applicant/Assignee: PAIN THERAPEUTICS, INC

Application No.: 12/329318   Filing Date: 05/Dec/2008

Abstract:Novel compositions, formulations and dosage forms comprising stabilized micronized opioid particles are disclosed. Exemplary opioids include oxycodone, oxymorphone, hydrocodone, and hydromorphone, including as free bases or as salts. Stabilized micronized opioid particles having a Dv90 particle size distribution of less and or equal to 10mu or less than or equal to 20mu are disclosed. Methods for micronizing an opioid to provide stabilized micronized opioid particles are also disclosed.

Priority: US20070012033P Applic. Date: 2007-12-06; US20080110855P Applic. Date: 2008-11-03

Inventor: ZAMLOOT MICHAEL [US]; FU CHERNG-CHYI [US]; CHAO DE-HWA [US]; BLASKO ANDREI [US]; YUM SU LL [US]


Application No.: US20090170955A1  Published: 02/Jul/2009

Title: Fast Release Paracetamol Tablets

Applicant/Assignee:

Application No.: 12/295941   Filing Date: 03/Apr/2007

Abstract:A pharmaceutical composition such as a swallow tablet or capsule formulation is described comprising paracetamol, calcium carbonate, at least one binding agent and at least one disintegrating agent in the form of a granulate, optionally combined with one or more pharmaceutically acceptable extragranular components.

Priority: GB20060007085 Applic. Date: 2006-04-07; WO2007US65829 Applic. Date: 2007-04-03

Inventor: ALUR HEMANT H [US]


Application No.: US20090175935A1  Published: 09/Jul/2009

Title: PHARMACEUTICAL COMPOSITIONS OF DULOXETINE

Applicant/Assignee: TORRENT RESEARCH LTD

Application No.: 11/993283   Filing Date: 10/Aug/2007

Abstract:The present invention relates to solid oral pharmaceutical compositions of duloxetine, process for preparing such compositions and method of using such compositions. Preferably, the invention relates to a delayed release composition of duloxetine comprising a core comprising duloxetine, optional separating coat and an enteric coat, wherein the enteric coat comprises methacrylic acid copolymer.

Priority: IN2006MU01279 Applic. Date: 2006-08-14; WO2007IB02315 Applic. Date: 2007-08-10

Inventor: SETTY UMESH [IN]; SHETH RAKESH KIRITBHAI [IN]; RAJHANS SUJAY KAMALAKAR [IN]; BHUTADA PRAVIN MEGHRAJ [IN]; PATEL HASMUKH MATHURBHAI [IN]


Application No.: US20090175938A1  Published: 09/Jul/2009

Title: Controlled Release Flurbiprofen and Muscle Relaxant Combinations

Applicant/Assignee: SANOVEL ILAC SANAYI VE TICARET A.S

Application No.: 12/344039   Filing Date: 24/Dec/2008

Abstract:This invention is a novel controlled release (CR) flurbiprofen and muscle relaxant combinations for oral administration with anti-inflammatory, analgesic, myorelaxant activity and methods of its manufacture. The pharmaceutical composition of the present invention is administered orally in tablet, multilayer tablet, multicoated tablet and capsule form.

Priority: TR20070008925 Applic. Date: 2007-12-26

Inventor: CIFTER UMIT [TR]; TURKYILMAZ ALI [TR]; TURP HASAN ALI [TR]


Application No.: US20090175997A1  Published: 09/Jul/2009

Title: Reduced calorie sweetener composition

Applicant/Assignee: PHARMED MEDICARE PRIVATE LIMITED

Application No.: 11/658750   Filing Date: 01/Aug/2005

Abstract:A sweetener composition is described which augments full benefit of reduced calorific value associated through use of high intensity sweeteners as dominant sweetness contributors, and yet avoids problem of loss of favorable organoleptic properties associated with their use by incorporating sugars and other non-sugar low intensity sweeteners in small but an amount enough to provide a correction in organoleptic properties.

Priority: IN2004MU00812 Applic. Date: 2004-07-30; WO2005IN00253 Applic. Date: 2005-08-01

Inventor: RATNAM RAKESH [IN]; AURORA SUNEET [IN]; ZANNONI JOSEPH M [US]


Application No.: US20090176755A1  Published: 09/Jul/2009

Title: PHARMACEUTICAL COMPOSITIONS COMPRISING AN ANTIBIOTIC

Applicant/Assignee:

Application No.: 12/208417   Filing Date: 11/Sep/2008

Abstract:The present invention relates to cefdinir. More particularly to pharmaceutical formulations comprising cefdinir in a defined polymorphic form and processes for the preparation thereof. Furthermore, the present invention relates to processes to keep cefdinir in a defined polymorphic form.

Priority: US2005-295929 Applic. Date: 2005-12-07

Inventor: JENNEWEIN HERWIG [AT]


Application No.: US20090176787A1  Published: 09/Jul/2009

Title: Crystalline Forms of lamotrigine

Applicant/Assignee: THAR PHARMACEUTICALS

Application No.: 12/291517   Filing Date: 10/Nov/2008

Abstract:The invention is directed to novel crystalline forms of lamotrigine. These novel crystalline forms of lamotrigine have improved dissolution and in-vivo absorption profile, as compared to pure lamotrigine. These novel crystalline forms of lamotrigine provide a substantial increase in the blood concentration of lamotrigine, as compared to pure lamotrigine when administered to a subject. These novel crystalline forms of lamotrigine also provide a slower, steady build up of lamotrigine blood concentration suitable for sustained release of lamotrigine in-vivo, as compared to pure lamotrigine.

Priority: US20070002594P Applic. Date: 2007-11-09

Inventor: HANNA MAZEN [GB]; SHAN NING [US]; CHENEY MIRANDA L [US]


Application No.: US20090176832A1  Published: 09/Jul/2009

Title: POLYMORPHIC FORMS OF 3-(4-AMINO-1-OXO-1,3 DIHYDRO-ISOINDOL-2-YL)-PIPERIDINE-2,6-DIONE

Applicant/Assignee:

Application No.: 12/353383   Filing Date: 14/Jan/2009

Abstract:Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione are disclosed. Compositions comprising the polymorphic forms, methods of making the polymorphic forms and methods of their use are also disclosed.

Priority: US2008-220336 Applic. Date: 2008-07-23; US2004-934863 Applic. Date: 2004-09-03; US20030499723P Applic. Date: 2003-09-04

Inventor: JAWORSKY MARKIAN S [US]; CHEN ROGER SHEN-CHU [US]; MULLER GEORGE W [US]; SAINDANE MANOHAR T [US]; CAMERON LOUISE M [US]


Application No.: US20090181078A1  Published: 16/Jul/2009

Title: VACCINE COMPOSITION CONTAINING SYNTHETIC ADJUVANT

Applicant/Assignee: INFECTIOUS DISEASE RESEARCH INSTITUTE

Application No.: 12/351710   Filing Date: 09/Jan/2009

Abstract:Compositions and methods, including vaccines and pharmaceutical compositions for inducing or enhancing an immune response are disclosed based on the discovery of useful immunological adjuvant properties in a synthetic, glucopyranosyl lipid adjuvant (GLA) that is provided in substantially homogeneous form. Chemically defined, synthetic GLA offers a consistent vaccine component from lot to lot without the fluctuations in contaminants or activity that compromise natural-product adjuvants. Also provided are vaccines and pharmaceutical compositions that include GLA and one or more of an antigen, a Toll-like receptor (TLR) agonist, a co-adjuvant and a carrier such as a pharmaceutical carrier.

Priority: US2008-134127 Applic. Date: 2008-06-05; US2008-154663 Applic. Date: 2008-05-22; US2007-862122 Applic. Date: 2007-09-26; US20060847404P Applic. Date: 2006-09-26

Inventor: REED STEVEN G [US]; CARTER DARRICK [US]


Application No.: US20090181080A1  Published: 16/Jul/2009

Title: Oral cannabinnoid liquid formulations and methods of treatment

Applicant/Assignee: INSYS THERAPEUTICS INC

Application No.: 12/222541   Filing Date: 06/Aug/2008

Abstract:A room temperature stable aqueous cannabinoid formulation is disclosed. In preferred embodiments, the cannabinoid formulation comprises dronabinol in a mixture of buffer solution, and organic cosolvents such as ethanol, propylene glycol and polyethylene glycol.

Priority: US20070963987P Applic. Date: 2007-08-06

Inventor: KOTTAYIL S GEORGE [US]; GOSKONDA VENKAT R [US]; ZHU ZHONGYUAN [US]; KATTOOKARAN LINET [US]


Application No.: US20090181083A1  Published: 16/Jul/2009

Title: Porous tablets as carriers for liquid formulations

Applicant/Assignee: LIFEBYCLE PHARMAS A/S

Application No.: 11/631180   Filing Date: 27/Jun/2005

Abstract:A novel tablet product that in an easy, flexible and reproducible manner can be loaded with a relatively high amount of a pharmaceutically acceptable liquid formulation e.g. carrying a therapeutically, prophylactically and/or diagnostically active substance. The novel loadable tablet product may be produced in large-scale batches and stored until use and each batch or sub-batch may be loaded with the same or different pharmaceutically acceptable liquid formulations and/or active substances. A loadable tablet according to the invention has a porosity of 30% v/v or more. The invention also provides tablets that have been loaded with such a liquid formulation as well as a method for the preparation thereof.

Priority: DK20040001011 Applic. Date: 2004-06-28; WO2005DK00436 Applic. Date: 2005-06-27

Inventor: HOLM PER [DK]; HOLM JANNIE E [DK]; RUHLAND THOMAS [DK]; DALSGAARD SIMON [DK]


Application No.: US20090181085A1  Published: 16/Jul/2009

Title: UTILIZATION OF DIALKYLFUMARATES

Applicant/Assignee: BIOGEN IDEC INTERNATIONAL GMBH

Application No.: 12/405661   Filing Date: 17/Mar/2009

Abstract:The present invention relates to the use of certain dialkyl fumarates for the preparation of pharmaceutical preparations for use in transplantation medicine or for the therapy of autoimmune diseases and said compositions in the form of micro-tablets or pellets. For this purpose, the dialkyl fumarates may also be used in combination with conventional preparations used in transplantation medicine and immunosuppressive agents, especially cyclosporines.

Priority: DE19981053487 Applic. Date: 1998-11-19; US2007-765578 Applic. Date: 2007-06-20; US2002-197077 Applic. Date: 2002-07-17; US2001-831620 Applic. Date: 2001-05-10; WO1999EP08215 Applic. Date: 1999-10-29

Inventor: JOSHI RAJENDRA KUMAR [CH]; STREBEL HANS-PETER [CH]


Application No.: US20090181086A1  Published: 16/Jul/2009

Title: Rasagiline formulations, their preparation and use

Applicant/Assignee:

Application No.: 12/319576   Filing Date: 09/Jan/2009

Abstract:Disclosed are formulations which are designed to release rasagiline mesylate while maintaining specific pharmacokinetic properties.

Priority: US20080010860P Applic. Date: 2008-01-11

Inventor: SAFADI MUHAMMAD [IL]; LICHT DANIELLA [IL]; COHEN RACHEL [IL]


Application No.: US20090181900A1  Published: 16/Jul/2009

Title: NOVEL PEPTIDES AND METHODS FOR THE TREATMENT OF INFLAMMATORY DISEASE

Applicant/Assignee: AUCKLAND UNISERVICES LIMITED

Application No.: 11/575026   Filing Date: 09/Sep/2005

Abstract:The invention relates to an isolated peptides comprising at least the amino acid sequence YDRREY or a derivative thereof, nucleic acids encoding the peptides, pharmaceutical compositions and methods for modulating beta7 integrin function, including methods for treatment of inflammatory disorders, antibodies directed to said peptides and methods for identification of integrin beta7 functional interactors.

Priority: AU20040905153 Applic. Date: 2004-09-09; WO2005NZ00234 Applic. Date: 2005-09-09

Inventor: KRISSANSEN GEOFFREY WAYNE [NZ]


Application No.: US20090182047A1  Published: 16/Jul/2009

Title: UTILIZATION OF DIALKYLFUMARATES

Applicant/Assignee: BIOGEN IDEC INTERNATION GMBH

Application No.: 12/405665   Filing Date: 17/Mar/2009

Abstract:The present invention relates to the use of certain dialkyl fumarates for the preparation of pharmaceutical preparations for use in transplantation medicine or for the therapy of autoimmune diseases and said compositions in the form of micro-tablets or pellets. For this purpose, the dialkyl fumarates may also be used in combination with conventional preparations used in transplantation medicine and immunosuppressive agents, especially cyclosporines.

Priority: WO1999EP08215 Applic. Date: 1999-10-29; DE19981053487 Applic. Date: 1998-11-19; US2007-765578 Applic. Date: 2007-06-20; US2002-197077 Applic. Date: 2002-07-17; US2001-831620 Applic. Date: 2001-05-10

Inventor: JOSHI RAJENDRA KUMAR [CH]; STREBEL HANS-PETER [CH]


Application No.: US20090186093A1  Published: 23/Jul/2009

Title: METHODS FOR PREPARING CORE-SHELL COMPOSITES HAVING CROSS-LINKED SHELLS AND CORE-SHELL COMPOSITES RESULTING THEREFROM

Applicant/Assignee: RELYPSA, INC

Application No.: 12/088611   Filing Date: 02/Oct/2006

Abstract:The present invention provides methods and compositions for the treatment of ion imbalances using core-shell composites and compositions comprising such core-shell composites. In particular, the invention provides core-shell particles and compositions comprising potassium binding polymers, and core-shell particles and compositions comprising sodium binding polymers, and in each case, pharmaceutical compositions thereof. Methods of use of the polymeric and pharmaceutical compositions for therapeutic and/or prophylactic benefits are also disclosed. The compositions and methods of the invention offer improved approaches for treatment of hyperkalemia and other indications related to potassium ion homeostasis, and for treatment of hypertension and other indicates related to sodium ion homeostasis.

Priority: US20050723055P Applic. Date: 2005-09-30; WO2006US38900 Applic. Date: 2006-10-02

Inventor: LIU FUTIAN [US]; CHANG HAN-TING [US]; CHARMOT DOMINIQUE [US]; CONNOR ERIC [US]; MANSKY PAUL [US]; LIU MINGJUN [US]


Application No.: US20090186824A1  Published: 23/Jul/2009

Title: NOVEL PEPTIDES FOR TREATING AND PREVENTING IMMUNE-RELATED DISORDERS, INCLUDING TREATING AND PREVENTING INFECTION BY MODULATING INNATE IMMUNITY

Applicant/Assignee:

Application No.: 12/404965   Filing Date: 16/Mar/2009

Abstract:In one aspect, the present invention provides isolated novel peptides that can be used to modulate innate immunity in a subject and/or for the treatment of an immune-related disorder, including treating and preventing infection by modulating innate immunity. Also provided are an agent reactive with the peptide, a pharmaceutical composition that includes the peptide, an isolated nucleic acid molecule encoding the peptide, a recombinant nucleic acid construct that includes the nucleic acid molecule, at least one host cell comprising the recombinant nucleic acid construct, and a method of producing the peptide using the host cell. The present invention further provides a method for treating and/or preventing infection in a subject by administering the peptide of the invention to the subject, thereby modulating innate immunity in the subject. Additionally, the present invention provides a method for predicting whether a subject would be responsive to treatment with a peptide of the invention.

Priority: WO2006CA01650 Applic. Date: 2006-10-04; US2007-730695 Applic. Date: 2007-04-03

Inventor: DONINI OREOLA [CA]; ROZEK ANNETT [CA]; LENTZ SHANNON WAYNE [CA]


Application No.: US20090188495A1  Published: 30/Jul/2009

Title: PRE-METERED DRY POWDER INHALER FOR MOISTURE-SENSITIVE MEDICAMENTS

Applicant/Assignee: BOEHRINGER INGELHEIM INTERNATIONAL GMBH

Application No.: 12/417771   Filing Date: 03/Apr/2009

Abstract:The invention discloses a pre-metered dry powder inhaler for use in treatment of respiratory disorders. The inhaler comprises a foil cutter arranged for opening a dry, moisture-tight seal formed by a dose container with tiotropium particles and a seal foil fixed to the container. The tiotropium-containing dose protected from moisture ingress by the moisture-tight barrier seal is loaded in the container using volumetric or electric field dose forming techniques.

Priority: SE20030003269 Applic. Date: 2003-12-03; SE20030003569 Applic. Date: 2003-12-22; US2008-186577 Applic. Date: 2008-08-06; US2004-933219 Applic. Date: 2004-09-03

Inventor: NILSSON THOMAS [CH]; MYRMAN MATTIAS [SE]; CALANDER SVEN [SE]; NIEMI ALF [SE]; ZIERENBERG BERND [DE]; MEMMESHEIMER HOLGER [DE]; LUKENHEIMER CHRISTINE [DE]


Application No.: US20090188496A1  Published: 30/Jul/2009

Title: INHALABLE TIOTROPIUM AND CONTAINER THEREFOR

Applicant/Assignee: BOEHRINGER INGELHEIM INTERNATIONAL GMBH

Application No.: 12/417795   Filing Date: 03/Apr/2009

Abstract:A medical product suitable for storing and delivering a pre-metered dose of tiotropium, devices containing the same, and methods of using the same.

Priority: SE20030003269 Applic. Date: 2003-12-03; SE20030003570 Applic. Date: 2003-12-22; US2008-235803 Applic. Date: 2008-09-23; US2004-834037 Applic. Date: 2004-04-29

Inventor: NILSSON THOMAS [CH]; MYRMAN MATTIAS [SE]; CALANDER SVEN [SE]; NIEMI ALF [SE]; ZIERENBERG BERND [DE]; MEMMESHEIMER HOLGER [DE]; LUNKENHEIMER CHRISTINE [DE]


Application No.: US20090188497A1  Published: 30/Jul/2009

Title: MEDICAL PRODUCT CONTAINING TIOTROPIUM

Applicant/Assignee: BOEHRINGER INGELHEIM INTERNATIONAL GMBH

Application No.: 12/417835   Filing Date: 03/Apr/2009

Abstract:The invention discloses a medical product that may be used in a treatment of respiratory disorders.

Priority: SE20030003269 Applic. Date: 2003-12-03; SE20030003571 Applic. Date: 2003-12-22; US2008-255030 Applic. Date: 2008-10-21; US2004-921192 Applic. Date: 2004-08-19

Inventor: NILSSON THOMAS [CH]; MYRMAN MATTIAS [SE]; CALANDER SVEN [SE]; NIEMI ALF [SE]; ZIERENBERG BERND [DE]; MEMMESHEIMER HOLGER [DE]; LUNKENHEIMER CHRISTINE [DE]


Application No.: US20090191265A1  Published: 30/Jul/2009

Title: Capsule Formulation of Pirfenidone and Pharmaceutically Acceptable Excipients

Applicant/Assignee: INTERMUNE, INC

Application No.: 12/426182   Filing Date: 17/Apr/2009

Abstract:A capsule formulation of pirfenidone is provided that includes pharmaceutically acceptable excipients. In one embodiment, this capsule formulation is capable of sustaining desirable pharmacokinetic responses in a patient. Further provided are methods of treating fibrotic conditions and other cytokine-mediated disorders by administering pirfenidone capsules of such formulation to a patient in need.

Priority: US2006-067712 Applic. Date: 2006-09-22; WO2006US37057 Applic. Date: 2006-09-22; US20050720257P Applic. Date: 2005-09-22

Inventor: RADHAKRISHNAN RAMACHANDRAN [US]; VLADYKA RONALD [US]; SULTZBAUGH KENNETH [US]


Application No.: US20090191267A1  Published: 30/Jul/2009

Title: Oral Compositions Containing a Salivation Inducing Agent

Applicant/Assignee:

Application No.: 12/411638   Filing Date: 26/Mar/2009

Abstract:Oral dosage forms, and particles used therein, containing salivation inducing agents are disclosed. The salivation agents may be in the core of the dosage form and/or in coatings applied thereto, or alternatively may be within particles and/or the matrix of such dosage forms, in coatings applied to such particles, or on the surface of such coated particles. The particles may be produced into a tablet form, such as a chewable tablet form, that provides for the immediate release of the active ingredient. Other oral dosage forms include thin film strips, gummi, foam tabs, and lozenges.

Priority: US2005-239974 Applic. Date: 2005-09-30

Inventor: WYNN DAVID W [US]; ROBINSON RONNI [US]


Application No.: US20090191275A1  Published: 30/Jul/2009

Title: VISCOUS BUDESONIDE FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE GASTROINTESTINAL TRACT

Applicant/Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, SAN DIEGO

Application No.: 12/269693   Filing Date: 12/Nov/2008

Abstract:Provided herein are methods for preventing or alleviating the symptoms of and inflammation associated with inflammatory diseases and conditions of the gastrointestinal tract, for example, those involving the esophagus. Also provided herein are pharmaceutical compositions useful for the methods of the present invention.

Priority: US2006-595513 Applic. Date: 2006-11-09; US20050735340P Applic. Date: 2005-11-12; US20080090575P Applic. Date: 2008-08-20

Inventor: DOHIL RANJAN [US]; BASTIAN JOHN [US]; ACEVES SEEMA [US]; PHILLIPS ELAINE [US]; HILL MALCOLM [US]


Application No.: US20090191282A1  Published: 30/Jul/2009

Title: CONTROLLED RELEASE COMPOSITION CONTAINING A STRONTIUM SALT

Applicant/Assignee: OSTEOLOGIX A/S

Application No.: 12/341439   Filing Date: 22/Dec/2008

Abstract:A controlled release pharmaceutical composition comprising a strontium salt. The invention also relates to the use of a strontium salt for treating a male suffering from diseases and conditions affecting metabolism and/or structural integrity of cartilage and/or bone. The invention also relates to the use of a strontium-containing compound for preventing a cartilage and/or bone condition in a subject, and for the treatment and/or prophylaxis of secondary osteoporosis.

Priority: DK20030000691 Applic. Date: 2003-05-07; DK20030001043 Applic. Date: 2003-07-08; DK20030001821 Applic. Date: 2003-12-09; US2004-556150 Applic. Date: 2004-05-06; WO2004DK00326 Applic. Date: 2004-05-06; US20030528409P Applic. Date: 2003-12-09

Inventor: HANSEN CHRISTIAN [DK]; NILSSON HENRIK [DK]; ANDERSEN JENS E T [DK]; CHRISTGAU STEPHAN [DK]


Application No.: US20090192185A1  Published: 30/Jul/2009

Title: MEDICAL PRODUCT

Applicant/Assignee: BOEHRINGER INGELHEIM INTERNATIONAL GMBH

Application No.: 12/417814   Filing Date: 03/Apr/2009

Abstract:The invention discloses a medical product for use in a treatment of respiratory disorders, and comprises a metered dose of a tiotropium dry powder formulation, directly loaded and sealed into a container made to act as a dry high barrier seal to prevent the capture and ingress of moisture into the tiotropium powder. The dose of tiotropium is further adapted for inhalation and the container is so tight that the efficacy of the dose when delivered is unaffected by moisture. In a further aspect of the invention a type of inhaler is illustrated, which may accept at least one sealed, moisture-tight container of a dose of tiotropium, to deliver the dose with a consistent fine particle dose, over the expected shelf life of the product.

Priority: SE20030003269 Applic. Date: 2003-12-03; US2008-255086 Applic. Date: 2008-10-21; US2003-728986 Applic. Date: 2003-12-08

Inventor: NILSSON THOMAS [CH]; MYRMAN MATTIAS [SE]; CALANDER SVEN [SE]; NIEMI ALF [SE]; ZIERENBERG BERND [DE]; MEMMESHEIMER HOLGER [DE]; LUNKENHEIMER CHRISTINE [DE]


Application No.: US20090196872A1  Published: 06/Aug/2009

Title: HUMAN MONOCLONAL ANTIBODIES TO INFLUENZA M2 PROTEIN AND METHODS OF MAKING AND USING SAME

Applicant/Assignee: KIRIN BEER KABUSHIKI KAISHA

Application No.: 11/577695   Filing Date: 05/Dec/2005

Abstract:Human, humanized and chimeric monoclonal antibodies that bind to influenza M2 protein. A human monoclonal antibody that binds to influenza M2 protein having different amino acid sequences. The antibodies are useful for, among other things, treatment, diagnostics, purifying and isolating M2 or influenza virus, and identifying the presence of M2 or influenza virus in a sample or a subject.

Priority: US20040633846P Applic. Date: 2004-12-06; US20050724198P Applic. Date: 2005-10-06; WO2005IB04146 Applic. Date: 2005-12-05

Inventor: KATO SHINICHIRO [JP]; WANG RONGFANG [CN]


Application No.: US20090196919A1  Published: 06/Aug/2009

Title: OXCARBAZEPINE DOSAGE FORMS

Applicant/Assignee:

Application No.: 11/577902   Filing Date: 24/Oct/2005

Abstract:The present invention relates to dosage forms of oxcarbazepine for oral administration that contain oxcarbazepine having a median particle size of from about 14 mum to about 30 mum and to processes for the preparation of such dosage forms. The dosage form may be a solid or a liquid dosage form. The solid dosage form may be in the form of a tablet, a capsule, or a granulate. The liquid dosage form may be in the form of a solution or a suspension.

Priority: IN2004DE02084 Applic. Date: 2004-10-25; WO2005IB03168 Applic. Date: 2005-10-24

Inventor: SINGLA AJAY [IN]; ARORA SACHIN [IN]; DABRE RAHUL [IN]


Application No.: US20090196923A1  Published: 06/Aug/2009

Title: CONTROLLED RELEASE FORMULATION COMPRISING ANTI-EPILEPTIC DRUGS

Applicant/Assignee:

Application No.: 12/303021   Filing Date: 23/Apr/2007

Abstract:The present invention relates to pharmaceutical formulation of antiepileptic drug preferably oxcarbazepine. The formulation comprises multiple tablets or pellets of immediate release or controlled release nature, which are filled, inside the capsule to provides drug effect for 24 hours and is suitable for once a day administration. The patent also provides process of preparation of the dosage form.

Priority: IN2006MU00651 Applic. Date: 2006-04-26; WO2007IN00160 Applic. Date: 2007-04-23

Inventor: MANDAL JAYANTA KUMAR [IN]; PANDYA NITESH NALINCHANDRA [IN]; PILLAI SUMITRA ASHOK [IN]; MAHESHWARI KIRTI BANSIDHAR [IN]


Application No.: US20090196924A1  Published: 06/Aug/2009

Title: CONTROLLED-RELEASE LAMOTRIGINE FORMULATIONS

Applicant/Assignee:

Application No.: 12/364708   Filing Date: 03/Feb/2009

Abstract:Pharmaceutical controlled-release formulations comprising particles comprising lamotrigine or a pharmaceutically acceptable salt thereof, coated with a modified-release coating comprising a modified-release coating agent and a pore-former.

Priority: US20080025878P Applic. Date: 2008-02-04

Inventor: KHARWADE PRAMOD [IN]; VISHWANATHAN NARAYANAN BADRI [IN]


Application No.: US20090196932A1  Published: 06/Aug/2009

Title: PHARMACEUTICAL COMPOSITIONS OF ATORVASTATIN

Applicant/Assignee: PFIZER INC

Application No.: 12/423330   Filing Date: 14/Apr/2009

Abstract:A dry-granulated pharmaceutical composition comprising atorvastatin or a pharmaceutically acceptable salt thereof, as well as a dry-granulated pharmaceutical composition comprising atorvastatin or a pharmaceutically acceptable salt thereof in combination with at least one other active drug, methods for preparing said compositions, kits for containing such compositions, and a method of treating hypercholesterolemia and/or hyperlipidemia, osteoporosis, benign prostatic hyperplasia (BPH), and Alzheimer's disease using a therapeutically effective amount of the pharmaceutical composition.

Priority: US2004-828398 Applic. Date: 2004-04-20; US20030477916P Applic. Date: 2003-06-12; US20030477917P Applic. Date: 2003-06-12

Inventor: LUNER PAUL E [US]; WATERMAN KENNETH CRAIG [US]


Application No.: US20090196935A1  Published: 06/Aug/2009

Title: Pharmaceutical Capsules Comprising Extended Release Dipyridamole Pellets

Applicant/Assignee:

Application No.: 12/364241   Filing Date: 02/Feb/2009

Abstract:The present invention is directed to pharmaceutical capsules comprising extended release formulations of dipyridamole, processes for preparing such dipyridamole extended release formulations and their use in the treatment of stroke.

Priority: US20080025743P Applic. Date: 2008-02-01

Inventor: AHMED SALAH U [US]; KATIKANENI PRUTHVIPATHY R [US]; ZU YANMING [US]


Application No.: US20090197874A1  Published: 06/Aug/2009

Title: SOLID FORMS CONTAINING MELOXICAM WITH IMPROVED BUCCAL TASTE AND PROCESS FOR THEIR PREPARATION

Applicant/Assignee: ALPEX PHARMA SA

Application No.: 12/299838   Filing Date: 11/Jun/2007

Abstract:A solid dosage form of meloxicam containing an acid and sugars or polyalcohols or a mixture thereof.

Priority: EP20060012353 Applic. Date: 2006-06-15; WO2007EP55706 Applic. Date: 2007-06-11

Inventor: STROPPOLO FEDERICO [CH]; ARDALAN SHAHBAZ [CH]


Application No.: US20090197903A1  Published: 06/Aug/2009

Title: PROCESS FOR PREPARING SPRAY DRIED FORMULATION OF TMC125

Applicant/Assignee: TIBOTEC PHARMACEUTICALS LTD

Application No.: 12/302366   Filing Date: 06/Jun/2007

Abstract:This invention relates to a process for producing a spray-dried powder comprising microcrystalline cellulose in a solid dispersion of the anti-HIV compound etravirine (TMC125) in a water-soluble polymer.

Priority: EP20060115029 Applic. Date: 2006-06-06; WO2007EP55607 Applic. Date: 2007-06-06

Inventor: KIEKENS FILIP RENE IRENE [BE]; VOORSPOELS JODY FIRMIN MARCELINE [BE]; BAERT LIEVEN ELVIRE COLETTE [BE]


Application No.: US20090202509A1  Published: 13/Aug/2009

Title: METHODS AND AGENTS FOR REDUCING OXIDATIVE STRESS

Applicant/Assignee: ETREN

Application No.: 12/280749   Filing Date: 01/Mar/2007

Abstract:The present invention relates to novel methods for enhancing endogenous protection mechanisms against oxidative stress, and agents for use in such methods. In particular, the present invention provides a pharmaceutical composition which provides an oxidative signal upon administration to a subject, the signal triggering a therapeutic or prophylactic effect by priming the subject's body to combat the effects of oxidative stress.

Priority: GB20060003975 Applic. Date: 2006-03-01; WO2007EP51966 Applic. Date: 2007-03-01

Inventor: LEVERVE XAVIER [FR]


Application No.: US20090202596A1  Published: 13/Aug/2009

Title: PHARMACEUTICAL COMPOSITIONS WITH BIOLOGICAL BARRIERS PERMEATION ENHANCING PROPERTIES

Applicant/Assignee: FARMATRON LIMITED

Application No.: 12/304164   Filing Date: 12/Jun/2007

Abstract:Pharmaceutical compositions comprising a water/oil/water (W1/O2/W3) or an oil/water/oil (O1/W2/O3) double microemulsion, with droplets size below one micron, with the drug included in the internal water phase W1 or internal oil phase 01, whereas the external oil 02 and second water phase W3 or the external water phase W2 and second oil phase 03 contain substances able to inhibit the enzymes, present in the mucosa or biological barrier to be permeated or physiological environment of administration, capable to degrade the drug or to cause its efflux from the barrier

alternatively the external oil and second water phase or external water phase and second oil phase contain permeation enhancing agents, i.e., substances able to increase the diffusion of the drug through the biological barrier.

Priority: EP20060012080 Applic. Date: 2006-06-13; WO2007EP05171 Applic. Date: 2007-06-12

Inventor: PEDRANI MASSIMO [GB]; CARLI FABIO [IT]


Application No.: US20090202597A1  Published: 13/Aug/2009

Title: Ache-Nmda Combination Wafer

Applicant/Assignee:

Application No.: 12/308236   Filing Date: 04/Jun/2007

Abstract:Sheet-like pharmaceutical preparations based on hydrophilic polymers, which rapidly disintegrate upon contact with moisture and which are used to treat dementia-related illnesses The dosage form contains an active agent combination of at least two active agents which are suitable for the treatment of dementia (antidementia agents). The antidementia agents should be chosen from the group comprising acetyl cholinesterase inhibitors (AChE inhibitors) and NMDA antagonists (n-methyl-D-asparaginic acid antagonists). The use of such an active agent combination for producing an orally administrable pharmaceutical product for the treatment of dementia-related illnesses such as Alzheimer's disease, as well as a procedure for the symptomatic treatment of Alzheimer's disease by the oral administration of one of the above pharmaceutical products is also provided.

Priority: DE200610027791 Applic. Date: 2006-06-16; WO2007EP04951 Applic. Date: 2007-06-04

Inventor: HOFFMANN HANS-RAINER [DE]; BRANDLI RETO [US]; THEOBALD FRANK [DE]


Application No.: US20090202636A1  Published: 13/Aug/2009

Title: Pharmaceutical Composition

Applicant/Assignee: LEK PHARMACEUTICALS D.D

Application No.: 12/304942   Filing Date: 14/Jun/2007

Abstract:A stable formulation of telmisartan and hydrochlorothiazide having both substances in separate units is prepared, exhibiting exceptional stability when subjecting to stress conditions.

Priority: EP20060012381 Applic. Date: 2006-06-16; WO2007EP05248 Applic. Date: 2007-06-14

Inventor: BESO ADNAN [SI]; LEGEN IGOR [SI]; REVEN SEBASTJAN [SI]


Application No.: US20090202639A1  Published: 13/Aug/2009

Title: Biomaterials Consisting of Sulphated Hyaluronic Acid and Gellan to be Used in the Prevention of Spinal Adhesions

Applicant/Assignee: FIDIA ADVANCED BIOPOLUMERS S.R.L

Application No.: 11/664754   Filing Date: 03/Oct/2005

Abstract:New biomaterials consisting of a combination of sulphated hyaluronic acid and gellan (as well as gellan that has not been associated with other polymers), to be used as a highly effective barrier to prevent post-surgical adhesions in abdominal, pelvic and, above all, spine surgery.

Priority: IT2004PD00245 Applic. Date: 2004-10-08; WO2005EP10645 Applic. Date: 2005-10-03

Inventor: BELLINI DAVIDE [IT]; LONGINOTTI CRISTINA [IT]; CRESCENZI VITTORIO [IT]; TAGLIENTI ANNA [IT]


Application No.: US20090203144A1  Published: 13/Aug/2009

Title: HIV-GAG CODON-OPTIMISED DNA VACCINES

Applicant/Assignee:

Application No.: 12/015756   Filing Date: 17/Jan/2008

Abstract:The invention provides a nucleotide sequence that encodes an HIV-1 gag protein or fragment thereof containing a gag epitope and a second HIV antigen or a fragment encoding an epitope of said second HIV antigen, operably linked to a heterologous promoter. Preferred polynucleotide sequences further encodes nef or a fragment thereof and RT or a fragment thereof.

Priority: WO2001GB04207 Applic. Date: 2001-09-20; GB20010029604 Applic. Date: 2001-12-11; GB20020006462 Applic. Date: 2002-03-19; US2004-490011 Applic. Date: 2004-10-25; WO2002EP10592 Applic. Date: 2002-09-18

Inventor: BEATON ANDREW [GB]; ERTL PETER FRANZ [GB]; GOUGH GERALD WAYNE [GB]; LEAR ANDREW [GB]; TITE JOHN PHILIP [GB]; VAN WELY CATHERINE ANN [GB]


Application No.: US20090203670A1  Published: 13/Aug/2009

Title: Combination Antidepressants Wafer

Applicant/Assignee: LTS LOHMANN THERAPIE-SYSTEME AG

Application No.: 12/308194   Filing Date: 04/Jun/2007

Abstract:A sheet-like pharmaceutical preparation (dosage form) that quickly disintegrates on contact with moisture, based on hydrophilic polymers for the release of at least one active agent. The dosage form contains an active agent combination for treating depression, and at least one active agent selected from the antidepressant group of drugs. In addition, the use of such a combination of active agents for the production of an orally administrable pharmaceutical product for the treatment of depression, and the therapeutic treatment of depression by oral administration of one of the named pharmaceutical preparations, is provided.

Priority: DE200610027792 Applic. Date: 2006-06-16; WO2007EP04936 Applic. Date: 2007-06-04

Inventor: HOFFMANN HANS-RAINER [DE]; BRANDLI RETO [US]; THEOBALD FRANK [DE]


Application No.: US20090203777A1  Published: 13/Aug/2009

Title: ORGANIC COMPOUNDS

Applicant/Assignee:

Application No.: 11/911391   Filing Date: 12/Apr/2006

Abstract:The invention describes novel pharmaceutically acceptable salt forms of camostat, processes for lyophilisation, taste-masked formulations, nebulised formulations and the use of each of the fore-going in the treatment of respiratory diseases, particularly cystic fibrosis and chronic obstructive pulmonary disease (COPD).

Priority: GB20050007577 Applic. Date: 2005-04-14; WO2006EP03387 Applic. Date: 2006-04-12

Inventor: DANAHAY HENRY LUKE [GB]; LEGRAND DARREN MARK [GB]; TULLY DAVID C [US]; HARRIS JENNIFER LESLIE [US]; HEUERDING SILVIA [CH]; SINGH DILRAJ [CH]; MAAS JANET CATHERINE [GB]; ROETTELE JUERGEN [DE]; REBER JEAN-LOUIS [FR]; MONNIER STEPHANIE [FR]


Application No.: US20090208539A1  Published: 20/Aug/2009

Title: STABLE ATORVASTATIN FORMULATIONS

Applicant/Assignee:

Application No.: 11/719791   Filing Date: 22/Nov/2005

Abstract:A simple yet efficient formulation for providing excellent bioefficacy, wherein the formulation includes atorvastatin or a salt thereof, in crystalline or amorphous form, with at least one pharmaceutical excipient selected to a form of atorvastatin that has beneficial properties, such as enhanced stability. These formulations do not need to include a stabilizer.

Priority: US20040629412P Applic. Date: 2004-11-22; WO2005IL01235 Applic. Date: 2005-11-22

Inventor: PENHASI ADEL [IL]; ATTALI YAAKOV STEPHANE [IL]


Application No.: US20090208564A1  Published: 20/Aug/2009

Title: Compositions of asymmetric interfering RNA and uses thereof

Applicant/Assignee:

Application No.: 12/199797   Filing Date: 27/Aug/2008

Abstract:The present invention provides asymmetrical duplex RNA molecules that are capable of effecting sequence-specific gene silencing. The RNA molecule comprises a first strand and a second strand. The first strand is longer than the second strand. The RNA molecule comprises a double-stranded region formed by the first strand and the second strand, and two ends independently selected from the group consisting of 5'-overhang, 3'-overhang, and blunt end. The RNA molecules of the present invention can be used as research tools and/or therapeutics.

Priority: US20070968257P Applic. Date: 2007-08-27; US20080029753P Applic. Date: 2008-02-19; US20080038954P Applic. Date: 2008-03-24

Inventor: LI CHIANG JIA [US]; SUN XIANGAO [US]; ROGOFF HARRY [US]; LI YOUZHI [US]


Application No.: US20090208576A1  Published: 20/Aug/2009

Title: Orally Disintegrating Tablets

Applicant/Assignee:

Application No.: 12/293857   Filing Date: 30/Mar/2007

Abstract:The present invention describes a directly compressible composite prepared by co-processing a water-soluble excipient and calcium silicate. The present invention further describes the incorporation of the co-processed composite into a tablet formulation. The orally disintegrating tablets are of optimal mechanical strength and disintegrate within 60 seconds in the oral cavity.

Priority: IN2006MU00498 Applic. Date: 2006-03-31; WO2007IN00138 Applic. Date: 2007-03-30

Inventor: GANDHI ANILKUMAR S [IN]; BAGDE PRADNYA [IN]; MORVEKAR HETAL N [IN]; PILGAONKAR PRATIBHA S [US]; RUSTOMJEE MAHARUKH T [IN]


Application No.: US20090209635A1  Published: 20/Aug/2009

Title: TOPICAL CROMOLYN FORMULATIONS

Applicant/Assignee: EMISPHERE TECHNOLOGIES, INC

Application No.: 11/569285   Filing Date: 19/May/2005

Abstract:The present invention provides a topical composition comprising (a) at least one delivery agent compound and (b) a cromoglycic acid compound. Methods of treatment, and methods of preparing the topical composition are also provided.

Priority: US20040572896P Applic. Date: 2004-05-19; WO2005US17816 Applic. Date: 2005-05-19

Inventor: LIU PUCHUN [US]; DINH STEVEN [US]; ARBIT EHUD [US]; GOLDBERG MICHAEL M [US]


Application No.: US20090214472A1  Published: 27/Aug/2009

Title: Interferon-beta polymer conjugates

Applicant/Assignee: ENZON PHARMACEUTICALS INC

Application No.: 10/590421   Filing Date: 28/Feb/2005

Abstract:Biologically-active, interferon-beta 1b-polymer conjugate compositions are disclosed. The polymer portion is preferably a polyalkylene oxide polymer having a molecular weight of at least about 12 kDa. Methods of making and using the same are also disclosed.

Priority: US20040549109P Applic. Date: 2004-03-01; WO2005US06575 Applic. Date: 2005-02-28

Inventor: FILPULA DAVID RAY [US]; YANG KAREN [US]; BASU AMARTYA [US]; WANG MAOLIANG [US]


Application No.: US20090214642A1  Published: 27/Aug/2009

Title: COATED FORMULATIONS FOR TOLTERODINE

Applicant/Assignee: LEK PHARMACEUTICALS D.D

Application No.: 12/294571   Filing Date: 29/Mar/2007

Abstract:A sustained release pharmaceutical composition comprising coating comprising at least one water-insoluble permeable polymer and at least one water soluble polymer and homogenous cores containing only tolterodine or a salt thereof and microcrystalline cellulose is described.

Priority: EP20060006979 Applic. Date: 2006-03-31; WO2007EP53027 Applic. Date: 2007-03-29

Inventor: LEGEN IGOR [SI]; KUHAR POLONCA [SI]


Application No.: US20090214648A1  Published: 27/Aug/2009

Title: PHARMACEUTICAL FORMULATIONS COMPRISING IBUPROFEN AND DIPHENHYDRAMINE

Applicant/Assignee:

Application No.: 12/370955   Filing Date: 13/Feb/2009

Abstract:A pharmaceutical dosage form comprising diphenhydramine, or a pharmaceutically acceptable salt thereof, and ibuprofen, wherein the dosage form provides both diphenhydramine and ibuprofen in a single monolayer tablet, and processes for preparation of dosage forms.

Priority: IN2008CH00389 Applic. Date: 2008-02-15; US20080081231P Applic. Date: 2008-07-16

Inventor: KANDAKATLA MALATHI [IN]; CHAKOLE DINESH DAYARAMJI [IN]; CHELLEKKAGARI PRADEEP KUMAR REDDY [IN]; PALLEMPALLI VENKATA SIVAREDDY [IN]; PILLAI RAVIRAJ SUKUMAR [IN]


Application No.: US20090214665A1  Published: 27/Aug/2009

Title: Controlled Release Muscarinic Receptor Antagonist Formulation

Applicant/Assignee:

Application No.: 12/037124   Filing Date: 26/Feb/2008

Abstract:An oral controlled release pharmaceutical composition for muscarinic receptor antagonist, preferably tolterodine, that employs a drug core, a rapidly disintegrating or rapidly dissolving coating applied to the drug core and a controlled release coating.

Priority:

Inventor: LAI FELIX S [US]; TING RICHARD [US]; SIEW LEE FOONG [US]; CHUANG KING YU-KUANG [US]; UCPINAR SIBEL [US]


Application No.: US20090215701A1  Published: 27/Aug/2009

Title: Enhancement of Iron Chelation Therapy

Applicant/Assignee: CHILDREN'S HOSPITAL & RESEARCH CENTER AT OAKLAND

Application No.: 11/565456   Filing Date: 30/Nov/2006

Abstract:The present invention provides methods of enhancing the rate of iron release from ferritin. By increasing the amount of iron available for chelation, the invention also provides methods of treating conditions associated with iron overload. The invention also provides in one embodiment agents which are useful for treating iron overload.

Priority: US2003-389424 Applic. Date: 2003-03-13; US20020365094P Applic. Date: 2002-03-14

Inventor: THEIL ELIZABETH [US]


Application No.: US20090215731A1  Published: 27/Aug/2009

Title: Reduction of Side Effects From Aromatase Inhibitors Used for Treating Breast Cancer

Applicant/Assignee: CHAVAH PTY LTD

Application No.: 12/083771   Filing Date: 18/Oct/2006

Abstract:The present invention is directed generally to pharmaceutical compositions, methods, and kits for improving side effects associated with aromatase inhibitor treatment in a subject diagnosed with breast cancer. More specifically, the present invention provides compositions, methods, and kits comprising an aromatase inhibitor and an androgenic agent.

Priority: AU20050905768 Applic. Date: 2005-10-19; US20050732662P Applic. Date: 2005-11-03; US20060798308P Applic. Date: 2006-05-08; WO2006AU01539 Applic. Date: 2006-10-18

Inventor: BIRRELL STEPHEN NIGEL [AU]


Application No.: US20090215744A1  Published: 27/Aug/2009

Title: Solid Formulations

Applicant/Assignee: ASTRAZENECA AB

Application No.: 12/093956   Filing Date: 18/Nov/2006

Abstract:The present invention is directed to solid formulations of the pharmaceutical compound 11-piperazin-1-yldibenzo[b,f][1,4]thiazepine as well as preparations, and pharmaceutical uses thereof.

Priority: US20050737863P Applic. Date: 2005-11-18; WO2006US61071 Applic. Date: 2006-11-18

Inventor: BROWN DAN B [US]; KOREY DANIEL [US]; MAIN KAREN B [US]; CREEKMORE RICHARD J R [US]


Application No.: US20090215808A1  Published: 27/Aug/2009

Title: Oral pharmaceutical dosage forms

Applicant/Assignee:

Application No.: 12/315868   Filing Date: 05/Dec/2008

Abstract:Abuse-resistant oral dosage forms suitable for administration of pharmacologically active agents are provided.

Priority: US20070005681P Applic. Date: 2007-12-06; US20070005685P Applic. Date: 2007-12-06; US20080198201P Applic. Date: 2008-11-03

Inventor: YUM SU IL [US]; CHAO WENDY [US]; SU HUEY-CHING [US]; FU ROGER [US]; ZAMLOOT MICHAEL [US]


Application No.: US20090215811A1  Published: 27/Aug/2009

Title: Novel Pharmaceutical Composition and Its Use in a Method For Treatment of Patients With Upper Respiratory Mucosal Congestion

Applicant/Assignee: AFT PHARMACEUTICALS LIMITED

Application No.: 11/922271   Filing Date: 17/Jun/2005

Abstract:The present invention relates to a pharmaceutical composition including loratidine, its use in the treatment of upper respiratory mucosal congestion and a method of administration of the composition. Particularly, though not exclusively, the invention relates to a pharmaceutical composition including loratidine in an amount suitable for administration a maximum of 4 times a day, and a second active that is a hydroxyl-alpha-[(methylamino) methyl]-benzenemethanol, such 3-hydroxyl-alpha-[(methylamino) methyl]-benzenemethanol (phenylephrine), or salt thereof.

Priority: WO2005NZ00132 Applic. Date: 2005-06-17

Inventor: ATKINSON HARTLEY [NZ]


Application No.: US20090215852A1  Published: 27/Aug/2009

Title: COMPOSITIONS AND METHODS FOR AMELIORATING CACHEXIA

Applicant/Assignee: CHROMA GROUP, INC

Application No.: 11/817772   Filing Date: 21/Mar/2006

Abstract:The invention provides preparations, formulations, kits and other products of manufacture (e.g., blister packs) comprising combinations of beneficial ingredients that are serviceable as therapies for improving states and disease symptoms such as involving inflammation, excessive sympathoneural drive, cachexia, anorexia, and anorexia-cachexia, as well as stress or anxiety related thereto, and methods of making and using them. The invention provides compositions and therapies comprising use of a beta adrenergic antagonist (also called "beta blockers", e.g., propranolol) in combination with an anti-inflammatory agent, e.g., a nonsteroidal anti-inflammatory drug (NSAID), an angiotensin-converting enzyme (ACE) inhibitor, an angiotensin receptor blocker (ARB), an anabolic steroid, a natural oil or fatty acid or any combination thereof.

Priority: US20050664225P Applic. Date: 2005-03-21; US20050713526P Applic. Date: 2005-08-31; US20050735432P Applic. Date: 2005-11-10; US20050753436P Applic. Date: 2005-12-22; WO2006US10510 Applic. Date: 2006-03-21

Inventor: BASCOMB NEWELL [US]; MAKI JOHN [US]; YOUNG FREDRIC [US]


Application No.: US20090215889A1  Published: 27/Aug/2009

Title: Novel Use of Zinc Gluconate for Treating Hydradenitis Suppurativa

Applicant/Assignee: LABCATAL

Application No.: 11/918317   Filing Date: 06/Apr/2006

Abstract:The invention relates to a novel therapeutic use of zinc gluconate. The zinc gluconate is used in a form for oral administration, at a daily dosage of between 45 and 125 mg, for treating suppurative hidradenitis, or Verneuil's disease.

Priority: FR20050003695 Applic. Date: 2005-04-13; WO2006FR00761 Applic. Date: 2006-04-06

Inventor: SUCK CATHERINE [FR]; DRENO BRIGITTE [FR]; BODIN JACQUES [FR]


Application No.: US20090215892A1  Published: 27/Aug/2009

Title: Octanol Formulations and Methods of Treatment Using the Same

Applicant/Assignee:

Application No.: 12/083141   Filing Date: 05/Oct/2006

Abstract:The invention features pharmaceutical formulations containing octanol and esters thereof. The pharmaceutical formulations are useful for the treatment of involuntary tremors.

Priority: US20050724635P Applic. Date: 2005-10-07; WO2006US38892 Applic. Date: 2006-10-05

Inventor: NAHAB FATTA B [US]; HALLETT MARK [US]; SERBIN JEFF [US]; MCLANE JOHN A [US]


Application No.: US20090215904A1  Published: 27/Aug/2009

Title: COLCHICINE COMPOSITIONS AND METHODS

Applicant/Assignee: MUTUAL PHARMACEUTICAL COMPANY, INC

Application No.: 12/465210   Filing Date: 13/May/2009

Abstract:Stable ultrapure colchicine compositions comprising ultrapure colchicine and a pharmaceutically acceptable excipient are described. The compositions can be tablets. Methods for preparing such compositions and methods of use are also disclosed. Methods of treating gout flares with colchicine compositions are also disclosed.

Priority: US2008-246034 Applic. Date: 2008-10-06; US20070977796P Applic. Date: 2007-10-05; US20080090965P Applic. Date: 2008-08-22

Inventor: DAVIS MATTHEW W [US]; WATSON SHAWN G [US]; FENG HENGSHENG [US]


Application No.: US20090216317A1  Published: 27/Aug/2009

Title: Delivery of Highly Lipophilic Agents Via Medical Devices

Applicant/Assignee:

Application No.: 11/886815   Filing Date: 22/Mar/2006

Abstract:An apparatus and system for delivering a lipophilic agent associated with a medical device including: a medical device, a first lipophilic agent capable of penetrating a body lumen, wherein the transfer coefficients of the first lipophilic agent is by an amount that is statistically significant of at least approximately 5,000, wherein the first lipophilic agent is associated with the medical device, wherein the first lipophilic agent/medical device is placed adjacent to said body lumen, and wherein a therapeutically effective amount of the first lipophilic agent is delivered to a desired area within a subject. Furthermore, the invention relates to a method for improving patency in a subject involving placement of a medical device in a body lumen for treating and/or preventing adjacent diseases or maintaining patency of the body lumen.

Priority: US20050664328P Applic. Date: 2005-03-23; WO2006US10307 Applic. Date: 2006-03-22

Inventor: CROMACK KEITH R [US]; TONER JOHN L [US]; BURKE SANDRA E [US]; KRASULA RICHARD W [US]; SCHWARTZ LEWIS B [US]


Application No.: US20090220585A1  Published: 03/Sep/2009

Title: Biological Active Blood Serum Fraction S-1-10, Methods for Producing It and Uses Thereof

Applicant/Assignee: OWEN HOLDING LTD

Application No.: 12/096295   Filing Date: 08/Dec/2006

Abstract:The present invention relates to a method for preparing a biological active fraction of blood serum, the biological active fraction (S-1-10) and a pharmaceutical composition comprising said fraction as well as uses thereof in the treatment of various diseases and conditions, in particular seizures, cardiovascular diseases and proliferative diseases.

Priority: EP20050027005 Applic. Date: 2005-12-09; US20050749332P Applic. Date: 2005-12-09; WO2006EP11866 Applic. Date: 2006-12-08

Inventor: SHESTAKOV A VITALI [RU]


Application No.: US20090220591A1  Published: 03/Sep/2009

Title: Pharmaceutical Compositions Comprising Non-Steroidal Antiinflammatory Drug, Antipyretic-Analgesic Drug and Proton Pump Inhibotor

Applicant/Assignee:

Application No.: 12/226524   Filing Date: 27/Apr/2007

Abstract:The present invention relates to pharmaceutical compositions in the form of fixed combination comprising non-steroidal anti-inflammatory drug or its single enantiomers or salts thereof, antipyretic-analgesic drug and proton pump inhibitor or its single enantiomers or salts thereof. The invention also relates to processes for the preparation of such compositions.

Priority: IN2006MU00665 Applic. Date: 2006-04-28; IN2006MU00666 Applic. Date: 2006-04-28; IN2006MU00667 Applic. Date: 2006-04-28; IN2006MU00668 Applic. Date: 2006-04-28; WO2007IB01110 Applic. Date: 2007-04-27

Inventor: MAINDE CHANDRASHEKHAR [IN]; VAHILE PRADEEP RAMDAS [IN]


Application No.: US20090220595A1  Published: 03/Sep/2009

Title: COMBINATION OF ERYTHROPOIETIN GLYCOISOFORMS

Applicant/Assignee:

Application No.: 12/093365   Filing Date: 07/Nov/2006

Abstract:This invention relates to a combination of erythropoietin glycoisoforms, wherein such glycoisoforms may include a quantity of sialic acid ranging from 4 to 10 molecules of sialic acid per molecule of erythropoietin. The combination of glycoisoforms can be used for the treatment or prevention of sepsis, and used to prepare a pharmaceutical composition including such combination. The invention also encompasses a cell line producing a combination of erythropoietin glycoisoforms, procedures to obtain the cell line, a procedure to produce such a combination of glycoisoforms, and methods of treatment and prevention of sepsis.

Priority: AR2005P104712 Applic. Date: 2005-11-10; WO2006ES70171 Applic. Date: 2006-11-07

Inventor: LOPEZ RICARDO AGUSTIN [AR]; DAELLI MARCELO GUSTAVO [AR]; PEREIRA BACCI DARDO ALEXIS [AR]; AMADEO GABRIEL IGNACIO [AR]; PEREIRO MIRIAM PATRICIA [AR]; ARTANA CRISTINA NOEMI [AR]; MASKIN NESTOR [AR]; PISTILLO BERNARDO CESAR [AR]; DIDIER CAROLINA [AR]; ETCHEVERRIGARAY MARINA [AR]; KRATJE RICARDO [AR]


Application No.: US20090220609A1  Published: 03/Sep/2009

Title: PROCESS TO CONTROL PARTICLE SIZE

Applicant/Assignee: ALPHAPHARM PTY LTD

Application No.: 12/093045   Filing Date: 10/Nov/2006

Abstract:A multi-stage process to control the particle size of a pharmaceutical substance comprising the steps of: passing the pharmaceutical substance through a first stage of a particle size reduction process with a first set of particle size control parameters to obtain a feedstock of reduced median particle size and lesser distribution of median particle size for a second stage of a particle size reduction process

passing the feedstock, through a second stage of a particle size reduction process with a second set of particle size control parameters

optionally, using the product of the second stage or subsequent stages as a feedstock in further stages of a multi-stage particle size reduction process with a set of particle size control parameters for each stage

and collecting a pharmaceutical substance with a median particle size greater than 10 mum and with a narrow, reproducible distribution of median particle sizes.

Priority: AU20050906227 Applic. Date: 2005-11-10; WO2006AU01687 Applic. Date: 2006-11-10

Inventor: MOONEY BRETT ANTONY [AU]; KERAMIDAS PANAGIOTIS PETER [AU]


Application No.: US20090220613A1  Published: 03/Sep/2009

Title: CONTROLLED RELEASE DELIVERY DEVICE COMPRISING AN ORGANOSOL COAT

Applicant/Assignee:

Application No.: 12/225954   Filing Date: 03/Apr/2007

Abstract:A controlled release delivery device for controlled release of an active ingredient comprising: (i) a core particle comprising the active ingredient homogenously dispersed or dissolved therein

and (ii) an organosol polymeric coat comprising a homogenous mixture of, (a) a water soluble gel forming polymer and a water insoluble organosoluble polymer in a dry weight ratio of from about 20:80 to about 50:50, (b) an organosolvent, and (c) an anti-tacking agent

the organosol polymeric coal being applied directly to and substantially enveloping the core particle.

Priority: US2006-396166 Applic. Date: 2006-04-03; WO2007CA00550 Applic. Date: 2007-04-03

Inventor: ODIDI ISA [CA]; ODIDI AMINA [CA]


Application No.: US20090220623A1  Published: 03/Sep/2009

Title: NOVEL HERBAL ACNE CONTROL COMPOSITION, METHOD OF MANUFACTURING THE SAME AND USE THEREOF

Applicant/Assignee: HIMALAYA GLOBAL HOLDINGS LIMITED HIMALAYA GLOBAL HOLDINGS, LTD

Application No.: 12/180279   Filing Date: 25/Jul/2008

Abstract:Disclosed herein a novel herbal acne control compositions comprising extracts of Swietenia mahagoni, Salix tetrasperma, Aloe vera and Curcuma longa and pharmaceutically acceptable excipients. Also disclosed are the methods of making the composition, formulating the same into different delivery systems and use thereof for the prevention of acne related skin disorders in human beings.

Priority: IN2008DE00478 Applic. Date: 2008-02-28

Inventor: MITRA SHANKAR KUMAR [IN]; SAXENA EKTA [IN]; BABU UDDAGIRI VENKANNA [IN]


Application No.: US20090221540A1  Published: 03/Sep/2009

Title: Method of Treating An Acute Vascular Disorder

Applicant/Assignee: PANTARHEI BIOSCIENCE B.V

Application No.: 12/160275   Filing Date: 09/Jan/2007

Abstract:The invention relates to a method of treating an acute vascular disorder in a mammal. The method comprises orally administering to the mammal an effective amount of a steroid. The steroid is selected from the group consisting of: substances represented by formula (I), in which R1, R2, R3, R4 independently are a hydrogen atom, a hydroxyl group or an alkoxy group with 1-5 carbon atoms

each of R5, R6, R7 is a hydroxyl group

no more than 3 of R1, R2, R3, R4 are hydrogen atoms

precursors capable of liberating a substance according to the aforementioned formula when used in the present method

and mixtures of one or more of the aforementioned substances and/or precursors.

Priority: EP20060100159 Applic. Date: 2006-01-09; US20060757027P Applic. Date: 2006-01-09; WO2007NL50006 Applic. Date: 2007-01-09

Inventor: BENNINK HERMAN JAN TIJMEN COELINGH [NL]


Application No.: US20090221545A1  Published: 03/Sep/2009

Title: Ophthalmic Pharmaceutical Composition Containing Amphiphilic Polyaspartamide Copolymers

Applicant/Assignee: SIFI S.P.A

Application No.: 12/293148   Filing Date: 15/Mar/2007

Abstract:The present invention relates in general to the use of amphiphilic graft-type copolymers of polyaspartamide for the ophthalmic administration of drugs, such as for example steroidal and non-steroidal anti-inflammatory agents, antimicrobial agents such as aminoglycosides, macrolides, cephalosporin, tetracycline, quinolones, penicillin, beta-lactams, anti-glaucoma agents such as prostaglandins, alpha- and beta-blockers, inhibitors of carbonic anhydrase, cannabinoids, antiviral agents, diagnostic agents, anti-angiogenic agents, antioxidants.

Priority: IT2006MI00494 Applic. Date: 2006-03-17; WO2007IT00188 Applic. Date: 2007-03-15

Inventor: GIAMMONA GAETANO [IT]; CAVALLARO GENNARA [IT]; LICCIARDI MARIANO [IT]; CIVIALE CLAUDINE [IT]; PALADINO GRAZIA MARIA [IT]; MAZZONE MARIA GRAZIA [IT]


Application No.: US20090226393A1  Published: 10/Sep/2009

Title: POLYMER PACLITAXEL CONJUGATES AND METHODS FOR TREATING CANCER

Applicant/Assignee: NITTO DENKO CORPORATION

Application No.: 12/397545   Filing Date: 04/Mar/2009

Abstract:Pharmaceutical compositions comprising a PGGA-PTX conjugate are prepared. The pharmaceutical compositions are used to treat a variety of cancers, such as lung cancer, skin cancer, kidney cancer, liver cancer and spleen cancer.

Priority: US20080034423P Applic. Date: 2008-03-06; US20080044214P Applic. Date: 2008-04-11

Inventor: WANG XINGHE [US]; ZHAO GANG [US]; VAN SANG [US]; YU LEI [US]


Application No.: US20090226530A1  Published: 10/Sep/2009

Title: POWDERED PROTEIN COMPOSITIONS AND METHODS OF MAKING SAME

Applicant/Assignee:

Application No.: 12/354665   Filing Date: 15/Jan/2009

Abstract:A method for preparing a protein or peptide powder is provided that includes spray drying a solution including more than, e.g., about 50 mg/mL of a protein or peptide (e.g., an antibody or antigen binding portion thereof), and at least one excipient. Also provided are stable powdered compositions including a protein and an excipient having less than, e.g., about 6% residual moisture.

Priority: US20080021298P Applic. Date: 2008-01-15

Inventor: LASSNER PETER K [DE]; ADLER MICHAEL [DE]; LEE GEOFFREY [DE]; KRAUSE HANS-JUERGEN [DE]; SIEDLER MICHAEL [DE]


Application No.: US20090226551A1  Published: 10/Sep/2009

Title: PHARMACEUTICAL COMPOSITION FOR PREVENTION AND/OR TREATMENT OF BONE LOSS

Applicant/Assignee: KO DA PHARMACEUTICAL CO., LTD

Application No.: 12/044577   Filing Date: 07/Mar/2008

Abstract:A pharmaceutical composition for preventing and/or treating bone loss is disclosed. The pharmaceutical composition includes an effective amount of a licorice, black bean, Cnidi Fructus, and buckhorn.

Priority:

Inventor: CHEN CHAO HSIANG [TW]; CHIEN MEI-YIN [TW]; FU WEN-MEI [TW]; CHANG JIN-MING [TW]


Application No.: US20090227546A1  Published: 10/Sep/2009

Title: PHARMACEUTICAL COMPOSITION OF DROSPIRENONE AND ETHYNYLESTRADIOL

Applicant/Assignee: LABORATORIES LICONSE, S.A

Application No.: 11/573499   Filing Date: 02/Aug/2005

Abstract:A pharmaceutical composition of drospirenone and ethynylestradiol with an improved dissolution rate. A method of preparation of a pharmaceutical formulation of drospirenone and ethynylestradiol in order to improve its dissolution profile. The formulation can be used to produce an anovulatory effect when administered correctly in humans.

Priority: EP20040103837 Applic. Date: 2004-08-09; WO2005EP53759 Applic. Date: 2005-08-02

Inventor: SANDRONE CARLOS ARIEL [AR]; SAKSON JOSE MARIO [AR]; CAJARVILLE BASAISTEGUI MARIA D [UY]; LARROSA POMI JOSE DANIEL [UY]


Application No.: US20090232744A1  Published: 17/Sep/2009

Title: Macrolide compositions having improved taste and stability

Applicant/Assignee: PARI PHARMA GMBH

Application No.: 12/380378   Filing Date: 26/Feb/2009

Abstract:The invention provides an aqueous pharmaceutical composition for administration as an aerosol to the respiratory tract, nose or oropharyngeal region comprising (i) a macrolide having a poor taste and poor chemical stability in aqueous solution

(ii) at least one salt selected from the group consisting of sodium gluconate, sodium aspartate, sodium acetate, sodium lactate, sodium succinate, sodium maleate, magnesium gluconate, magnesium aspartate, magnesium citrate, magnesium acetate, magnesium lactate, magnesium succinate, and magnesium maleate

or mixtures thereof and (iii) a taste-masking agent different from said salt

wherein (a) the concentration of said macrolide in the composition is in the range of about 0.25 wt.-% to about 15 wt.-%

(b) the molar ratio of said macrolide:said salt is in the range from about 1:0.5 to about 1:100

(c) the pH of the composition is in the range of about 3 to 9

and (d) the osmolality of the composition is in the range of about 150 mOsmol/kg to about 1500 mOsmol/kg. The invention further provides a method of generating an aerosol, preferably by means of a nebuliser, which uses such an aqueous pharmaceutical composition. The macrolide may be used alone or in combination with other drugs. The composition is suitable to treat inflammatory disorders and/or infections of the respiratory tract. It has an improved taste and stability.

Priority: US20080068218P Applic. Date: 2008-03-05

Inventor: KELLER MANFRED [DE]; CORBANIE EVY [DE]


Application No.: US20090232810A1  Published: 17/Sep/2009

Title: IMMUNOCONJUGATES TARGETING CD138 AND USES THEREOF

Applicant/Assignee:

Application No.: 12/342407   Filing Date: 23/Dec/2008

Abstract:Disclosed are immunoconjugates having in particular specificity for CD138 expressed on target cells and which display homogenous targeting. The immunoconjugates may be sterially hindered and/or contain a cleavable linker.

Priority: US20070016620P Applic. Date: 2007-12-26; US20080087466P Applic. Date: 2008-08-08; US20080087590P Applic. Date: 2008-08-08

Inventor: KRAUS ELMAR [DE]; BRUECHER CHRISTOPH [DE]; DAELKEN BENJAMIN [DE]; ZENG STEFFEN [DE]; OSTERROTH FRANK [DE]; UHEREK CHRISTOPH [DE]; AIGNER SILKE [DE]; GERMER MATTHIAS [DE]


Application No.: US20090232885A1  Published: 17/Sep/2009

Title: Drug Delivery Systems Comprising Weakly Basic Drugs and Organic Acids

Applicant/Assignee:

Application No.: 12/209285   Filing Date: 12/Sep/2008

Abstract:The present invention is directed to pharmaceutical compositions, and methods of making such compositions, wherein the compositions comprise a plurality of TPR and RR particles, wherein: the TPR particles each comprise a core coated with a TPR layer

the core comprises a weakly basic, poorly soluble drug and a pharmaceutically acceptable organic acid separated from each other by an SR layer

the RR particles each comprise the weakly basic, poorly soluble drug, and release at least about 80 wt.% of the weakly basic, poorly soluble drug in about 5 minutes when dissolution tested using United States Pharmacopoeia (USP) dissolution methodology (Apparatus 2-paddles@ 50 RPM and a two-stage dissolution medium at 37 DEG C., (first 2 hours in 0.1N HCl followed by testing in a buffer at pH 6.8).

Priority: US20080035840P Applic. Date: 2008-03-12

Inventor: VENKATESH GOPI [US]; LAI JIN-WANG [US]; VYAS NEHAL H [US]; PUROHIT VIVEK [US]


Application No.: US20090232888A1  Published: 17/Sep/2009

Title: SUSTAINED DELIVERY OF ANTIBIOTICS

Applicant/Assignee: ORIENT PHARMA

Application No.: 12/403896   Filing Date: 13/Mar/2009

Abstract:The present invention is directed to compositions for the sustained delivery of an antibiotic, for example vancomycin, to achieve desirable release profiles. This application is also directed to methods of using the compositions and processes for manufacturing the compositions.

Priority: US20080064631P Applic. Date: 2008-03-17

Inventor: CHIANG CHIN-CHIH [US]; CHEN REMY [TW]


Application No.: US20090232889A1  Published: 17/Sep/2009

Title: CRYSTALLINE SALTS OF QUINOLINE COMPOUNDS AND METHODS FOR PREPARING THEM

Applicant/Assignee: ACTIVE BIOTECH AB

Application No.: 12/405413   Filing Date: 17/Mar/2009

Abstract:A stable solid pharmaceutical composition consisting essentially of an effective amount of a crystalline salt of formula (II) together with an alkaline-reacting component maintaining the pH preferably above 8, or a salt with a divalent metal cation

and at least one pharmaceutical excipient

said salt of formula (II) being essentially stable during storage at room temperature for a period of at least 3 years. A process for stabilizing the salt of formula (II). A crystalline salt of formula (II) and a process for preparing said salt.

Priority: SE20040000235 Applic. Date: 2004-02-06; US2005-050441 Applic. Date: 2005-02-04

Inventor: JANSSON KARL [SE]; FRISTEDT TOMAS [SE]; WANNMAN HANS [SE]; BJORK ANDERS [SE]


Application No.: US20090232896A1  Published: 17/Sep/2009

Title: Use of Magnesium Stearate Dihydrate for Lubrication of Solid Pharmaceutical Compositions

Applicant/Assignee: MALLINCKRODT INC

Application No.: 12/369013   Filing Date: 11/Feb/2009

Abstract:The invention provides lubricant compositions comprising magnesium stearate dihydrate. The lubricant compositions may be used to lubricate a variety of bioactive formulations including pharmaceutical compositions.

Priority: US20080027580P Applic. Date: 2008-03-11; US20080042001P Applic. Date: 2008-04-03; US20080055157P Applic. Date: 2008-05-22

Inventor: WU STEPHEN H [US]; CHENG BRIAN K [US]; NICHOLS GARY A [US]; PARK JAE H [US]


Application No.: US20090233889A1  Published: 17/Sep/2009

Title: STABILIZED 1,25-DIHYDROXYVITAMIN D2 AND METHOD OF MAKING SAME

Applicant/Assignee:

Application No.: 12/403271   Filing Date: 12/Mar/2009

Abstract:A stabilized 1,25-dihydroxyvitamin D2 composition which is particularly well suited for pharmaceutical formulations, pharmaceutical formulations of the 1,25-dihydroxyvitamin D2 composition, and a method of making the purified composition by purifying a crude 1,25-dihydroxyvitamin D2 from acetone/water, are disclosed.

Priority: US20080036021P Applic. Date: 2008-03-12

Inventor: SAHA UTTAM [CA]


Application No.: US20090238900A1  Published: 24/Sep/2009

Title: NOVEL ANTI-DIABETIC HERBAL COMPOSITION, METHOD FOR PREPARING THE SAME AND USE THEREOF

Applicant/Assignee: HIMALAYA GLOBAL HOLDINGS LIMITED

Application No.: 12/199621   Filing Date: 27/Aug/2008

Abstract:Disclosed is an herbal composition for the treatment of Type II diabetes and their associated secondary complications in humans, wherein said composition comprising extract of roots of Cipadessa baccifera and pharmaceutically acceptable excipients, method for preparing the same and use thereof. The anti-diabetic herbal composition disclosed herein is effective to reduce the glucose, triglyceride levels in blood or other complications related to Type-II diabetes and its secondary complications thereof.

Priority: IN2008DE00734 Applic. Date: 2008-03-24

Inventor: MITRA SHANKAR KUMAR [IN]; SAXENA EKTA [IN]; BABU UDDAGIRI VENKANNA [IN]


Application No.: US20090238903A1  Published: 24/Sep/2009

Title: PROCESS FOR THE PREPARATION OF SOUR CHERRY SEED EXTRACT, USE OF THE EXTRACT FOR THE PREPARATION OF PHARMACEUTICAL COMPOSITIONS AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAID EXTRACT

Applicant/Assignee: DEBRECENI EGYETEM

Application No.: 12/091440   Filing Date: 25/Oct/2006

Abstract:The present invention relates to a process for the isolation of the components of seed of Primus cerasus (sour cherry), the components thus obtained, pharmaceutical compositions containing said components as well as the use of the components for the preparation of cardioprotective pharmaceutical compositions. The components according to the invention are especially useful for improving circulation, preventing stenosis or ameliorating ischemia-induced myocardial damages.

Priority: HU20050000975 Applic. Date: 2005-10-25; WO2006HU00093 Applic. Date: 2006-10-25

Inventor: TOSAKI ARPAD [HU]; VECSERNYES MIKLOS [HU]; FESUS LASZLO [HU]; BAK ISTVAN [HU]; JUHASZ BELA [HU]; PAPP LASZLO [HU]; TOTH SZILVIA [HU]


Application No.: US20090238906A1  Published: 24/Sep/2009

Title: FLAVOR IMPROVING AGENT

Applicant/Assignee: ADEKA CORPORATION

Application No.: 12/092842   Filing Date: 20/Jun/2007

Abstract:A taste improving agent containing as an active ingredient a whey mineral satisfying all the criteria (a), (b), (c), (d), and (e) below: (a) an ash content in an solid portion of the whey mineral is 25 to 75% by mass

(b) a calcium content in a solid portion of the whey mineral is less than 2% by mass

(c) a calcium content in an ash portion of the whey mineral is less than 5% by mass

(d) a lactic acid content in a solid portion of the whey mineral is 1.0% by mass or more

and (e) a pH of an aqueous solution containing 0.1% by mass of a solid portion of the whey mineral is 6.0 to 7.5.

Priority: JP20060171940 Applic. Date: 2006-06-21; JP20060171941 Applic. Date: 2006-06-21; JP20060171942 Applic. Date: 2006-06-21; JP20060171943 Applic. Date: 2006-06-21; JP20060171944 Applic. Date: 2006-06-21; JP20060171945 Applic. Date: 2006-06-21; JP20060213708 Applic. Date: 2006-08-04; JP20060213712 Applic. Date: 2006-08-04; JP20060213713 Applic. Date: 2006-08-04; JP20060213710 Applic. Date: 2006-08-04; JP20060213711 Applic. Date: 2006-08-04; JP20070160736 Applic. Date: 2007-06-18; JP20070160732 Applic. Date: 2007-06-18; JP20070160733 Applic. Date: 2007-06-18; JP20070160734 Applic. Date: 2007-06-18; JP20070160735 Applic. Date: 2007-06-18; JP20070160737 Applic. Date: 2007-06-18; WO2007JP62461 Applic. Date: 2007-06-20

Inventor: IKEDA KENJI [JP]; TASHIRO SHUZO [JP]; HAMADA SATOSHI [JP]; SATO KATSUHIKO [JP]


Application No.: US20090239881A1  Published: 24/Sep/2009

Title: Combinations of Flibanserin with Caffeine, Process for Their Preparation and Use Thereof as Medicaments

Applicant/Assignee: BOEHRINGER INGELHEIM INTERNATIONAL GMBH

Application No.: 12/306946   Filing Date: 11/Jul/2007

Abstract:The invention is directed to a combination of flibanserin or a pharmaceutically acceptable derivative thereof and caffeine or a pharmaceutically acceptable derivative thereof for the treatment of Sexual Disorders in humans, particularly women.

Priority: US20060830989P Applic. Date: 2006-07-14; WO2007EP57065 Applic. Date: 2007-07-11

Inventor: BECKER REINHOLD [DE]


Application No.: US20090239900A1  Published: 24/Sep/2009

Title: QUININE AND QUINIDINE SALTS, METHODS FOR MAKING THEM, AND PHARMACEUTICAL FORMULATIONS COMPRISING THEM

Applicant/Assignee: UNIVERSITEIT GENT

Application No.: 12/053357   Filing Date: 21/Mar/2008

Abstract:The present invention provides a combination of: a N-containing drug molecule salt, wherein said drug molecule is selected from the group consisting of quinine and quinidine, and an aromatic mono- or dicarboxylic acid salt, e.g. quinine pamoate, which is useful for a pharmaceutical formulation such as a pediatric suspension, especially in the treatment of malaria.

Priority:

Inventor: REMON JEAN PAUL [BE]; VERVAET CHRIS [BE]


Application No.: US20090246232A1  Published: 01/Oct/2009

Title: Pharmaceutical composition

Applicant/Assignee: TAKEDA PHARMACEUTICAL COMPANY, LIMITED TAKEDA PHARMACEUTICAL COMPANY LIMITED

Application No.: 12/382691   Filing Date: 20/Mar/2009

Abstract:Pharmaceutical composition which comprises an insulin sensitivity enhancer in combination with other antidiabetics differing from the enhancer in the mechanism of action, which shows a potent depressive effect on diabetic hyperglycemia and is useful for prophylaxis and treatment of diabetes.

Priority: JP19950153500 Applic. Date: 1995-06-20; US2006-523771 Applic. Date: 2006-09-20; US2004-937494 Applic. Date: 2004-09-10; US2003-462793 Applic. Date: 2003-06-17; US2002-095453 Applic. Date: 2002-03-13; US2001-973689 Applic. Date: 2001-10-11; US1999-453521 Applic. Date: 1999-12-03; US1999-280710 Applic. Date: 1999-03-30; US1998-057465 Applic. Date: 1998-04-09; US1996-667979 Applic. Date: 1996-06-19

Inventor: IKEDA HITOSHI [JP]; SOHADA TAKASHI [JP]; ODAKA HIROYUKI [JP]


Application No.: US20090246276A1  Published: 01/Oct/2009

Title: Pharmaceutical Compositions

Applicant/Assignee:

Application No.: 12/360673   Filing Date: 27/Jan/2009

Abstract:The present invention relates to a pharmaceutical composition comprising a tablet core comprising a combination of actives selected from the group consisting of bupropion hydrochloride and escitalopram oxalate, bupropion hydrobromide and citalopram hydrochloride, bupropion hydrobromide and escitalopram oxalate, and bupropion hydrobromide and quetiapine fumarate, and at least one pharmaceutically acceptable excipient, and a control-releasing coat surrounding the tablet core, wherein said composition surprisingly provides for a synchronous release of the combination of active agents across in-vitro. The once-daily pharmaceutical composition surprisingly also provides for enhanced absorption of bupropion hydrobromide when administered to a subject in need of such administration.

Priority: US20080023951P Applic. Date: 2008-01-28

Inventor: JACKSON GRAHAM [BB]; WALSH EDWIN [IE]; OBEREGGER WERNER [CA]; JIN XIAOPIN [CA]


Application No.: US20090246288A1  Published: 01/Oct/2009

Title: Taste-masking oral dosage form and method of preparing the same

Applicant/Assignee: PHARMACEUTICAL INDUSTRY TECHNOLOGY AND DEVELOPMENT CENTER

Application No.: 12/457151   Filing Date: 02/Jun/2009

Abstract:The present invention provides a taste-masking oral dosage form which comprises a taste-masked microparticle and an excipient. The taste-masked microparticle comprises a taste-masked crystal containing an active pharmaceutical ingredient masked by a hydrophilic polymer and a starch. The present invention also provides a method for making the taste-masked microparticles and taste-masking oral dosage form.

Priority: TW20040104745 Applic. Date: 2004-02-25; US2004-839243 Applic. Date: 2004-05-06

Inventor: YANG CHIH-CHIANG [TW]; WANG WEN-CHE [TW]; CHEN HUI-YU [TW]


Application No.: US20090247529A1  Published: 01/Oct/2009

Title: TOPICAL COMPOSITIONS

Applicant/Assignee: DR. REDDY'S LABORATORIES LTD DR. REDDY'S LABORATORIES, INC

Application No.: 12/304420   Filing Date: 14/Jun/2007

Abstract:Single phase pharmaceutical compositions for topical application, in addition to kits and methods of use and administration are provided. The compositions comprise a biologically active agent

a delivery vehicle comprising at least a non-polymeric crystallization inhibitor and a film-former

and a volatile solvent

wherein the biologically active agent is present in the composition in a subsaturated state, the biologically active agent is present in the delivery vehicle in a supersaturated state, and the crystallization inhibitor is capable of delaying crystallization of the biologically active agent in the delivery vehicle. Biologically active agents include terbinafine and acyclovir. Treatments for onychomycosis and Varicella zoster infection, HSV-1 infection or HSV-2 infection are provided.

Priority: US20060813372P Applic. Date: 2006-06-14; US20060820542P Applic. Date: 2006-07-27; US20060820546P Applic. Date: 2006-07-27; WO2007US71212 Applic. Date: 2007-06-14

Inventor: LINDAHL AKE [SE]; SVENSSON BIRGITTA [SE]; HOLMBERG ANNA [SE]; ENGBLOM JOHAN [SE]


Application No.: US20090247532A1  Published: 01/Oct/2009

Title: Crystalline polymorph of sitagliptin phosphate and its preparation

Applicant/Assignee: MAE DE LTD

Application No.: 12/321146   Filing Date: 21/Jan/2009

Abstract:The present invention is directed to a novel polymorph form of crystalline sitagliptin phosphate, named as Form V herein. The present invention further provides processes for preparations of Form V, pharmaceutical composition comprising Form V and its use in therapy. Form V can be prepared from recrystallizing sitagliptin phosphate in a mixture of methanol and water, a mixture of acetone and water, or from distillation of a mixture of organic solvents and water followed by recrystallization in the remaining aqueous solution.

Priority: US20080072107P Applic. Date: 2008-03-28

Inventor: HUANG CAI GU [CN]; HUANG HUI MIN HE [CN]


Application No.: US20090247575A1  Published: 01/Oct/2009

Title: STABILIZING LIPID COMPOSITIONS FOR ORAL PHARMACEUTICAL AGENTS

Applicant/Assignee: TARO PHARMACEUTICALS NORTH AMERICA, INC

Application No.: 12/412029   Filing Date: 26/Mar/2009

Abstract:The present invention relates to a pharmaceutical composition for oral administration comprising an exceptionally labile active agent, a stabilizing vehicle comprising liquid triglycerides and a desiccant, wherein the composition is storage stable for an extended period without substantial degradation of the active agent.

Priority: US20080064782P Applic. Date: 2008-03-26; US20080064783P Applic. Date: 2008-03-26

Inventor: ASOTRA SATISH [CA]; GAO SHEN [CA]; YACOBI AVRAHAM [US]; MOROS DANIEL A [US]; ZADYKOWICZ JERZY [CA]


Application No.: US20090247614A1  Published: 01/Oct/2009

Title: Folate Conjugates

Applicant/Assignee: ALNYLAM PHARMACEUTICALS, INC

Application No.: 12/328537   Filing Date: 04/Dec/2008

Abstract:The present invention provides iRNA agent including at least one monomer having the structure shown in formula (I') wherein: A and B are each independently for each occurrence O, N(RN) or S

X is H, a protecting group, a phosphate group, a phosphodiester group, an activated phosphate group, an activated phosphite group, a phosphoramidite, a solid support, -P(Z')(Z'')O-nucleoside, -P(Z')(Z'')O-oligonucleotide, a lipid, a PEG, a steroid, a polymer, -P(Z')(Z'')O-L6-Q'-L7-OP(Z''')(Z'''')O-oligonucleotide, a nucleotide, or an oligonucleotide

Y is H, a protecting group, a phosphate group, a phosphodiester group, an activated phosphate group, an activated phosphite group, a phosphoramidite, a solid support, -P(Z')(Z'')O-nucleoside, -P(Z')(Z'')O-oligonucleotide, a lipid, a PEG, a steroid, a lipophile, a polymer, -P(Z')(Z'')O-L6-Q'-L7-OP(Z''')(Z'''')O-oligonucleotide, a nucleotide, or an oligonucleotide

R is folate, a folate analog a folate mimic or a folate receptor binding ligand

L6 and L1 are each independently for each occurrence -(CH2)n-, -C(R')(R'')(CH2)n-, -(CH2)nC(R')(R'')-, -(CH2CH2O)mCH2CH2-, or -(CH2CH2O)mCH2CH2NH-

Q' is NH, O, S, CH2, C(O)O, C(O)NH, -NH-CH(Ra)-C(O)-, -C(O)-CH(Ra)-NH-, CO, where Ra is H or amino acid side

chain. R' and R'' are each independently H, CH3, OH, SH, NH2, NH(Alkyl=Me, Et, Pr, isoPr, Bu, Bn) or N(diAlkyl=Me2, Et2, Bn2)

Z', Z'', Z''' and Z'''' are independently O or S

n represent independently for each occurrence 1-20

and m represent independently for each occurrence 0-50.

Priority: US20070992309P Applic. Date: 2007-12-04; US20070013597P Applic. Date: 2007-12-13

Inventor: MANOHARAN MUTHIAH [US]; RAJEEV KALLANTHOTTATHIL G [US]; JAYARAMAN MUTHUSAMY [US]; NARAYANANNAIR JAYAPRAKASH K [US]


Application No.: US20090247644A1  Published: 01/Oct/2009

Title: MEMANTINE FORMULATIONS

Applicant/Assignee: FOREST LABORATORIES HOLDINGS LIMITED

Application No.: 12/412447   Filing Date: 27/Mar/2009

Abstract:The present invention relates to pharmaceutical compositions prepared from equant-shaped crystals of memantine, such as orally dissolving formulations, e.g., tablets (ODTs) and films (ODFs), and to methods of treating conditions, including childhood behavioral disorders (e.g., autism) and Alzheimer's disease by administering the same.

Priority: US20080040171P Applic. Date: 2008-03-28

Inventor: DEDHIYA MAHENDRA G [US]; SARKAR RANAJOY [US]


Application No.: US20090252786A1  Published: 08/Oct/2009

Title: Use of a Biologically Active Blood Serum for the Treatment of a Disorder Characterized in a Reduced Function of a GABA Receptor

Applicant/Assignee:

Application No.: 12/411509   Filing Date: 26/Mar/2009

Abstract:The present invention relates to a method of preventing or treating in a subject a disorder characterized in a reduced GABA receptor function by administering to the subject a therapeutically effective amount of a pharmacologically active blood serum product obtainable by a method comprising electrostimulation of a non-human animal, withdrawal of blood from said animal isolation of serum from said blood, and gamma irradiation of said serum.

Priority: US20080040813P Applic. Date: 2008-03-31

Inventor: HANZ CHRISTOPH [CH]


Application No.: US20090252787A1  Published: 08/Oct/2009

Title: GRANULAR PHARMACEUTICAL COMPOSITIONS

Applicant/Assignee: DR. REDDY'S LABORATORIES LTD DR. REDDY'S LABORATORIES, INC

Application No.: 12/375269   Filing Date: 19/Jul/2007

Abstract:Pharmaceutical compositions comprising a plurality of formulated particles containing at least one active ingredient and at least one pharmaceutically acceptable excipient, granulated with a granulating composition containing at least one pharmaceutical excipient.

Priority: US20060820629P Applic. Date: 2006-07-28; WO2007US73889 Applic. Date: 2007-07-19

Inventor: PASHA MOHAMMAD BALA [IN]; KANDARAPU RAGHUPATHI [IN]; SHETTY VASANTH KUMAR [IN]; BHUSHAN INDU [IN]; MOHAN MAILATUR SIVARAMAN [IN]


Application No.: US20090252788A1  Published: 08/Oct/2009

Title: Balsalazide formulations and manufacture and use thereof

Applicant/Assignee: SALIX PHARMACEUTICALS, INC

Application No.: 12/072112   Filing Date: 22/Feb/2008

Abstract:The invention relates to formulations and dosage schedules of balsalazide. The invention further relates to methods of producing pharmaceutical formulations of balsalazide.

Priority: WO2006US33255 Applic. Date: 2006-08-24; US20050711300P Applic. Date: 2005-08-24

Inventor: LOCKHART JOSEPH [US]; SWANSON BROCK [US]; JOHNSON LORIN [US]


Application No.: US20090252790A1  Published: 08/Oct/2009

Title: TABLET FORMULATION

Applicant/Assignee: NOVO NORDISK A/S

Application No.: 12/300662   Filing Date: 10/May/2007

Abstract:The present invention relates to a pharmaceutical fixed dose combination tablet comprising repaglinide and metformin. The present invention also provides a method of producing said tablet.

Priority: EP20060009902 Applic. Date: 2006-05-13; EP20060121953 Applic. Date: 2006-10-09; WO2007EP54510 Applic. Date: 2007-05-10

Inventor: WADA KOICHI [JP]; FUJITA HIKARU [JP]; NAKATANI MANABU [JP]; FRIEDL THOMAS [DE]


Application No.: US20090252792A1  Published: 08/Oct/2009

Title: METHOD TO REDUCE THE SYMPTOMS OF HEARTBURN AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GERD) BY SPECIFIC POLYSACCHARIDES

Applicant/Assignee:

Application No.: 12/300632   Filing Date: 16/May/2007

Abstract:The invention is directed to the use of a specific group of polysaccharides for reducing the symptoms or heartburn and gastroesophageal reflux isease. In addition, a pharmaceutical preparation is provided comprising a specific group of polysaccharides having a high hydration rate, a high viscosity, and a high stability at low pH. Such a preparation is particularly effective in reducing the symptoms of heartburn and/or gastro-oesophageal reflux disease, particularly when consumed in dry form.

Priority: EP20060076056 Applic. Date: 2006-05-16; US20060806313P Applic. Date: 2006-06-30; WO2007NL50224 Applic. Date: 2007-05-16

Inventor: VERBRUGGEN MARIA ANNA [NL]; KELLY CALVIN T [CA]; SUDOM BLAINE G [CA]


Application No.: US20090252801A1  Published: 08/Oct/2009

Title: Process for the Preparation of Micronised Sterile Steroids

Applicant/Assignee: FARMBIOS S.P.A

Application No.: 12/085602   Filing Date: 28/May/2008

Abstract:The present invention relates to a process for the preparation of micronised sterile steroids, comprising sterilisation of the steroids in crystalline form by means of irradiation with gamma or beta rays, and subsequent sterile micronisation.

Priority: WO2005EP56307 Applic. Date: 2005-11-29

Inventor: FORTUNATO GIUSEPPE [IT]; POZZOLI CLAUDIO GIANLUCA [IT]; RICCI FRANCO [IT]


Application No.: US20090252803A1  Published: 08/Oct/2009

Title: GLYCYRRHETINIC ACID-MEDIATED NANOPARTICLES OF HEPATIC TARGETED DRUG DELIVERY SYSTEM, PROCESS FOR PREPARING THE SAME AND USE THEREOF

Applicant/Assignee: NANKAI UNIVERSITY & TIAN SI POLYMER MATERIALS TECHNOLOGY DEVELOPMENT CO., LTD

Application No.: 12/338966   Filing Date: 18/Dec/2008

Abstract:Disclosed are a hepatic targeted drug delivery system and a process for preparing the same. Also disclosed is a method for treating liver cancer.

Priority: CN20081052635 Applic. Date: 2008-04-08; CN20081052636 Applic. Date: 2008-04-08

Inventor: YUAN ZHI [CN]; HUANG WEI [CN]; TIAN QIN [CN]; ZHANG CHUANGNIAN [CN]; HAN LIANG [CN]; LIU TONG [CN]; ZHANG YUE [CN]; CHEN YUE [CN]


Application No.: US20090252807A1  Published: 08/Oct/2009

Title: Nanoparticulate and Controlled Release Compositions Comprising Prostaglandin Derivatives

Applicant/Assignee: ELAN PHARMA INTERNATIONAL LIMITED

Application No.: 11/568698   Filing Date: 13/Apr/2006

Abstract:The present invention is directed to compositions comprising a nanoparticulate prostaglandin derivative, preferably limaprost or a salt or derivative thereof, having improved bioavailability. The nanoparticulate prostaglandin derivative particles of the composition have an effective average particles size of less than about 2000 nm and are useful in the treatment of ischemic symptoms. The invention also relates to a controlled release composition comprising a prostaglandin derivative, such as limaprost alfadex, or a nanoparticulate prostaglandin derivative, such as limaprost or a salt or derivative thereof, that in operation delivers the drug in a pulsed or bimodal manner for the treatment of ischemic symptoms.

Priority: US20050670831P Applic. Date: 2005-04-13; WO2006US13784 Applic. Date: 2006-04-13

Inventor: JENKINS SCOTT [US]; LIVERSIDGE GARY [US]


Application No.: US20090252810A1  Published: 08/Oct/2009

Title: Aryl/alkyl Succinic Anhydride-Hyaluronan Derivatives

Applicant/Assignee: NOVOZYMES BIOPOLYMER A/S

Application No.: 11/572954   Filing Date: 26/Sep/2006

Abstract:The present invention relates to the modification of hyaluronic acid (HA) with aryl/alkyl succinic anhydrides (ASA) to produce aryl/alkyl succinic anhydride HA derivatives, to the derivatives as such, and to their applications and uses, particularly in the cosmetic and biomedical industries. The ASA-HA derivatives are expected to have interesting properties that can be used for advanced formulation (bind stronger to the skin compared to non-modified HA), possibly also in delivery systems for actives or drugs by encapsulation (nano/micro capsules) or formation of nano/micro spheres. Further, the low MW ASA-HA derivatives are expected to penetrate the skin more efficiently than non-modified HA of the same MW.

Priority: DK20050001332 Applic. Date: 2005-09-26; US20050721232P Applic. Date: 2005-09-27; WO2006DK00523 Applic. Date: 2006-09-26

Inventor: TOMMERAAS KRISTOFFER [SE]; EENSCHOOTEN CORINNE [FR]


Application No.: US20090253651A1  Published: 08/Oct/2009

Title: DRUG DELIVERY SYSTEM BASED ON REGIOSELECTIVELY AMIDATED HYALURONIC ACID

Applicant/Assignee: EURAND PHARMACEUTICALS LTD

Application No.: 12/375379   Filing Date: 27/Jul/2007

Abstract:New drug delivery systems (DDS) are described containing hyaluronic acid and a therapeutic agent, wherein the therapeutic agent is linked, directly or via a linker, to 6-aminohyaluronic acid and where the linkage of the drug or linker with 6-aminohyaluronic acid is realised by an amide bond. Preferred therapeutic agents for use in the present DDS are anti-inflammatory, antibiotic, antitumor drugs. Preferred linkers are: succinic acid, succinic acid linked to aminoacids, succinic acid linked to peptides. The DDS are stable and free of undesired reaction by-products and impurities, and show a high level of pharmacological efficacy.

Priority: IE20060000565 Applic. Date: 2006-07-28; WO2007EP57772 Applic. Date: 2007-07-27

Inventor: NORBEDO STEFANO [IT]; BOSI SUSANNA [IT]; BERGAMIN MASSIMO [IT]; KHAN RIAZ AHMED [GB]; MURANO ERMINIO [IT]; DINON FRANCESCA [IT]


Application No.: US20090253664A1  Published: 08/Oct/2009

Title: COMBINATION ANDOLAST/GLUCOCORTICOIDS

Applicant/Assignee:

Application No.: 12/375609   Filing Date: 07/Apr/2009

Abstract:The invention relates to the combination of Andolast, a calcium-activated potassium channel opener and glucocorticoids for the treatment of patients suffering for airway diseases. Pharmaceutical compositions comprising Andoalst and glucocorticoids are also disclosed.

Priority: WO2006EP64840 Applic. Date: 2006-07-31

Inventor: MAKOVEC FRANCESCO [IT]; D AMATO MASSIMO MARIA [IT]; GIORDANI ANTONIO [IT]; ROVATI LUCIO CLAUDIO [IT]


Application No.: US20090253743A1  Published: 08/Oct/2009

Title: COMPOSITIONS OF TOLPERISONE

Applicant/Assignee: AVIGEN, INC SANOCHEMIA PHARMAZEUTIKA, AG

Application No.: 12/324387   Filing Date: 26/Nov/2008

Abstract:The present disclosure is directed to methods for providing tolperisone having extremely low levels of 4-MMPPO (2-methyl-1-(4-methylphenyl)-propenone), as well as related compositions. The invention further relates to methods of treating a subject with tolperisone under conditions that limit exposure of the subject to tolerable levels of 4-MMPPO, among other features.

Priority: AT20070001953 Applic. Date: 2007-11-29; AT20070000658 Applic. Date: 2007-04-26; US20080023799P Applic. Date: 2008-01-25; US20080027287P Applic. Date: 2008-02-08

Inventor: GAETA FEDERICO [US]; WELZIG STEFAN [AT]; ROTHENBURGER JAN [AT]; KALZ BEATE [AT]; GUNGL JOZSEF [HU]; GERDES KLAUS [AT]


Application No.: US20090258067A1  Published: 15/Oct/2009

Title: MODIFIED RELEASE COMPOSITION OF AT LEAST ONE FORM OF VENLAFAXINE

Applicant/Assignee: BIOVAIL LABORATORIES INTERNATIONAL S.R.L

Application No.: 12/425819   Filing Date: 17/Apr/2009

Abstract:The present invention relates to a modified release composition of at least one form of venlafaxine, which is an enhanced absorption delayed controlled release composition. The composition comprises a core comprising at least one form of venlafaxine, less than 10% of a gelling agent and a pharmaceutically acceptable excipient. The composition further comprises a modified release coating which substantially surrounds the core which provides a delayed controlled release of the at least one form of venlafaxine.

Priority: US2007-947883 Applic. Date: 2007-11-30; US2006-445198 Applic. Date: 2006-06-02; US20050686461P Applic. Date: 2005-06-02; US20050691282P Applic. Date: 2005-06-17

Inventor: ZHOU FANG [US]; MAES PAUL [FR]; FRISBEE STEVEN [US]


Application No.: US20090258845A1  Published: 15/Oct/2009

Title: Combination Dosage Forms and Therapies for Supporting Bone Health

Applicant/Assignee: PRIMUS PHARMACEUTICALS, INC

Application No.: 12/409090   Filing Date: 23/Mar/2009

Abstract:Combined therapies and oral dosage forms based on genistein for the support of osteoporotic health.

Priority: US20080038792P Applic. Date: 2008-03-24

Inventor: BURNETT BRUCE P [US]; WEIR J D [US]; SQUADRITO FRANCESCO [IT]


Application No.: US20090258947A1  Published: 15/Oct/2009

Title: NOVEL LOW DOSE PHARMACEUTICAL COMPOSITIONS COMPRISING NIMESULIDE, PREPARATION AND USE THEREOF

Applicant/Assignee:

Application No.: 12/298054   Filing Date: 23/Apr/2007

Abstract:Low dose pharmaceutical dosage form comprising nimesulide or its pharmaceutically acceptable salts, esters, solvates or hydrates thereof, along with one or more pharmaceutically acceptable excipient(s) are provided. The present invention also provides process of preparing such dosage forms and therapeutic methods of using such dosage forms. The low dose compositions 10 are designed to exhibit such bioavailability, which is effective in the treatment of NSAID indicated disorders particularly, which require long-term treatment regimens such as arthritis. Such compositions reduce the cost of therapy in diseases, which require long-term therapies, are easy to manufacture, and also result in the reduction of dose related side effects associated with nimesulide therapy.

Priority: IN2006DE01033 Applic. Date: 2006-04-24; WO2007IN00162 Applic. Date: 2007-04-23

Inventor: JAIN RAJESH [IN]; JINDAL KOUR CHAND [IN]


Application No.: US20090263333A1  Published: 22/Oct/2009

Title: Pharmaceutical compounds and compositions

Applicant/Assignee: CIPLA LIMITED

Application No.: 11/721866   Filing Date: 19/Dec/2005

Abstract:The invention provides three polymorphic forms of crystalline levosalbutamol sulphate designated herein as Forms I, II and III. Crystalline levosalbutamol sulphate Form I is characterised by a powder XRD pattern with peaks at 10.8, 11.9, 13.0, 18.3, 28.5+-0.2 degrees 2 theta. Crystalline levosalbutamol sulphate Form II is characterised by a powder XRD pattern with peaks at 8.7, 9.6, 15.2, 15.7, 19.1, 27.2, 30.7+-0.2 degrees 2 theta. Crystalline levosalbutamol sulphate Form III is characterised by a powder XRD pattern with peaks at 5.5, 6.9, 7.3, 18.7+-0.2 degrees 2 theta. Processes for making the new polymorphic forms and pharmaceutical compositions comprising them are also provided. A pharmaceutical composition comprises a therapeutically effective isomer of salbutamol or a salt, solvate, ester, derivative or polymorph thereof, a glucocorticoid and a pharmaceutically acceptable carrier or excipient and optionally one or more other therapeutic agents. Preferably the composition is an aerosol formulation comprising the drugs, a propellant and optionally one or more other ingredients, such as a surfactant, cosolvent, or bulking agent. Alternatively, DPI or inhalation suspensions may be used.

Priority: IN2004MU01356 Applic. Date: 2004-12-17; IN2005MU00040 Applic. Date: 2005-01-14; IN2005MU00343 Applic. Date: 2005-03-24; WO2005GB04935 Applic. Date: 2005-12-19

Inventor: LULLA AMAR [IN]; MALHOTRA GEENA [IN]; RAO DHARMARAJ RAMACHANDRA [IN]; KANKAN RAJENDRA NARAYANRAO [IN]; CHAUDHARY ALKA [IN]


Application No.: US20090263370A1  Published: 22/Oct/2009

Title: METHODS FOR TREATING TACHYKININ-MEDIATED DISEASES WITH CHOLINESTERASE

Applicant/Assignee:

Application No.: 12/427801   Filing Date: 22/Apr/2009

Abstract:Methods for treating or preventing a tachykinin-mediated disease, a skin disorder, or a symptom thereof in a mammal by administering to a mammal in need thereof cholinesterase or a pharmaceutical composition of cholinesterase.

Priority: CN20061157321 Applic. Date: 2006-11-30; CN20081066673 Applic. Date: 2008-04-23; WO2007CN02871 Applic. Date: 2007-09-29

Inventor: TAO GUOLIANG [CN]; XU HANHONG [CN]


Application No.: US20090263432A1  Published: 22/Oct/2009

Title: STABLE COMBINATIONS OF AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE

Applicant/Assignee:

Application No.: 12/489198   Filing Date: 22/Jun/2009

Abstract:The present invention provides a pharmaceutical composition comprising benazepril and amlodipine wherein the benazepril and the amlodipine are in physical contact with one another, and methods for making the same.

Priority: US2005-238496 Applic. Date: 2005-09-28

Inventor: KADOSH MALI [IL]; LESKA FANNY [IL]


Application No.: US20090263480A1  Published: 22/Oct/2009

Title: TASTE-MASKED PHARMACEUTICAL COMPOSITIONS PREPARED BY COACERVATION

Applicant/Assignee:

Application No.: 12/466855   Filing Date: 15/May/2009

Abstract:There is provided a method for preparing an orally disintegrating tablet (ODT) composition comprising microparticles of one or more taste-masked active pharmaceutical ingredients, rapidly-dispersing microgranules, and other optional, pharmaceutically acceptable excipients wherein the ODT disintegrates rapidly with saliva in the buccal cavity forming a smooth, easy-to-swallow suspension. Furthermore, the microparticles (crystals, granules, beads or pellets containing one or more actives) with a taste-masking membrane applied by a modified solvent coacervation process comprising a water-insoluble polymer and at least one gastrosoluble inorganic or organic pore-former, exhibit a pleasant taste when placed in the oral cavity and provide rapid, substantially-complete release of the dose on entry into the stomach.

Priority: US2005-213266 Applic. Date: 2005-08-26; US20040627525P Applic. Date: 2004-11-12

Inventor: LAI JIN-WANG [US]; QIAN KEN KANGYI [US]; VENKATESH GOPI M [US]


Application No.: US20090264385A1  Published: 22/Oct/2009

Title: STABILIZED COMPOSITIONS CONTAINING ALKALINE LABILE DRUGS

Applicant/Assignee:

Application No.: 12/294367   Filing Date: 22/Mar/2007

Abstract:A stabilized bioadhesive composition containing an alkaline labile drug and a method for its preparation are provided. In one aspect, the composition is a hot-melt extruded (HME) composition comprising a preformed excipient mixture comprising an acidic component and an alkaline thermoplastic matrix-forming material, e.g. polymer. The excipient mixture is formed before blending with an alkaline labile drug. The blend is then hot-melt extruded to form the HME composition. By so doing, the acidic component is able to neutralize or render moderately acidic the excipient mixture. This particular process has been shown to substantially reduce the degradation of an alkaline labile drug during hot-melt extrusion. The excipient mixture softens or melts during hot-melt extrusion. It can dissolve or not dissolve drug-containing particles during extrusion. Various functional excipients can be included in the carrier system to improve process performance and/or improve the chemical or physical properties of the HME composition.

Priority: US20060785505P Applic. Date: 2006-03-24; WO2007US64714 Applic. Date: 2007-03-22

Inventor: CROWLEY MICHAEL M [US]; KEEN JUSTIN M [US]; KOLENG JOHN J [US]; ZHANG FENG [US]


Application No.: US20090264460A1  Published: 22/Oct/2009

Title: CLOPIDOGREL PHARMACEUTICAL FORMULATIONS

Applicant/Assignee:

Application No.: 12/426548   Filing Date: 20/Apr/2009

Abstract:Formulations of clopidogrel or pharmaceutically acceptable salts thereof, processes of preparation of such formulations, and methods of using them.

Priority: IN2008CH00983 Applic. Date: 2008-04-21; US20080081542P Applic. Date: 2008-07-17

Inventor: MISHRA MAMTA [IN]; CHAKOLE DINESH [IN]; PALLEMPALLI VENKATA SIVAREDDY [IN]


Application No.: US20090269342A1  Published: 29/Oct/2009

Title: Hemagglutinin Polypeptides, and Reagents and Methods Relating Thereto

Applicant/Assignee: MASSACHUSETTS INSTITUTE OF TECHNOLOGY

Application No.: 12/348266   Filing Date: 02/Jan/2009

Abstract:The present invention provides a system for analyzing interactions between glycans and interaction partners that bind to them. The present invention also provides HA polypeptides that bind to umbrella-topology glycans, and reagents and methods relating thereto.

Priority: US2008-969040 Applic. Date: 2008-01-03; WO2007US18160 Applic. Date: 2007-08-14; US20080018783P Applic. Date: 2008-01-03; US20060837868P Applic. Date: 2006-08-14; US20060837869P Applic. Date: 2006-08-14

Inventor: SASISEKHARAN RAM [US]; VISWANATHAN KARTHIK [US]; CHANDRASEKARAN AARTHI [US]; RAMAN RAHUL [US]; SRINIVASAN ARAVIND [US]; RAGURAM S [US]; SASISEKHARAN VISWANATHAN [US]


Application No.: US20090269393A1  Published: 29/Oct/2009

Title: Chewable Bilayer Tablet Formulation

Applicant/Assignee: JUBLIANT ORGANOSYS LIMITED

Application No.: 12/304511   Filing Date: 12/Jun/2007

Abstract:Disclosed herein is a tablet formulation of an objectionable tasting drug cetirizine or its pharmaceutically acceptable salt in a form of chewable bilayer tablet, wherein the formulation comprises said cetirizine, a combination of water-insoluble and water-soluble polymer in a ratio of about 1:0.5 to about 1:5 and a low molecular weight polyol, wherein the molar ratio of the low molecular weight polyol to cetirizine is more than 10, and the inactive formulation layer comprises beta-cyclodextrin and other pharmaceutically acceptable excipients. Further, the present invention provides a process for preparing the formulation.

Priority: IN2006DE01399 Applic. Date: 2006-06-12; WO2007IN00234 Applic. Date: 2007-06-12

Inventor: KASHID NAMDEV [IN]; CHOUHAN PRADEEP [IN]; MUKHERJI GOUR [IN]


Application No.: US20090269402A1  Published: 29/Oct/2009

Title: MODIFIED RELEASE COMPOSITION OF AT LEAST ONE FORM OF VENLAFAXINE

Applicant/Assignee: BIOVAIL LABORATORIES INTERNATIONAL S.R.L

Application No.: 12/425972   Filing Date: 17/Apr/2009

Abstract:The present invention relates to a modified release composition of at least one form of venlafaxine, which is a delayed controlled release composition. The composition comprises a core comprising at least one form of venlafaxine selected from the group consisting of venlafaxine, an active metabolite of venlafaxine, a pharmaceutically acceptable salt of venlafaxine, a pharmaceutically acceptable salt of an active metabolite of venlafaxine, and combinations thereof, less than 10% of a gelling agent and a pharmaceutically acceptable excipient. The composition further comprises a modified release coating which substantially, surrounds the core which provides a delayed controlled release of the at least one form of venlafaxine.

Priority: US2006-445198 Applic. Date: 2006-06-02; US20050691282P Applic. Date: 2005-06-17; US20050686461P Applic. Date: 2005-06-02

Inventor: ZHOU FANG [US]; OBEREGGER WERNER [CA]; MAES PAUL [FR]


Application No.: US20090269405A1  Published: 29/Oct/2009

Title: ENZYME MEDIATED DELIVERY SYSTEM

Applicant/Assignee: APPIAN LABS, LLC

Application No.: 12/420745   Filing Date: 08/Apr/2009

Abstract:The present invention includes compositions, methods, and systems for the development of a novel delivery vehicle that affects release of an agent upon the degradation of components of said vehicle by one or more enzymes. In one example, the system comprises components designed to degrade upon the presence of desired concentrations of proteinases, specifically matrix metalloproteinases, and subsequent release of the agent.

Priority: US20080043386P Applic. Date: 2008-04-08

Inventor: WINDSOR J BRIAN [US]; NITIN NITIN [US]


Application No.: US20090269409A1  Published: 29/Oct/2009

Title: PHARMACEUTICAL COMPOSITIONS COMPRISING ESZOPICLONE

Applicant/Assignee:

Application No.: 12/428818   Filing Date: 23/Apr/2009

Abstract:Pharmaceutical compositions comprising eszopiclone, including its pharmaceutically acceptable salts, hydrates, clathrates, solvates, polymorphs, and mixtures thereof. The invention also relates to processes for preparing the compositions and their methods of use.

Priority: IN2008CH01018 Applic. Date: 2008-04-24; US20080081829P Applic. Date: 2008-07-18

Inventor: GARG MUKESH KUMAR [IN]; BORDE PARAG PRAKASH [IN]; GUPTA PRADEEP KUMAR [IN]


Application No.: US20090270358A1  Published: 29/Oct/2009

Title: PHARMACEUTICAL FORMULATION OF CLAVULANIC ACID

Applicant/Assignee: REXAHN PHARMACEUTICALS, INC

Application No.: 12/258062   Filing Date: 24/Oct/2008

Abstract:The present invention generally relates to stable pharmaceutical compositions, and methods of making and administering such compositions. In one aspect, the invention features stabilized pharmaceutical compositions that include pharmaceutically active ingredients such as potassium clavulanate or Clavitesse(TM), preferably in an immediate-release solid dosage form or an extended-release solid dosage form. Also provided are methods for making and using such immediate-release and stabilized compositions or extended-release and stabilized compositions.

Priority: US20070996079P Applic. Date: 2007-10-26

Inventor: LEE YOUNG B [US]; KIM DEOG J [US]; AHN CHANG H [US]; SCHOLTZ EDWARD C [US]


Application No.: US20090270515A1  Published: 29/Oct/2009

Title: ACTIVE INGREDIENT CONTAINING STABILISED SOLID MEDICINAL FORMS AND METHOD FOR THE PRODUCTION THEREOF

Applicant/Assignee:

Application No.: 12/441629   Filing Date: 14/Sep/2007

Abstract:The invention relates to solid medicinal forms containing at least one active ingredient and at least one pharmaceutically compatible, water soluble drying agent which is selected from the group consisting of trimagnesium dicitrate and/or calcium chloride, the solid medicinal form having a drying loss of at most 6% and a relative equilibrium moisture content of 25% or less. The invention also relates to solid medicinal forms containing a moisture-sensitive active ingredient and trimagnesium dicitrate.

Priority: EP20060020008 Applic. Date: 2006-09-25; WO2007EP08006 Applic. Date: 2007-09-14

Inventor: GRUBER PETER [DE]; SPICKERMANN DIRK [DE]


Application No.: US20090274732A1  Published: 05/Nov/2009

Title: Type-2 Diabetes Combination Wafer

Applicant/Assignee: LTS LOHMANN THERAPIE-SYSTEME AG

Application No.: 12/308242   Filing Date: 04/Jun/2007

Abstract:Rapidly disintegrating oral dosage forms for the application of active agent combinations for diabetes therapy. The dosage forms contain at least two active agents suitable for treating type-2 diabetes. The antidiabetic active agents are selected from the group comprising sulfonylureas, glitazones, glinides, biguanides, and absorption-delaying agents. The use of the active agent combination to produce an oral dosage form for the treatment of diabetes, a method for the therapeutic treatment of diabetes, and a method for the production of a sheet-like dosage form are also disclosed.

Priority: DE200610027790 Applic. Date: 2006-06-16; WO2007EP04953 Applic. Date: 2007-06-04

Inventor: HOFFMANN HANS-RAINER [DE]; BRANDLI RETO [US]; THEOBALD FRANK [DE]


Application No.: US20090275552A1  Published: 05/Nov/2009

Title: Therapy for Treating Resistant Bacterial Infections

Applicant/Assignee:

Application No.: 12/226525   Filing Date: 27/Apr/2007

Abstract:The invention relates to an improved therapy for treating resistant bacterial infections caused by extended-spectrum beta-lactamase (ESBLs)-producing strains in a warm-blooded animal, adjuvant step down therapy, and pharmaceutical compositions for such therapies. The invention also relates to a method for inhibiting bacterial resistance in ESBLs-producing strains so as to have better control over the therapy

achieve reduced hospital stay and adjuvant step down therapy so as to avoid recrudescence. In particular, the therapy includes antibacterial combination of cefepime with sulbactam via parenteral route, followed by oral third generation cephalosporin with a suitable beta lactamase inhibitor.

Priority: IN2006MU00672 Applic. Date: 2006-04-28; IN2006MU00673 Applic. Date: 2006-04-28; WO2007IB01104 Applic. Date: 2007-04-27

Inventor: PATEL MAHESH VITHALBHAI [IN]; GUPTE SHRIKANT VINAYAK [IN]; BHAGWAT SACHIN SUBHASH [IN]; JAFRI MOHAMMAD ALAM [IN]; JAIN GIRISH KUMAR [IN]; KODGULE MANDAR MADHUKAR [IN]


Application No.: US20090275622A1  Published: 05/Nov/2009

Title: NIZATIDINE FORMULATIONS

Applicant/Assignee:

Application No.: 12/433065   Filing Date: 30/Apr/2009

Abstract:Pharmaceutical formulations comprising nizatidine or salts thereof. Further the invention relates to liquid pharmaceutical formulations comprising nizatidine or salts thereof.

Priority: IN2008CH01074 Applic. Date: 2008-04-30; US20080081834P Applic. Date: 2008-07-18

Inventor: LINGA PRASOONA [IN]; MANTRI ARUNKUMAR HARIDAS [IN]; DHOKE SHRIKANT VITTHALRAO [IN]; PILLAI RAVIRAJ SUKUMAR [IN]


Application No.: US20090280174A1  Published: 12/Nov/2009

Title: Solid Pharmaceutical Preparation

Applicant/Assignee: NIPPON ZOKI PHARMACEUTICAL CO.,LTD

Application No.: 12/225498   Filing Date: 30/Mar/2007

Abstract:It is intended to provide a long-acting solid pharmaceutical preparation which has an immediate release part and a sustained release part containing tramadol or a pharmaceutically acceptable salt thereof, is fast-acting and stably has an excellent release property showing little pH dependency in the initial elution. The invention relates to a long-acting solid pharmaceutical preparation characterized by having an immediate release part and a sustained release part, containing tramadol or a pharmaceutically acceptable salt thereof as an active ingredient in both parts and containing partially pregelatinized starch and an excipient as additives in the immediate release part. The preparation of the invention is a long-acting preparation in which an effective blood concentration is reached rapidly after taking it for rapid pain-relief and a drug action can be sustained for a long time thereafter and is practical as a preparation showing a stable, pH-independent and rapid initial elution behavior and, further, having a sufficient hardness enough to meet the need for avoidance of defacement, cracking, chipping, etc. during tablet coating.

Priority: JP20060093207 Applic. Date: 2006-03-30; WO2007JP57221 Applic. Date: 2007-03-30

Inventor: ISHITSUBO NAOKI [JP]


Application No.: US20090280183A1  Published: 12/Nov/2009

Title: MULTIPARTICULATE FORM OF ADMINISTRATION, COMPRISING NUCLEIC ACID-CONTAINING MUCOADHESIVE ACTIVE INGREDIENTS, AND METHOD FOR PRODUCING SAID FORM OF ADMINISTRATION

Applicant/Assignee:

Application No.: 11/721399   Filing Date: 05/Nov/2005

Abstract:The invention relates to an oral, multiparticulate form of administration, comprising pellets in the size ranging from 50 to 2500 $g(m)m which are substantially constituted of a) an inner matrix layer containing nanoparticles that contain a nucleic acid active ingredient and being embedded in a matrix of a polymer having a mucoadhesive effect, and b) an outer film coating, substantially consisting of an anionic polymer or copolymer that is optionally formulated with pharmaceutically conventional adjuvants, especially emollients.

Priority: DE200410059792 Applic. Date: 2004-12-10; WO2005EP11864 Applic. Date: 2005-11-05

Inventor: LIZIO ROSARIO [DE]; PETEREIT HANS-ULRICH [DE]; TRUPTI DAVE [DE]; GOTTSCHALK MICHAEL [DE]


Application No.: US20090281032A1  Published: 12/Nov/2009

Title: Modified CCK peptides

Applicant/Assignee:

Application No.: 12/177306   Filing Date: 22/Jul/2008

Abstract:The invention concerns a peptide based on biologically active CCK-8. The peptide has improved characteristics for the treatment of at least one of obesity and type 2 diabetes and has the structure: (Z)-Asp1-Aaa2(X)-Aaa3Gly4Trp5Aaa6Asp7(Y)Aaa8K, wherein the amino acids may be either D or L amino acids

the bond between amino acid residues is either a peptide bond or a non-peptide isostere bond

Aaa2 is selected from the group comprising Tyr and Phe

when Aaa2 is Tyr, X is selected from the group comprising SO3H-, PO3H2- and a polymer moiety of the general formula -O-(CH2-O-CH2)n-H, in which n is an integer between 1 and about 22, wherein the X is covalently bound to the para phenyl oxygen of Tyr, and, when Aaa2 is Phe, X is CH2SO3Na, wherein the X is covalently bound to the para phenyl position of Phe

Aaa3 is selected from the group comprising Met, norleucine, 2-aminohexanoic acid and Thr

Aaa6 is selected from the group comprising Met, norleucine, 2-aminohexanoic acid and Phe

Aaa8 is selected from the group comprising Phe and Met

Y is covalently bound to the nitrogen of Aaa8 and is selected from the group consisting of H and CH3

K is selected from the group consisting of the hydroxyl group of Phe8, an amide covalently bound to Phe8, an ester covalently bound to Phe8, a salt of the hydroxyl group of Phe8, a salt of an amide covalently bound to Phe8, a salt of an ester covalently bound to Phe8 and a polymer moiety of the general formula -O-(CH2-O-CH2)n-H, in which n is an integer between 1 and about 22

and Z comprises at least one amino acid modification, wherein said at least one modification comprises an N-terminal extension, or an N-terminal modification, but excludes Asp1-glucitol CCK-8 where Aaa2 is Tyr and X is SO3H-. The peptides, and Asp1-glucitol CCK-8, are useful to at least one of inhibit food intake, induce satiety, stimulate insulin secretion, moderate blood glucose excursions, enhance glucose disposal and exhibit enhanced stability in plasma compared to native CCK-8

Priority: GB20010005069 Applic. Date: 2001-03-01; US2004-469655 Applic. Date: 2004-02-05; WO2002GB00827 Applic. Date: 2002-02-28

Inventor: FLATT PETER RAYMOND [GB]; O'HARTE FINBARR PAUL MARY [GB]


Application No.: US20090281058A1  Published: 12/Nov/2009

Title: Compositions of partially deacetylated chitin derivatives

Applicant/Assignee: GENIS EHF

Application No.: 11/922014   Filing Date: 14/Jun/2006

Abstract:The present invention relates to compositions comprising biologically active chitinous oligomers and their endotoxin purified and partially deacetylated chitin polymer precursors, and their use in pharmaceutical compositions, biomaterial compositions, medical devices, and processes to produce the said oligomers. More specifically the present invention relates to novel compositions and processes to produce such compositions. The compositions include therapeutic hetero polymer and hetero oligomer compositions comprising specific sequences of N-acetyl glucosamine and glucosamine, developed to optimize chemical and structural features which are important for the therapeutic activity of these compositions. In addition, the present invention provides methods to use degree of deacetylation of a partially deacetylated chitin polymer in order to modulate physical and biological parameters in a calcium phosphate composite for bone implant applications.

Priority: IS20050007895 Applic. Date: 2005-06-14; WO2006IS00013 Applic. Date: 2006-06-14

Inventor: GISLASON JOHANNES [IS]; EINARSSON JON M [IS]; CHUEN HOW NG [IS]; BAHRKE SVEN [DE]


Application No.: US20090281070A1  Published: 12/Nov/2009

Title: Method for Preparing a Solid Pharmaceutical Composition with Sustained and Controlled Release by High Pressure Treatment

Applicant/Assignee:

Application No.: 11/794542   Filing Date: 20/Dec/2005

Abstract:The invention concerns a method for preparing a unit-dose of a solid pharmaceutical composition with prolonged and controlled release by high pressure treatment of a solid composition comprising at least one active principle and at least one polymer. The invention also concerns the resulting solid pharmaceutical compositions.

Priority: FR20040014099 Applic. Date: 2004-12-30; WO2005FR03203 Applic. Date: 2005-12-20

Inventor: KALTSATOS VASSILIOS [FR]; FORGET PATRICK [FR]; BOIVIN ELIANE [FR]


Application No.: US20090281132A1  Published: 12/Nov/2009

Title: Pharmaceutical formulation for use in hiv therapy

Applicant/Assignee:

Application No.: 12/310693   Filing Date: 31/Aug/2007

Abstract:The invention discloses a formulation prepared by granulating at least one anti-retro viral drug and at least one pharmaceutically acceptable additive, using an organic solvent

milling the product

finally processing the milled product to form tablets or capsules.

Priority: IN2006CH01597 Applic. Date: 2006-09-04; WO2007IN00382 Applic. Date: 2007-08-31

Inventor: VELAVENI KIRAN KUMAR NARSAIAH [IN]; VERMA SANJAY DESHRAJ [IN]; DIXIT AKHILESH ASHOK [IN]; DESHMUKH ABHIJIT MUKUND [IN]; SETHI SANJEEV MEHARCHAND [IN]; MITRA SOURAV DILIPKUMAR [IN]


Application No.: US20090285891A1  Published: 19/Nov/2009

Title: Pharmaceutical preparation for oral administration with controlled active ingredient release in the small intestine and method for its production

Applicant/Assignee: DR. R. PFLEGER CHEMISCHE FABRIK GMBH

Application No.: 12/309198   Filing Date: 05/Jul/2007

Abstract:Any pharmaceutical preparation for oral administration with controlled release of active ingredient in the small bowel, on the basis of active ingredient carriers provided with at least one active ingredient which are provided with an inner layer to control the release of active ingredient and with a gastro-resistant coating layer disposed thereon, which is characterized in that the inner layer is formed from at least two diffusion layers whose permeability for the diffusing active ingredient decreases from the inside to the outside, and a method for the production thereof, are described.

Priority: EP20060014244 Applic. Date: 2006-07-10; WO2007EP05970 Applic. Date: 2007-07-05

Inventor: JUNG GERD [DE]; SCHAUPP ALBERT [DE]


Application No.: US20090285944A1  Published: 19/Nov/2009

Title: Food Composition

Applicant/Assignee:

Application No.: 12/440890   Filing Date: 06/Sep/2007

Abstract:The invention relates to a food composition consisting of a continuous aqueous phase, wherein said food composition has a water activity (Aw) of 0.3 to 0.99 and a fat content of less than 15% by weight relative to the total weight of the food composition, and comprises at least one non-gelatinized starch.

Priority: FR20060007937 Applic. Date: 2006-09-11; WO2007FR51884 Applic. Date: 2007-09-06

Inventor: RABAULT JEAN-LUC [FR]; BELOUIN FRANCOIS [FR]


Application No.: US20090286752A1  Published: 19/Nov/2009

Title: ORAL FORMULATIONS OF CYTIDINE ANALOGS AND METHODS OF USE THEREOF

Applicant/Assignee:

Application No.: 12/466213   Filing Date: 14/May/2009

Abstract:The present disclosure provides pharmaceutical compositions comprising cytidine analogs for oral administration, wherein the compositions release the cytidine analog substantially in the stomach. Also provided are methods of treating diseases and disorders using the oral formulations provided herein.

Priority: US20080053609P Applic. Date: 2008-05-15; US20090157875P Applic. Date: 2009-03-05; US20080201145P Applic. Date: 2008-12-05

Inventor: ETTER JEFFREY B [US]; LAI MEI [US]; BACKSTROM JAY THOMAS [US]


Application No.: US20090291062A1  Published: 26/Nov/2009

Title: PROTEIN FORMULATIONS AND METHODS OF MAKING SAME

Applicant/Assignee:

Application No.: 12/325049   Filing Date: 28/Nov/2008

Abstract:The invention provides an aqueous formulation comprising water and a protein, and methods of making the same. The aqueous formulation of the invention may be a high protein formulation and/or may have low levels of conductivity resulting from the low levels of ionic excipients. Also included in the invention are formulations comprising water and proteins having low osmolality.

Priority: US20070004992P Applic. Date: 2007-11-30

Inventor: FRAUNHOFER WOLFGANG [US]; BARTL ANNIKA [DE]; KRAUSE HANS-JUERGEN [DE]; TSCHOEPE MARKUS [DE]; KALETA KATHARINA [DE]


Application No.: US20090291123A1  Published: 26/Nov/2009

Title: Opioid Combination Wafer

Applicant/Assignee:

Application No.: 12/308208   Filing Date: 04/Jun/2007

Abstract:Sheet-like dosage forms for pain therapy, based on hydrophilic polymers, which rapidly dissolve or disintegrate in an aqueous environment and which release active agent combinations when placed into a body orifice or body cavity, and which are preferably orally administrable, with the dosage form containing an active agent combination consisting of an opioid and a second substance The second active agent is a non-steroidal anti-rheumatic (NSAR) or an antidepressant.

Priority: DE200610027793 Applic. Date: 2006-06-16; WO2007EP04954 Applic. Date: 2007-06-04

Inventor: HOFFMANN HANS-RAINER [DE]; BRAENDLI RETO [US]; THEOBALD FRANK [DE]


Application No.: US20090291132A1  Published: 26/Nov/2009

Title: Enhanced delivery of antifungal agents

Applicant/Assignee:

Application No.: 12/454387   Filing Date: 15/May/2009

Abstract:Tetrahydrofuran antibiotics formulated with certain diacylglycerol-poltethyleneglycol (DAG-PEG) lipids have increased water solubility and bioavailability. PEG-12 GDO, PEG-12 GDLO, PEG-12 GDM and PEG-12 GDP are particularly suitable for forming liposomes that incorporate tetrahydrofurans in the bilayer.

Priority: US2008-006820 Applic. Date: 2008-01-04; US20080128011P Applic. Date: 2008-05-16

Inventor: KELLER BRIAN CHARLES [US]; WU NIAN [US]


Application No.: US20090291146A1  Published: 26/Nov/2009

Title: PROCESS FOR MANUFACTURING LACTOSE

Applicant/Assignee: GLAXO GROUP LIMITED

Application No.: 12/375716   Filing Date: 08/Aug/2007

Abstract:A process for producing lactose particles comprises combining a predetermined quantity of lactose seed particles to a first aqueous solution comprising a plurality of lactose particles to form a second solution, wherein the predetermined quantity of lactose seed particles is present in a well dispersed suspension and the first aqueous solution is saturated with said plurality of lactose particles

and subjecting the second solution to conditions sufficient to induce crystallization of the lactose seed particles to form a second plurality of lactose particles having a median particle size of about 25 microns to about 100 microns.

Priority: US20060821872P Applic. Date: 2006-08-09; WO2007US17647 Applic. Date: 2007-08-08

Inventor: ROCHE TREVOR CHARLES [GB]; WOOD-KACZMAR MARIAN WLADYSLAW [GB]


Application No.: US20090291900A1  Published: 26/Nov/2009

Title: METHODS FOR TREATMENT OF HEADACHES BY ADMINISTRATION OF OXYTOCIN

Applicant/Assignee:

Application No.: 12/409419   Filing Date: 23/Mar/2009

Abstract:The present invention relates to methods for the treatment of headache and headache disorders. The methods comprise administration of an oxytocin peptide for the treatment of primary and secondary headaches or trigeminal neuralgia.

Priority: US2008-210866 Applic. Date: 2008-09-15; US2006-511997 Applic. Date: 2006-08-28; US20050711950P Applic. Date: 2005-08-26; US20060794004P Applic. Date: 2006-04-21

Inventor: YEOMANS DAVID C [US]; ANGST MARTIN S [US]; FREY II WILLIAM H [US]; JACOBS DANIEL I [US]


Application No.: US20090297441A1  Published: 03/Dec/2009

Title: Imaging Agents

Applicant/Assignee:

Application No.: 11/992292   Filing Date: 22/Sep/2006

Abstract:The use of silicon as an imaging agent is described.

Priority: GB20050019391 Applic. Date: 2005-09-22; WO2006GB03522 Applic. Date: 2006-09-22

Inventor: CANHAM LEIGH TREVOR [GB]; KLUCZEWSKA ANNA AGNIESZKA [AU]; BARLEY JEROME PAUL [AU]; VARAJAO RAPHAELA FORTES DRUMMO [AU]


Application No.: US20090297457A1  Published: 03/Dec/2009

Title: Preparation Of Suspension Aerosol Formulations

Applicant/Assignee: GENERICS [UK] LIMITED

Application No.: 11/665093   Filing Date: 12/Oct/2005

Abstract:The present invention provides processes for preparing suspension aerosol formulations, wherein the particles for inhalation are formed in situ during the process of manufacturing the formulation. In one aspect of the invention, a process for preparing a suspension aerosol formulation comprises the steps of: (a) dissolving one or more medicaments in one or more solvents to form a solution

and (b) mixing one or more propellants with the solution under conditions effective to precipitate, entirely or partially, at least one of the medicaments.

Priority: US20040617686P Applic. Date: 2004-10-12; WO2005GB50183 Applic. Date: 2005-10-12

Inventor: BOVET LI LI [US]; HOLT JAY T [US]


Application No.: US20090297598A1  Published: 03/Dec/2009

Title: THERAPEUTIC COMBINATION

Applicant/Assignee:

Application No.: 12/427420   Filing Date: 21/Apr/2009

Abstract:This invention relates to pharmaceutical combinations of amlodipine or a pharmaceutically acceptable acid addition salt thereof and atorvastatin or a pharmaceutically acceptable salt thereof, kits containing such combinations and methods of using such combinations to treat subjects suffering from angina pectoris, atherosclerosis, combined hypertension and hyperlipidemia and to treat subjects presenting with symptoms of cardiac risk, including humans. This invention also relates to additive and synergistic combinations of amlodipine and atorvastatin whereby those synergistic combinations are useful in treating subjects suffering from angina pectoris, atherosclerosis, combined hypertension and hyperlipidemia and those subjects presenting with symptoms of cardiac risk, including humans.

Priority: US2006-499753 Applic. Date: 2006-08-07; US2002-214058 Applic. Date: 2002-08-07; US2000-512914 Applic. Date: 2000-02-25; WO1998IB01225 Applic. Date: 1998-08-11; US19970057275P Applic. Date: 1997-08-29

Inventor: BUCH JAN [US]; SCOTT ROBERT ANDREW DONALD [US]


Application No.: US20090297599A1  Published: 03/Dec/2009

Title: PHARMACEUTICAL COMPOSITIONS CONTAINING ROSUVASTATIN CALCIUM

Applicant/Assignee:

Application No.: 12/441396   Filing Date: 11/Sep/2007

Abstract:A pharmaceutical composition is disclosed containing amorphous rosuvastatin calcium and at least one of the following stabilizing agents: magnesium hydroxide, calcium acetate, calcium gluconate, calcium glycerophosphate, or aluminum hydroxide, together with at least one pharmaceutically acceptable excipient.

Priority: HU20060000728 Applic. Date: 2006-09-18; WO2007HU00082 Applic. Date: 2007-09-11

Inventor: VIRAGH MARIA [HU]; MONOSTORI IIDIKO [HU]


Application No.: US20090297600A1  Published: 03/Dec/2009

Title: NOVEL PHARMACEUTICAL FORMULATION CONTAINING A BIGUANIDE AND AN ANGIOTENSIN ANTAGONIST

Applicant/Assignee:

Application No.: 12/535833   Filing Date: 05/Aug/2009

Abstract:A pharmaceutical dosage form comprising a controlled release component comprising an antihyperglycemic drug in combination with a second component comprising a angiotensin antagonist is herein disclosed and described.

Priority: US2006-628066 Applic. Date: 2006-11-28; WO2005US18939 Applic. Date: 2005-05-27; US20040575259P Applic. Date: 2004-05-28

Inventor: HAHN ELLIOTT F [US]


Application No.: US20090297604A1  Published: 03/Dec/2009

Title: METAL OXIDE HYDROGELS AND HYDROSOLS, THEIR PREPARATION AND USE

Applicant/Assignee:

Application No.: 12/304513   Filing Date: 12/Jun/2007

Abstract:A process for preparing a hydrosol of one or more metal oxides, e.g. titanium dioxide, comprising preparing a metal alkoxide solution in a water-miscible organic solvent, e.g. an alcohol

providing an aqueous solvent

mixing the metal alkoxide solution with the aqueous solvent in a volume or weight proportion to form a single-phase aqueous sol colloid (hydrosol) of hydrated metal oxide in absence of a non-ionic block polymer surfactant. Also disclosed is a corresponding hydrogel

water-insoluble particles encapsulated in hydrated metal oxide and a process for their encapsulation

uses of the encapsulation products.

Priority: US20060812779P Applic. Date: 2006-06-12; WO2007SE00577 Applic. Date: 2007-06-12

Inventor: KESSLER VADIM G [SE]; SEISENBAEVA GULAIM A [SE]; HAAKANSSON SEBASTIAN [SE]; UNELL MARIA [SE]


Application No.: US20090297637A1  Published: 03/Dec/2009

Title: Estrogenic Extracts of Anemarrhena Asphodeloides Bge. from the Liliaceae Family and Uses Thereof

Applicant/Assignee: BIONOVO, INC

Application No.: 12/422076   Filing Date: 10/Apr/2009

Abstract:Estrogenic extracts of Anemarrhena asphodeloides Bge. from the Liliaceae Family are provided. Also provided are methods of using said extracts to achieve an estrogenic effect, especially in a human, e.g. a female human. In some embodiments, the methods include treatment of climacteric symptoms. In some embodiments, the methods include treatment of estrogen receptor positive cancer, such as estrogen responsive breast cancer. In some embodiments, the methods include treatment or prevention of osteoporosis.

Priority: US20080044405P Applic. Date: 2008-04-11

Inventor: COHEN ISAAC [US]


Application No.: US20090297638A1  Published: 03/Dec/2009

Title: ESTROGENIC EXTRACTS OF Anemarrhena asphodeloides Bge. from the Liliaceae Family and USES THEREOF

Applicant/Assignee: BIONOVO, INC

Application No.: 12/422132   Filing Date: 10/Apr/2009

Abstract:Estrogenic extracts of Anemarrhena asphodeloides Bge. from the Liliaceae Family are provided. Also provided are methods of using said extracts to achieve an estrogenic effect, especially in a human, e.g. a female human. In some embodiments, the methods include treatment of climacteric symptoms. In some embodiments, the methods include treatment of estrogen receptor positive cancer, such as estrogen responsive breast cancer. In some embodiments, the methods include treatment or prevention of osteoporosis.

Priority: US20080044405P Applic. Date: 2008-04-11

Inventor: COHEN ISAAC [US]


Application No.: US20090298742A1  Published: 03/Dec/2009

Title: PROCESS FOR MANUFACTURING LACTOSE

Applicant/Assignee: GLAXO GROUP LIMITED

Application No.: 12/375703   Filing Date: 08/Aug/2007

Abstract:A process for forming crystalline lactose suitable for use in a pharmaceutical formulation comprises subjecting a solution comprising a plurality of nanosized lactose particles to conditions sufficient to cause crystallization to occur on the nanosized lactose particles such that a plurality of lactose particles are formed therefrom having a median diameter ranging from about 4 mum to about 20 mum.

Priority: US20060821871P Applic. Date: 2006-08-09; WO2007US75432 Applic. Date: 2007-08-08

Inventor: ROCHE TREVOR CHARLES [GB]; WOOD-KACZMAR MARIAN WLADYSLAW [GB]; TAI XIANG [SG]; VAN OORT MICHIEL [US]


Application No.: US20090298901A1  Published: 03/Dec/2009

Title: (E)-1-(4-((1R,2S,3R)-1,2,3,4-TETRAHYDROXYBUTYL)-1H-IMIDAZOL-2-YL)ETHANONE OXIME DIHYDRATE AND METHODS OF ITS USE

Applicant/Assignee:

Application No.: 12/536714   Filing Date: 06/Aug/2009

Abstract:(E)-1-(4-((1R,2S,3R)-1,2,3,4-tetrahydroxybutyl)-1H-imidazol-2-yl)-ethanone oxime dihydrate, compositions comprising it, and methods of its use are disclosed.

Priority: US2008-101445 Applic. Date: 2008-04-11; US20070923037P Applic. Date: 2007-04-12

Inventor: WU WENXUE [US]; ZHANG HAIMING [US]


Application No.: US20090298941A1  Published: 03/Dec/2009

Title: ANTI-ADIPOCYTE FATTY ACID-BINDING PROTEIN (AP2), ANTI-FLAP AND ANTI-CYSLT1 RECEPTOR HERBAL COMPOSITIONS

Applicant/Assignee: LAILA IMPEX

Application No.: 12/477643   Filing Date: 03/Jun/2009

Abstract:Herbal compositions having anti-adipocyte fatty acid-binding protein (aP2), anti-5-lipoxygenase-activating protein (FLAP) and anti-Cysteinyl Leukotriene (CysLT)-1 receptor expression activity contain an extract of Boswellia serrata. More particularly, these herbal compositions comprise an effective amount of an enriched Boswellia extract containing from 10% to 99% by weight of 3-0-acetyl-11-keto-beta-boswellic acid

and an effective amount of a second extract selected from the group consisting of an extract of Aegle marmelos, an extract of Zingiber officinale, an extract of Garcinia mangostana, and mixtures thereof. These may be used in dietary supplements or pharmaceutical formulations for controlling diseases associated with or related to inflammation. These diseases in particular include respiratory disorders such as asthma, allergic rhinitis, hay fever, type-1 hypersensitivity and mild allergies. The compositions can also be useful for skin care.

Priority: US20080058271P Applic. Date: 2008-06-03

Inventor: GOKARAJU GANGA RAJU [IN]; GOKARAJU RAMA RAJU [IN]; TRIMURTULU GOLOKOTI [IN]; CHILLARA SIVARAMAKRISHNA [IN]; SENGUPTA KRISHANU [IN]; BHUPATHIRAJU KIRAN [IN]


Application No.: US20090304628A1  Published: 10/Dec/2009

Title: STABILIZED PHARMACEUTICAL FORMULATIONS THAT CONTAIN THE INTERFERONS GAMMA AND ALPHA IN SYNERGISTIC PROPORTIONS

Applicant/Assignee:

Application No.: 12/092440   Filing Date: 27/Oct/2006

Abstract:The present invention is related to stable pharmaceutical formulations to be applied by parenteral (liquids or freeze-dried), or topic way (gel, unguent or cream) that contain different quantities of the recombinant interferons gamma and alpha in synergistic proportions for the treatment of pathological events that contemplate the malignant or benign not-physiological growth of cells in tissue or organs.

Priority: CU20050000213 Applic. Date: 2005-11-02; WO2006CU00011 Applic. Date: 2006-10-27

Inventor: BELLO RIVERO IRALDO [CU]; LOPEZ SAURA PEDRO [CU]; GARCIA VEGA YANELDA [CU]; SANTANA MILIAN HECTOR [CU]; AGUILERA BARRETO ANA [CU]; PAEZ MEIRELES ROLANDO [CU]; ANASAGASTI ANGULO LORENZO [CU]


Application No.: US20090304755A1  Published: 10/Dec/2009

Title: PHARMACEUTICAL FORMULATION OF LOSARTAN

Applicant/Assignee:

Application No.: 12/091852   Filing Date: 06/Jan/2006

Abstract:A pharmaceutical composition comprising losartan and pharmaceutically acceptable salts thereof and a process of forming the same. The pharmaceutical composition of losartan comprises an active agent comprising an effective amount of losartan or its pharmaceutical salt thereof, and pharmaceutically acceptable additives, wherein d(0.9) of losartan is less than 50mu and/or specific surface area is more than 0.6 m2/gm. The process of preparation of pharmaceutical composition of losartan, comprises the steps of blending the losartan having d(0.9) less than 50mu and/or specific surface area more than 0.6 m2/gm, with the other intragranular excipients, dry compression, milling and screening to obtain granules, said granules being subsequently blended with extragranular excipients and compressed to tablets which is further coated.

Priority: IN2005KO00979 Applic. Date: 2005-10-27; WO2006IN00041 Applic. Date: 2006-01-06

Inventor: KASU RAGHU RAMI REDDY [IN]; MISTRY DHANASHREE [IN]; MANVI SUNDERRAJ [IN]; THOMMANDRU VIJAYA KUMAR [IN]; SEN HIMADRI [IN]


Application No.: US20090304790A1  Published: 10/Dec/2009

Title: CONTROLLED RELEASE PHARMACEUTICAL COMPOSITIONS COMPRISING A FUMARIC ACID ESTER

Applicant/Assignee: ADITECH PHARMA AB

Application No.: 11/576871   Filing Date: 07/Oct/2005

Abstract:The present invention relates to controlled release pharmaceutical compositions comprising fumaric acid ester(s) as active substance(s). The compositions are suitable for use in the treatment of e.g. psoriasis or other hyperproliferative, inflammatory or autoimmune disorders and are designated to release the fumaric acid ester in a controlled manner so that local high concentrations of the active substance within the gastrointestinal tract upon oral administration can be avoided and, thereby, enabling a reduction in gastro-intestinal related side-effects.

Priority: DK20040001546 Applic. Date: 2004-10-08; DK20040001736 Applic. Date: 2004-11-10; DK20050000211 Applic. Date: 2005-02-11; DK20050000419 Applic. Date: 2005-03-23; US20050691513P Applic. Date: 2005-06-16; WO2005DK00648 Applic. Date: 2005-10-07

Inventor: NILSSON HENRIK [DK]; SCHOENHARTING FLORIAN [DK]; MUELLER BERND W [DE]; ROBINSON JOSEPH R [US]; ROBINSON BONNA [US]


Application No.: US20090304791A1  Published: 10/Dec/2009

Title: SOLID ORAL FORMS OF EBASTINE

Applicant/Assignee: SIMBEC IBERICA, S.L

Application No.: 12/092477   Filing Date: 20/Oct/2006

Abstract:The invention relates to compositions in the form of matrices consisting of solid ebastine dispersions in nonionic surfactants having a HLB of between 10 and 20 and a melting point of between 30 DEG C. and 70 DEG C. The invention also relates to solid oral pharmaceutical forms of ebastine containing said matrices, particularly tablets, and having good solubility and bioavailability properties and improved stability.

Priority: ES20050002686 Applic. Date: 2005-11-04; WO2006ES00581 Applic. Date: 2006-10-20

Inventor: ROMA MILLAN JORDI [ES]; MESTRE CASTELL JOSE [ES]; SUNE NEGRE JOSE MARIA [ES]


Application No.: US20090304794A1  Published: 10/Dec/2009

Title: CONTROLLED RELEASE FORMULATIONS OF PRAMIPEXOLE

Applicant/Assignee: SUPERNUS PHARMACEUTICALS, INC

Application No.: 12/478979   Filing Date: 05/Jun/2009

Abstract:A controlled release formulation of pramipexole for once-a-day administration to a mammalian subject, which formulation releases pramipexole along a pre-determined release profile, is provided.

Priority: US20080129175P Applic. Date: 2008-06-09

Inventor: VIEIRA MICHAEL L [US]; BHATT PADMANABH P [US]; HUANG AUSTIN B [US]


Application No.: US20090304795A1  Published: 10/Dec/2009

Title: TABLETS WITH IMPROVED DRUG SUBSTANCE DISPERSIBILITY

Applicant/Assignee:

Application No.: 12/542163   Filing Date: 17/Aug/2009

Abstract:The present invention relates to a method for the preparation of pharmaceutical compositions in the form of tablets with improved drug substance dispersibility, which method comprises a) preparing a dispersion of at least one pharmaceutically active drug substance and at least one surfactant and/or binder in a liquid

b) preparing a carrier by dry blending at least one porous carrier and one or more excipient(s)

and c) spray granulating the dispersion prepared in step a) onto the carrier prepared in step b) to obtain a spray-granulated product.

Priority: EP20050101458 Applic. Date: 2005-02-25; US2006-357303 Applic. Date: 2006-02-17

Inventor: BERNIGAL NATHALIE [FR]; GARCIA ERIC [FR]; PAGE SUSANNE [DE]; TARDIO JOSEPH [FR]


Application No.: US20090304803A1  Published: 10/Dec/2009

Title: Compositions and methods relating to target-specific photodynamic therapy

Applicant/Assignee: THE GENERAL HOSPITAL CORPORATION

Application No.: 11/921597   Filing Date: 06/Jun/2006

Abstract:The invention generally provides methods and compositions useful for providing photodynamic therapy to specific cells or tissues.

Priority: US20050687800P Applic. Date: 2005-06-06; WO2006US22081 Applic. Date: 2006-06-06

Inventor: HASAN TAYYABA [US]


Application No.: US20090304822A1  Published: 10/Dec/2009

Title: Extract of Polygonum multiflorum Thunb. ex Murray var. hypoleucum and compositions for improving metabolic syndrome

Applicant/Assignee:

Application No.: 12/155743   Filing Date: 09/Jun/2008

Abstract:An extract of Polygonum multiflorum Thunb. ex Murray var. hypoleucum (Ohwi) or of Polygonum hypoleucum (Ohwi) for improving metabolic syndrome is prepared by the following method: (a) providing fresh or dry Polygonum multiflorum Thunb. ex Murray var. hypoleucum (Ohwi) or Polygonum hypoleucum (Ohwi) in partial or whole plant

(b) extracting the partial or whole plant by a solvent to obtain a crude extract

(c) condensing and drying the crude extract to obtain an extract product

and (d) collecting the extract product. The present invention also relates to a pharmaceutical and a food composition having the above extract for improving the metabolic syndromes. The extract of the present invention can be easily prepared and is demonstrated to modulate the levels of both blood glucose and blood lipid, to inhibit the activities of glycolytic enzymes and acetyl-CoA carboxylase, and to stimulate acyl-CoA oxidase. The extract of the present invention is capable of improving metabolic syndromes.

Priority:

Inventor: CHEN CHI-HUA [TW]; CHEN SHIOW-WEN [TW]; CHANG YUARN-YEE [TW]; LIU WEN-KIA [TW]


Application No.: US20090304825A1  Published: 10/Dec/2009

Title: ESTROGENIC EXTRACTS FOR USE IN TREATING VAGINAL AND VULVAR ATROPHY

Applicant/Assignee: BIONOVO, INC

Application No.: 12/436020   Filing Date: 05/May/2009

Abstract:Estrogenic extracts of Astragalus membranaceus, Astragalus mongholicus, Anemarrhenae asphodeloides and Achyranthes bidentata are provided. Also provided are methods of using said extracts to achieve an estrogenic effect, especially in a human, e.g. a female human. In some embodiments, the methods include treatment of climacteric symptoms. In some embodiments, the methods include treatment or prevention of osteoporosis.

Priority: US20080050925P Applic. Date: 2008-05-06

Inventor: COHEN ISAAC [US]


Application No.: US20090306024A1  Published: 10/Dec/2009

Title: Combination preparations of o-acetylsalicylic acid salts

Applicant/Assignee:

Application No.: 12/090179   Filing Date: 04/Oct/2006

Abstract:The present invention relates to a fixed combination comprising a salt of o-acetylsalicylic acid with a basic amino acid as component A and an HMG-CoA reductase inhibitor as component B, a medicament comprising this combination and a process for its production.

Priority: DE200510049293 Applic. Date: 2005-10-15; WO2006EP09573 Applic. Date: 2006-10-04

Inventor: LEDWOCH WOLFRAM [DE]; HAASE CLAUS GERT [DE]; FRANCKOWIAK GERHARD [DE]; WAGNER HEIKE [DE]; HAYAUCHI YUTAKA [DE]


Application No.: US20090306066A1  Published: 10/Dec/2009

Title: PEPTIDE DEFORMYLASE INHIBITORS

Applicant/Assignee:

Application No.: 12/265983   Filing Date: 06/Nov/2008

Abstract:The present invention is directed to certain {2-(alkyl)-3-[2-(5-fluoro-4-pyrimidinyl)hydrazino]-3-oxopropyl}hydroxyformamide derivatives, compositions containing them, the use of such compounds in the inhibition of bacterial peptide deformylase (PDF) activity, and in the treatment of bacterial infections. Specifically, the invention is directed to compounds of formula (I): wherein R1, R2 and R3 are defined herein and to pharmaceutically acceptable salts thereof. The compounds of this invention are bacterial peptide deformylase inhibitors and can be useful in the treatment of bacterial infections.

Priority: US20070986631P Applic. Date: 2007-11-09

Inventor: QIN DONGHUI [US]; NORTON BETH [US]; KNOX ANDREW NICHOLAS [US]; CHRISTENSEN SIEGFRIED B [US]; AUBART KELLY M [US]


Application No.: US20090306145A1  Published: 10/Dec/2009

Title: Pyridylisoxazole Derivatives

Applicant/Assignee:

Application No.: 12/308875   Filing Date: 26/Jun/2007

Abstract:This invention offers isoxazole derivatives represented by the following formula (I) in which R1 and R2 each stands for hydrogen, lower alkyl, amino and the like

R3 stands for substituted or unsubstituted aryl or hetero aryl

R4 stands for hydrogen or lower alkyl

R5 stands for substituted or unsubstituted phenyl, furyl and the like

and Y stands for -CH2-, -CO-, -O-, -NH- and the like, or pharmaceutically acceptable salts thereof which exhibit excellent p38MAPkinase-inhibiting action with reduced side-effects, and are useful for treating such diseases as chronic rheumatoid arthritis, ulcerative colitis and the like.

Priority: JP20060177950 Applic. Date: 2006-06-28; WO2007JP63207 Applic. Date: 2007-06-26

Inventor: HASUMI KOICHI [JP]; OHTA SHUJI [JP]; SAITO TAKAHISA [JP]; SATO SHUICHIRO [JP]; KATO JUN-YA [JP]; SATO JUN [JP]; SUZUKI HIROYUKI [JP]; ASANO HAJIME [JP]; OKADA MAMI [JP]; MATSUMOTO YASUHIRO [JP]; SHIROTA KAZUHIKO [JP]


Application No.: US20090306204A1  Published: 10/Dec/2009

Title: Pharmaceutical Composition Comprising Cyclobenzaprine and Aceclofenac in Association

Applicant/Assignee: INCREMENTHA P, D & I PESQUISA, DESENVOLVIMENTO E INOVACAO DE FARMACOS E MEDICAMENTOS LTDA

Application No.: 12/227971   Filing Date: 06/Jun/2007

Abstract:The present invention relates to an association of active ingredients. More specifically: to an association of cyclobenzaprine and aceclofenac. Additionally, the present invention is also related to the use of aceclofenac and cyclobenzaprine, in association for the preparation of a medicine useful in the treatment of painful muscular diseases, as well as to a method of treatment of painful muscular diseases using an association of aceclofenac and cyclobenzaprine.

Priority: BR2006PI02179 Applic. Date: 2006-06-08; WO2007BR00139 Applic. Date: 2007-06-06

Inventor: JUNIOR DANTE ALARIO [BR]; GAGLIARDI JULIO CESAR [BR]


Application No.: US20090311239A1  Published: 17/Dec/2009

Title: RECOMBINANT OR TRANSGENIC FACTOR VII COMPOSITION, EACH FACTOR VII MOLECULE HAVING TWO N-GLYCOSYLATION SITES WITH DEFINED GLYCAN UNITS

Applicant/Assignee: LFB BIOTECHNOLOGIES

Application No.: 12/300486   Filing Date: 31/May/2007

Abstract:The invention is related to a composition of recombinant or transgenic Factor VII, each molecule of Factor VII of the composition exhibiting two N-glycosylation sites, wherein, among all the molecules of FVII of the composition, the rate of Galalpha1,3Gal glycan moieties is comprised between 0 and 4%. The invention is also related to a process for preparing such a composition of FVII

Priority: FR20060004872 Applic. Date: 2006-05-31; WO2007FR00909 Applic. Date: 2007-05-31

Inventor: CHTOUROU ABDESSATAR SAMI [FR]; NONY EMMANUEL [FR]; BIHOREAU NICOLAS [FR]


Application No.: US20090311251A1  Published: 17/Dec/2009

Title: SCFV ANTIBODIES WHICH PASS EPITHELIAL AND/OR ENDOTHELIAL LAYERS

Applicant/Assignee: ESBATECH AG

Application No.: 12/307875   Filing Date: 10/Jul/2007

Abstract:scFv antibodies which specifically bind selected antigens and are obtainable by a method comprising (i) selecting from a pool of soluble and stable antibody frameworks a soluble and stable framework matching best the framework of a non-human antibody against the antigen with a certain binding specificity, (ii) either providing said soluble and stable framework with CDRs that bind specifically to said antigen, or mutating the framework of said non-human antibody towards the sequence of said soluble and stable framework, to generate scFv antibodies, (iii) testing the generated antibody for solubility and stability, and testing the generated antibody for antigen binding, and (iv) selecting an scFV that is soluble, stable and binds to the antigen specifically. Also provided are pharmaceutical compositions comprising said scFv antibody, methods of treatment and diagnosis for diseases related to over expression of antigens that are specifically bound by said antibody.

Priority: US20060819378P Applic. Date: 2006-07-10; US20070899907P Applic. Date: 2007-02-06; WO2007CH00334 Applic. Date: 2007-07-10

Inventor: AUF DER MAUR ADRIAN [CH]; BARBERIS ALCIDE [CH]; URECH DAVID M [CH]; LICHTLEN PETER [CH]


Application No.: US20090311275A1  Published: 17/Dec/2009

Title: Carrier for targeting nerve cells

Applicant/Assignee:

Application No.: 11/919302   Filing Date: 26/Apr/2006

Abstract:The present invention relates to a transport protein which can be obtained by modifying the heavy chain of the neurotoxin formed by Clostridium botulinum wherein (i) the protein binds specifically to nerve cells with a higher or lower affinity as the native neurotoxin

(ii) the protein has an increased or reduced neurotoxicity compared to the native neurotoxin, the neurotoxicity being preferably determined in the hemidiaphragma assay

and/or (iii) the protein comprises a lower affinity against neutralizing antibodies compared to the native neurotoxin. The invention also relates to methods for producing the same and the use thereof in cosmetic and pharmaceutical compositions.

Priority: DE200510019302 Applic. Date: 2005-04-26; WO2006EP03896 Applic. Date: 2006-04-26

Inventor: RUMMEL ANDREAS [DE]; WEIL TANJA [DE]; GUTCAITS ALEKSANDRS [LV]


Application No.: US20090311317A1  Published: 17/Dec/2009

Title: MODIFIED RELEASE TOLTERODINE FORMULATIONS

Applicant/Assignee: CAPRICORN PHARMA INC

Application No.: 12/466359   Filing Date: 14/May/2009

Abstract:Modified or extended release formulations containing tolterodine and associated methods are disclosed and described. Methods for making and administering said modified release formulations are also disclosed.

Priority: US20080127523P Applic. Date: 2008-05-14

Inventor: CHERUKURI SUBRAMAN RAO [US]; RAVELLA VENKAT N [IN]


Application No.: US20090311322A1  Published: 17/Dec/2009

Title: ATORVASTATIN FORMULATION

Applicant/Assignee: TEVA PHARMACEUTICAL INDUSTRIES LTD

Application No.: 12/544120   Filing Date: 19/Aug/2009

Abstract:Provided are atorvastatin compositions which reduce the effect of food on the bioavailability of atorvastatin and methods for making such compositions. Also provided are methods of reducing low density lipoprotein by administering the compositions of the invention.

Priority: US2005-285961 Applic. Date: 2005-11-23; US20050738828P Applic. Date: 2005-11-21

Inventor: DLUGATCH DAFNA [IL]; DOANI ZVIKA [IL]


Application No.: US20090312283A1  Published: 17/Dec/2009

Title: BRANCHED HYALURONIC ACID AND METHOD OF MANUFACTURE

Applicant/Assignee: NOVOZYMES BIOPOLYMER A/S

Application No.: 12/375425   Filing Date: 13/Jul/2007

Abstract:A branched hyaluronic acid, wherein the linear backbone comprises hyaluronic acid in which one or more N-Acetyl-Glucosamine has been deacetylated to Glucosamine, with branching sidechain(s) covalently linked to the primary amine(s) of said deacetylated Glucosamine thus forming a secondary amine(s)

a precursor for producing said branched hyaluronic acid

and a method for producing said branching hyaluronic acid

Priority: DK20060001034 Applic. Date: 2006-08-04; WO2007DK00358 Applic. Date: 2007-07-13

Inventor: TOEMMERAAS KRISTOFFER [SE]; SCHWACH-ABDELLAOUI KHADIJA [DK]


Application No.: US20090312380A1  Published: 17/Dec/2009

Title: NOVEL COMPOSITIONS AND METHODS

Applicant/Assignee:

Application No.: 12/439269   Filing Date: 31/Aug/2007

Abstract:This invention relates to active pharmaceutical ingredients (APIs) with specific water surface areas, to pharmaceutical compositions comprising said APIs, to processes for preparing such compositions, and to methods for determining the water surface areas of substances such as APIs and other particles.

Priority: GB20060017171 Applic. Date: 2006-08-31; WO2007GB50519 Applic. Date: 2007-08-31

Inventor: BECKER AXEL [DE]


Application No.: US20090312439A1  Published: 17/Dec/2009

Title: USE OF ROLL COMPACTED PYROGENICALLY PRODUCED SILICON DIOXIDE IN PHARMACEUTICAL COMPOSITIONS

Applicant/Assignee:

Application No.: 12/299984   Filing Date: 10/May/2006

Abstract:The use of Schülpen based on pyrogenically produced silicon dioxide in pharmaceutical compositions, the pharmaceutical compositions per se, as well as an adsorbate consisting of the Schülpen and at least one further substance selected from pharmaceutical active constituents and excipients, and the produce of such adsorbates, are described.

Priority: WO2006EP62216 Applic. Date: 2006-05-10

Inventor: HOFMANN RALPH [DE]; GRAY ANN [DE]; DRECHSLER MARGARETE [DE]


Application No.: US20090317437A1  Published: 24/Dec/2009

Title: CELLULOSE GEL FORMULATIONS

Applicant/Assignee:

Application No.: 12/096047   Filing Date: 06/Dec/2006

Abstract:The invention relates to dispersible cellulose powder compositions comprising non-seed cellulose powder derived from algae, fungi or tunicates, which compositions are useful in a variety of products such as food products, pharmaceuticals, cosmetics, paints, biocompatible materials for artificial tissue engineering and implantable biomaterials and relates to methods for preparing non-seed cellulose powder compositions.

Priority: US20050742749P Applic. Date: 2005-12-06; WO2006IB03571 Applic. Date: 2006-12-06

Inventor: MIHRANYAN ALBERT [SE]; STROEMME MARIA [SE]


Application No.: US20090317463A1  Published: 24/Dec/2009

Title: COMPOSITION FOR ORAL USE BASED ON S-ADENOSYLMETHIONINE AND A PROCESS FOR THEIR PREPARATION

Applicant/Assignee:

Application No.: 12/160225   Filing Date: 15/Nov/2006

Abstract:The present invention relates to solid dietary and/or nutraceutic pharmaceutical compositions for oral use based on SAMe, or salts thereof, in combination with inositol and/or derivatives thereof and to a process for their preparation. The present invention relates to a method of stabilising a solid composition for oral use based on SAMe or salts thereof, making use of inositol and/or derivatives thereof with the addition of magnesium oxide. The present invention also relates to the use of SAMe, or salts thereof, in combination with inositol and/or derivatives thereof with the possible further addition of melatonine, St. John's Wort and/or lemon balm for the treatment of depressive states and/or panic syndromes.

Priority: IT2006MI00026 Applic. Date: 2006-01-10; WO2006EP68533 Applic. Date: 2006-11-15

Inventor: SENECI ALESSANDRO [IT]; GIOVANNONE DANIELE [IT]; ZIO CESARE [IT]


Application No.: US20090317464A1  Published: 24/Dec/2009

Title: METHODS AND COMPOSITIONS FOR PRODUCING ANTI-ANDROGENIC EFFECTS

Applicant/Assignee: PANACEA BIOTEC LTD

Application No.: 12/305025   Filing Date: 05/Jul/2007

Abstract:The invention provides a method and a composition for producing an anti-androgenic effect in a mammal. The method comprises administering a modified release pharmaceutical composition of bicalutamide to a mammal, with a reduced dosing frequency, for improved patient convenience and compliance. The composition of the invention also provides for a higher bioavailability and improved pharmacokinetic profile as compared to a conventional bicalutamide composition.

Priority: IN2006MU01074 Applic. Date: 2006-07-07; WO2007IN00274 Applic. Date: 2007-07-05

Inventor: SINGH AMARJIT [IN]; SINGH SARABJIT [IN]; PUTHLI SHIVANAND [IN]


Application No.: US20090318375A1  Published: 24/Dec/2009

Title: Crystalline Azithromycin L-Malate Monohydrate and Pharmaceutical Composition Containing Same

Applicant/Assignee: HANMI PHARM CO., LTD

Application No.: 11/915929   Filing Date: 05/Jun/2006

Abstract:This invention provides a crystalline azithromycin L-malate monohydrate for treating various microbial infections, which has high thermostability, solubility and non-hygroscopicity, a method for preparing same, and a pharmaceutical composition containing same.

Priority: KR20050048923 Applic. Date: 2005-06-08; WO2006KR02157 Applic. Date: 2006-06-05

Inventor: KWON BO SUNG [KR]; KIM EUN SOOK [KR]; KIM HEE CHEOL [KR]; YUN SANGMIN [KR]; KO MYOUNG-SIL [KR]; SONG TAE HUN [KR]; KIM HAN KYONG [KR]; SUH KWEE HYUN [KR]; LEE GWANSUN [KR]


Application No.: US20090318560A1  Published: 24/Dec/2009

Title: FORMULATIONS FOR CATHEPSIN K INHIBITORS

Applicant/Assignee:

Application No.: 12/527876   Filing Date: 22/Feb/2008

Abstract:The instant invention relates to pharmaceutical compositions comprising cathepsin K inhibitors as the active ingredient with excipients which include binders, diluents, lubricants, and disintegrants. Also disclosed are processes for making said pharmaceutical compositions for oral and intravenous delivery.

Priority: US20070903493P Applic. Date: 2007-02-26; WO2008US02399 Applic. Date: 2008-02-22

Inventor: PARENT WAYNE [CA]; AFAGHI MAHTAB [CA]; BRESLIN DAVID [US]; GRANGER MIREILLE [CA]; WANG LEI [US]; ZIMMERMAN JEFF [US]


Application No.: US20090324711A1  Published: 31/Dec/2009

Title: Oral Pharmaceutical Composition of Anilinopyrimidine, Preparation and Use Thereof

Applicant/Assignee: ARES TRADING S.A

Application No.: 12/307605   Filing Date: 05/Jul/2007

Abstract:An oral pharmaceutical composition comprising a capsule dosage form containing a liquid fill composition including an anilinopyrimidine derivative of Formula (I) and a pharmaceutically acceptable excipient selected from the group consisting of polyethylene glycol, a glyceryl ester of capric acid or a mixture thereof. The liquid fill composition is formulated in a hard gelatin capsules and can be used for the preparation of a medicament for the treatment of cancer in particular AML.

Priority: EP20060116903 Applic. Date: 2006-07-10; US20060818831P Applic. Date: 2006-07-06; WO2007EP56859 Applic. Date: 2007-07-05

Inventor: FABIANO SANTA [IT]; MAIO MARIO [IT]


Application No.: US20090324715A1  Published: 31/Dec/2009

Title: HIGH DOSE ORAL PHARMACEUTICAL COMPOSITIONS OF ARTEMETHER AND LUMEFANTRINE

Applicant/Assignee:

Application No.: 12/305087   Filing Date: 22/Jun/2007

Abstract:The present invention relates to high dose oral pharmaceutical compositions of artemether and lumefantrine, and process for preparation thereof. The compositions comprise of artemether and lumefantrine comprising artemether in an amount of from about 40 mg to about 80 mg, lumefantrine in an amount of from about 240 mg to about 480 mg. The compositions are useful for treatment of uncomplicated infections with Plasmodium falciparum, including strains from multi-drug-resistant areas.

Priority: IN2006DE01492 Applic. Date: 2006-06-26; WO2007IB52436 Applic. Date: 2007-06-22

Inventor: MADAN SUMIT [IN]; BATRA VIKAS [IN]; ENOSE ARNO APPAVOO [IN]; ARORA VINOD [IN]


Application No.: US20090324717A1  Published: 31/Dec/2009

Title: Extended release pharmaceutical formulation of metoprolol and process for its preparation

Applicant/Assignee: FARMAPROJECTS, S. A

Application No.: 12/375524   Filing Date: 26/Jul/2007

Abstract:The invention provides an extended release coated granule comprising a granule having a particle size ranging from 0.2 to 2 mm, a friability lower than or equal to 1% and comprising metoprolol succinate as active ingredient in an amount ranging from 10 to 75% by weight of the granule and at least one binder selected from microcrystalline cellulose and methylcellulose, coated with a film-former coating agent. It also provides a process for the preparation of said extended release coated granules, as well as pharmaceutical formulations containing them.

Priority: EP20060118059 Applic. Date: 2006-07-28; WO2007EP57715 Applic. Date: 2007-07-26

Inventor: SUNE NEGRE JOSEP M [ES]; VALL PARES MARIA DEL CARMEN [ES]; ALVAREZ CASARES NOEMI [ES]; GUAL PUJOL FRANCISCO [ES]


Application No.: US20090324718A1  Published: 31/Dec/2009

Title: IMATINIB COMPOSITIONS

Applicant/Assignee:

Application No.: 12/439582   Filing Date: 04/Sep/2007

Abstract:Provided are compositions of imatinib, methods for their preparation, and methods for treatment using the same.

Priority: US20060841707P Applic. Date: 2006-09-01; WO2007US19338 Applic. Date: 2007-09-04

Inventor: ZALIT ILAN [IL]; PAL BOAZ [US]


Application No.: US20090324728A1  Published: 31/Dec/2009

Title: PHARMACEUTICAL COMPOSITIONS COMPRISING AMORPHOUS BENZIMIDAZOLE COMPOUNDS

Applicant/Assignee: DR. REDDY'S LABORATORIES LIMITED DR. REDDY LABORATORIES, INC

Application No.: 12/553409   Filing Date: 03/Sep/2009

Abstract:Compositions comprising amorphous substituted benzimidazole compounds.

Priority: IN2004CH01401 Applic. Date: 2004-12-20; US2007-722247 Applic. Date: 2007-06-20; WO2005US46393 Applic. Date: 2005-12-20

Inventor: BHUSHAN INDU [IN]; VERMANI KAVITA [IN]; KODIPYAKA RAVINDER [IN]; MEHTA PAVAK [IN]; MOHAN MAILATUR SIVARAMAN [IN]


Application No.: US20090325869A1  Published: 31/Dec/2009

Title: SYNTHETIC REGULATORS OF FERRITIN PROTEIN NANOCAGE PORES AND METHODS OF USE THEREOF

Applicant/Assignee:

Application No.: 12/122469   Filing Date: 16/May/2008

Abstract:The present invention provides synthetic regulators of ferritin pores, and compositions comprising the regulators. The regulators function to reduce ferritin demineralization rates. The regulators are useful for treating inflammatory conditions. The present invention also provides methods of treating inflammatory conditions. The present invention further provides synthetic regulators of bacterial mini-ferritins

such regulators are useful as antibacterial agents.

Priority: US20070939133P Applic. Date: 2007-05-21

Inventor: THEIL ELIZABETH [US]


Application No.: US20090325999A1  Published: 31/Dec/2009

Title: PERSONALIZED PHARMACEUTICAL KITS, PACKAGING AND COMPOSITIONS FOR THE TREATMENT OF ALLERGIC CONDITIONS

Applicant/Assignee:

Application No.: 12/147810   Filing Date: 27/Jun/2008

Abstract:This invention relates to personalized pharmaceutical kits, packaging, compositions, and methods for treatment of a mammal, comprising at least one antihistamine for treating an allergic disease or condition in a mammal, in combination with at least one wakefulness promoting agent for preventing sedative effects during day time use, while promoting the antihistamine and sedating effect during evening use.

Priority:

Inventor: DU JIE [US]

US Applications Published in 2009
US Applications Published in 2008
...or use our Search Engine to
search for patent documents by
number.
Search for anything. Simply
type the words in the box..
US PROVISIONAL PATENT APPLICATIONS IN EXCIPIENTS, DELIVERY AND RELEASE OF PHARMACEUTICAL COMPOSITIONS PUBLISHED IN 2009
This list includes Provisional Patent Applications published in the United States. The list was retrieved by searching the claims section of all patent applications. Salient search terms
included pharmaceutical formulations, excipients, strips, gums, cellulose, lozenge, tablets, capsules, suppositories; solid dosage, nasal inhalation; time, control or sustained drug release;
polysaccharides, polymeric excipients, hyaluronic acid, micro- and nano-spheres, carbomer, povidone, polyacrylates, polymerthacrylates; emulsions; enemas, vaginal, rectal, nasal, ocular
or buccal administration of medications, etc.
Clck to enlarge and view details